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A B S T R A C T 
Knowledge of melanocortins ( a - M S H , p-MSH, y-MSH, ACTH) and of their functional 
role has increased tremendously over the last 10 years w h e n five melanocortin receptor 
subtypes (MC1R-MC5R) were identified, cloned and characterized. Mos t studies are 
carried out to clarify action of MC1R, M C 4 R and a - M S H , while the role of M C 3 R and y-
M S H remains still unclear. However , attention may be payed to the fact that y-MSH 
peptides can bind wi th high affinity to MC3R. Besides, this subtype is abundantly 
expressed in structures of the dopaminergic mesol imbic system, such as ventral tegmental 
area (VTA) and nucleus accumbens (NACC). Dopamine (DA) A10 cells which are located 
in the VTA, receive projections from both inhibitory (GABAergic) and excitatory 
(glutamatergic) interneurons. In this context, our research studies are devoted to y-MSH 
peptides (yi- and Y2-MSH) to elucidate their neuropharmacological activities and a putative 
role in t he regulation of brain processes. Experiments were performed in laboratory animal 
models by use of behavioural and neurochemical tests, agonists and antagonists of different 
receptors. 
In t ra-VTA administration in rats demonstrated distinct behavioural responses caused by 
both y-MSH: y i -MSH (likely to previously described a - M S H ) induced excessive 
grooming and increased vertical activity that can be attributed to hyperactivation of the 
dopaminergic system. Unlike, y2-MSH caused psychodepressive state (catalepsy) indicating 
its anti-psychotic activity at the level of the dopaminergic mesolimbic system. Moreover , 
Y2-MSH showed antagonizing potency by reducing the yi-MSH-induced behavioural 
responses. These results are in good line with the data obtained in our neurochemical 
(microdialysis technique) studies. Concentrations of the N A C C extracellular D A and its 
metaboli te D O P A C after y i -MSH (and also a - M S H ) intra-VTA injection resulted in their 
considerable elevation, whereas y 2 - M S H caused a decrease in the concentrations of these 
monoamines. y 2 - M S H antagonized the y i -MSH effects. This phenomen indicates that these 
peptides are capable to modulate dopaminergic activity of the mesolimbic system in 
opposite manner. That was confirmed also by the data obtained in phencyclidine (PCP)-
induced hyperlocomotion test (shizoprenia model) in mice. y i -MSH potentiated the PCP 
locomotion activity, whereas y2-MSH reduced it, and also antagonized the observed y r 
MSH potentiating effect. Y2-MSH fully reduced neurotoxic effects caused by intra-VTA (in 
rats) injected N M D A, a glutamate receptor ligand. Intriguingly, analgesia test showed that 
Y2-MSH (but not y i -MSH) induced a stable and prolonged (90 min) non-opiate analgesia 
realized via G A B A A receptor-mediated processes. Thus, muscimol (agonist of G A B A site 
of the G A B A A receptor) potentiated y 2 - M S H analgesic activity, and bicucculine 
(competitive antagonist of the G A B A site) antagonized the y 2 - M S H analgesia. In turn, yi-
MSH acted as antagonist of diazepam, a ligand of the G A B A A receptor benzodiazepine 
site. B o t h peptides have distinct influence on analgesic effects caused by ethanol, a ligand 
of the G A B A A receptor modulatory site. The data obtained firstly show a pleiotropic 
influence of y -MSH peptides on brain processes by involving not only melanocortinergic 
mechanisms but also modulation of dopamin-, glutamat- and GABAergic processes. From 
our point of view, a distinct action of y i -MSH and y 2 - M S H and their mutual antagonism 
can be considered as the most important phenomenon, that gives us enough ground to 
postulate their endogenous regulatory role to maintain balanced psychoactivation/anti-
psychotic (anti-schizophrenic?) and pain perception states. These data may open new vistas 
in understanding of psychopathologies and their correction possibilities by use of 
melanocortins and novel M C R ligands. 
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A B B R E V I A T I O N S 
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NF-kB 
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adenosine 3 '5 '-cyclic monophosphate 
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deoxyribonucleic acid 
central nervous system 
3 '4 ' -dihydroxyphenylacet ic acid 
cerebrospinal fluid 
ethylenediamine tetraacetic acid 
y-aminobutyric acid 
y-aminobutyric acid A type receptor 
Growth Hormone 
h igh performance liquid chromatography 
International Union of Pure and Applied Chemistry-International 
Un ion of Biochemistry and Molecular Biology 
intracisternal 
intraperitoneal 
intracerebroventricular 
interleukin 
inositol r4'5'-triphosphate 
dissociation constant (in competitive binding analysis) 
l ipotroplns 
l ipopolysaccharide 
melanocortin receptor 1 
melanocortin receptor 2 
melanocortin receptor 3 
melanocortin receptor 4 
melanocortin receptor 5 
melanocyte stimulating hormone (melanocortin) 
nucleus accumbens 
Nuclear Factor-Kappa B 
N-methyl-D-aspartate 
nitric oxide 
prohormone convertase 
phencyclidine 
protein kinase A 
proopiomelanocortin 
messenger ribonucleic acid 
tumor necrosis factor - a 
ventral tegmental area 
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1. I N T R O D U C T I O N 
Since the beginning of the neuropeptide era started in the 1970 , a lot of studies on peptide 
formation, amino acid sequence and the functional role of their receptors have been increased 
tremendously. The first scientific report about the biological activity of a - M S H peptide appeared 
in 1912, however until the end of the 2 0 t h century very little was known about the mechanisms 
underlying the central effects of melanocortin peptides. Only in the beginning of the 1990 t h , 
peptides (ACTH, a - , (3-, y i - and Y2-MSH) that belong to the 'melanocort in family' became as the 
most studied peptides. During 1992-1993 the genes encoded five melanocortin receptor subtypes 
(MC1R-MC5R) were identified, cloned and characterized in different types of cells. These 
discoveries have shed a light in understanding of molecular mechanisms underlying different 
melanocortin-induced effects, such as skin darkening, changes in behaviour, food intake, as well 
as anti-inflammatory and lipolytic actions, analgesia and others. 
M C 1 R and M C 4 R have been studied more intensively than other types of the melanocortin 
receptors. T h e most clarified function of M C 1 R is the binding with a - M S H that leads to the 
stimulation of melanogenesis in melanocytes and thus induces the changes in the skin 
pigmentation. Over the last 5-7 years numerous studies have revealed the role of M C I R and 
a - M S H in melanoma tumorogenesis and in the regulation of anti-inflammatory processes. 
M C 4 R has important role in the control of feeding behavior. The latest investigations confirm 
that M C 4 R agonists are capable to reduced food intake thus exerting the anorexive effects. In 
contrast, M C 4 R antagonists induce overeating and weight gain. These findings stimulate an 
intensive drug design to obtain selective M C 4 R agonist that could be useful to treat obesity and 
antagonists in order to treat anorectic conditions. 
In compar ison to other melanocortins and M C receptors, less understandable is the functional 
role o f both y-MSHs and MC3R. y r M S H and y 2 - M S H show high binding activity to M C 3 R that 
is widely expressed in many regions of the brain. Particularly abundant expression of the MC3R 
(also the MC4R) is found in the brain mesolimbic dopaminergic system. It is well known that the 
mesolimbic dopaminergic system is involved in regulation of the motivational processes, drug 
dependence, manifestation of schizophrenic hyperactivation and emotion. The mesolimbic 
dopaminergic system involves t w o important brain structures: the ventral tegmental area (VTA) 
and nucleus accumbens (NACC). V T A contains A10 dopaminergic cells that receive 
interneurons from both the inhibitory (e.g.GABAergic) and the excitatory (e.g. glutamatergic) 
neurons, hence dopamine (DA) release in the N A C C can be modulated by these influences. 
Abnormal dopamine release in the N A C C may lead to psychoses, paranoidal delutions in 
schizophrenic patients and drug addicted persons. 
In Latvia, the functional role o f y-MSH peptides in central nervous system (CNS) have been 
investigated since 1995. The studies were started in the Laboratory of Pharmacology, Latvian 
Institute of Organic Synthesis and continued in the Department of Pharmacology, Faculty of 
Medicine, University of Latvia and supervised by Professor Vija Klusa. The collaboration 
between the Latvian scientists Swedish scientists group headed by Professor Jarl Wikberg 
(Uppsala Universi ty) , as well as financial support from the Howard Hughes Medical Institute 
(USA, 1995-2000) have given good basis for detailed studies by rise of variety of experimental 
approaches to disclose the central effects of melanocortins. 
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The main goal of the present study was to investigate the pharmacological effects of 
melanocortins (particularly the y-MSHs), and to clarify neurochemical mechanisms for MSH 
peptides. We have demonstrated that M S H peptides differ for each other by their behavioral 
repertoire in experimental animals, and these processes are provided not only via 
melanocortinergic mechanisms but also dopamine- , glutamate- and GABAergic pathways. The 
most intriguing fact that we have revealed was the opposite action of y i - M S H and Y2-MSH, as 
well as the antagonizing phenomena between both y-MSHs. The data obtained in our studies 
allow u s to suggest that y-MSH peptides may play a significant functional role in the regulation 
of brain processes, particularly the homeostasis of psychoactivation, pain perception (perhaps, 
also reward) processes. 
The obtained data open new avenues in understanding the central effects of melanocortins and 
their putative endogenous roles. That also may initiate a design and synthesis for novel 
substances-prototypes anti-psychotic, analgesic and motivation-regulating drug based on the 
completely new mechanisms discovered in the present pharmacological studies. 
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2. R E V I E W OF T H E LITERATURE 
2.1 Melanocortins 
2.1.1 History of the discovery of M S H peptides and their nomenclature 
According t o the IUPAC-ILIB convention the full name of the hormone that causes melanin 
dispersion is a melanocyte-stimulating hormone, abbreviated as MSH, and the trivial name is 
melanotropin. The term opiomelanocortins is used for any or all of the proopiomelanocortin 
(POMC) peptides, the term melanocortins relates only to A C T H and MSH-derived peptides [a -
MSH, p-MSH, Yi-MSH, y 2 - M S H and y 3 - M S H ] (Eberle, 1988). The first scientific report on 
biological activity o f melanocortins appeared in 1912 when it was demonstrated that pituitary 
extracts darken the skin o f frogs (Fuchs, 1912). The isolation of the melanophore stimulants has 
lead to the identification of a - M S H , and it w a s one of the first peptide hormones discovered 
(Lerner and Lee, 1955). a - M S H appeared as a right peptide responsible for the skin darkening 
by melanocyte dispersion process. In the 1960 t h a lot of studies were devoted to clarification of 
the functional role o f a - M S H and ACTH. In comparison to the quite well identified mechanisms 
of a - M S H , much less is known about the functional roles of y -MSH peptides. 
2.1.2 Proopiomelanocortin and the formation of the MSH peptides 
The melanocortins ( a - M S H , 3-MSH, yi-MSH, y 2 - M S H and y3 -MSH) as well as several other 
biologically active fragments including [3-endorphins, (3-lipotropin and y-lipotropin, are 
proteolytically cleaved from the c o m m o n precursor, a glycosylated protein proopiomelanocort in 
(POMC) having 2 4 0 amino acid residues (Uhler and Herbert, 1983). The P O M C sequences are 
identical in the pituitary, brain and peripheral tissues, however they are processed differentially 
at these sites that results in the release of active hormones (Smith and Funder, 1988). The 
prohormone convertases P C I and PC2 participate in processing of the P O M C . PCI may generate 
the ACTH, whereas PC2 may lead to cleavage o f the peptide bound after the first 13 amino acids 
of A C T H , yielding a - M S H . These PCs are soluble and primarily localized to large dense core 
vesicles in neurons and endocrine cells. Proteolytic cleavage occurs mostly at sites where two 
polar amino acids form a peptide bound, e.g., Arg-Arg (R-R), Lys-Lys (K-K), Arg-Lys (R-K), 
Lys-Arg (K-R). The prefix a ( a - M S H ) denotes the basic tridecapeptide derived from 
adrenocorticotropin (ACTH) and the prefix (3 ( p -MSH) the acidic octadecapeptide derived from 
lipotropin (LPH). see Fig. 1 (Eberle, 1988). 
POMC 
Fig. 1. Schematic presentation of the formation of POCM-der ived peptides 
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In the central nervous system, POMC-immunoreactive neurons form essentially two neural 
systems: one originates in cell bodies localized in the posterior hypothalamus, and the other in 
cell bodies of the brain stem. These neurons project to distinct regions of the central nervous 
system including the telencephalon, diencephalon, mesencephalon, brain stem and the spinal 
cord (Low et al., 1994). The main source of circulating melanocortins is the hypophysis 
(pituitary). Melanotrophs of the pars intermedia and corticotrophs of the anterior hypophysis are 
typical cells that are known to process POMC. a-MSH and p-lipotropin are the main products 
from the intermediate lobe. a-MSH is also detectable in hypothalamus, stomach, kidney, 
intestine, testis, placenta, ovaries, pancreas, adrenal medulla, skin and immuno-competent cells. 
Presence of y-MSHs was found in some regions of the CNS, neurons of intestines and adrenal 
medulla (Eberle, 1988). New discovery was done in 2003 when Delta-MSH has been detected in 
the POMC gene of a dogfish and a stingray (Dores et al., 2003). 
2.1.3 Primary structure of melanocortins 
Melanocortin peptides differ from each other by their amino acid sequences and length of the 
chain; however they all share a common pharmacophore unit, a tetrapeptide His 6-Phe 7-Arg 8-
Trp9 a-MSH has an identical amino acid sequence to the 13 first amino acids in ACTH, 
however a-MSH has acetyl group in the N-terminus and amide group in the C-terminus (Fig. 2). 
There are three naturally occurring forms of a-MSH: desacetyl-, monoacetyl - and diacetyl- a-
MSH. Desacetyl- a-MSH may be post-translationally processed into the a-MSH (Verburg-van 
Kemenade et al., 1987). The majority of a-MSH originates from pituitary melanotropic cells, 
whereas the hypothalamus releases the desacetylated form. The amino acid sequences of the 
y-MSH peptides are almost identical. These peptides differ from each other only with extra C-
terminal glycine residue in Y2-MSH molecule (Fig. 2). 
A K T H 
H-Ser-Tyr-Ser-Met-Glu-^-PJ^il^Xal-Gly-Lys-Pro-Val-Lys-Lys-Arg-Arg-
Pro-Val-Lys-Val-Tyr-Pro-Asn-Gly-Ala-Glu-Asp-Glu-Leu-Ala-Glu-Ala-Phe-
Pro-Leu-Glu-Phe-OH 
a-MSH (acetylated) y" •« 
Ac-Ser-Tyr-Ser-Met-Glu-His-Pl!e-Arg-Tip-Gly-Lys-Pro-Val-NH2 
Y.-MSH : 
H-Tyr-Val-Met-GlylHis-Phe-Arg-Trp-Asp-Arg-Phe)-NH2 
y^MS 
TyT-Val -MPt -n iy lHi^.Ph^Arg-Tr^-AQp-Arg -PhpLr . ly -nH 
Y^-MSH : : 
H-Tyr-Val-Met-Gly-llis-Phe-Ar^rTrp-Asp-Arg-Phe-Arg-Arg-Asn-Gly-Ser-
Ser-Ser-Ser-Gly-Val-Gly-GIy-Ala-Ala-Gin-OH 
Fig. 2. The primary structure of melanocortin peptides; the common pharmacophoric unit of the 
melanocortins is shown in the brown color, the homological amino acid sequence of yi-MSH 
and y2-MSH is framed. 
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2.1.4 Specific structure features of melanocortins in different species 
Phylogenetically, a - M S H is an ancient molecule that has remained essentially unchanged over 
million years. The amino acid sequence of a - M S H is remarkably conserved across different 
species. In seven mammal species from which a - M S H has been isolated (pig, sheep, horse, 
monkey, camel, rat and ox), it showed identity in the structures. Birds ' a - M S H (duck and 
turkey) shows a high degree of similarity with mammal ian hormone. The y-MSHs structures of 
different species have been deduced from the respective D N A sequences (Eberle, 1988). 
2.1.5 Expression of melanocortins in the CNS and peripheral tissues 
In the central nervous system, a - M S H immunoreactive perykaria are found in three regions: the 
nucleus arcuatus of the hypothalamus, the dorsolateral region of the hypothalamus and the 
nucleus tractus solitarius (Eberle, 1988). From these regions nerve fibres project throughout 
virtually the whole brain, including the hypothalamus, thalamus, midbrain, amygdala, medulla, 
spinal cord, hippocampus and cerebral cortex. Besides, a - M S H is widespread in peripheral 
tissue (Table 1.). y -MSH immunoreactivity is present in P O M C neurons of the nucleus arcuatus 
and nucleus commissuralis as well as in their projections (Bloom, 1980). In the peripheral 
tissues, y -MSH is found in the adrenal cortex, heart, kidney and other ones (Table 1 ) . a - M S H -
and y-MSH are present in the nerves of baroreceptor areas in the brainstem, thus indicating 
possible melanocortin regulation of cardiovascular activity (Palkovits, 1987). 
Table 1. Expression of MSH peptides in the hypophysal and peripheral tissues 
P E P T I D E S T I S S U E S 
a - M S H , y-MSH 
A C T H 
A C T H 
a - M S H 
y-MSH 
Hypophysis 
Pars intermedia 
Pars anterior 
Peripheral tissues 
Adrenal gland, stomach, small intestine, liver, colon, ovary, spleen, 
lung and kidney 
Adrenal gland, duodenum, heart, small intestine, liver, lung, ovary, 
placenta, spleen, skeletal muscle, skin, spinal cord, testis and thyroid 
Adrenal cortex, heart, kidney, ovary, stomach and blood vessels 
Var ious forms of stress induce a 2- to 8-fold increase in ACTH, a - M S H and y-MSH 
concentrations in rat plasma. The basal ys-MSH levels are similar to those of a - M S H , they are 
low in the morning (8.2pM) while in the evening they are slightly elevated. Basal morning 
plasma a - M S H concentrations vary from 10-50pM with an average of about 28pM. The rate of 
a - M S H breakdown in vitro pooled blood or plasma samples from rat are the same as for 
endogenous or synthetic peptides. The breakdown is proximately exponential with a mean half 
life of 39 min for samples kept at 37°C, 54 min for sample kept on ice. The P h e 7 - A r g 8 bond is 
particularly labile and thought to be the primary site for cleavage. Once this bond is cleaved, the 
fragments are degraded further to free amino acids by exopeptidases (Eberle, 1988). 
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2.2 Melanocortin receptors 
2.2.1 Discovery of melanocortin receptors 
Five different subtypes of melanocortin receptors (MC1-5R) were cloned during 1992 and 1993. 
In 1992 the genes encoding G protein coupled M S H receptor, termed MC1R, was cloned from 
cDNA libraries derived melanoma cell lines independently by two groups: Prof. Jarl Wikberg, 
Uppsala, Sweden, and Prof. Rogers Cone, Oregon, USA (Chhajlani and Wikberg, 1992; Montjoy 
et al., 1992). At the same time, a structurally similar receptor, now termed MC2R, was also 
cloned (Montjoy et al., 1992). In 1993, the genes encoding three larger M S H receptors, termed 
M C 3 , M C 4 and MC5R, were identified, cloned and characterized (Chhajlani et al., 1993; Gantz 
et al., 1993). 
2.2.2 Melanocortin receptor 1 (MC1R) 
The MCI receptors was firstly detected in melanoma cells and cells of solid melanoma tumours 
(Chhajlani and Wikberg, 1992) (Table 2 ) . However, the expression levels of the M C 1 R increase 
generally 10- to 20-fold upon transformation of the normal melanocytes into malignant 
melanoma (Loir et al., 1999). In normal adult human skin the immunoreactivity for the anti-MCl 
receptor antibody was detected in hair follicle epithelia, sebocytes, secretory and ductal epithelia 
of sweat glands (Bohm et al., 1999). N o w the M C 1 R has been cloned in a number of different 
mammal ian and non-mammalian species such as rodents, cows and birds (Wikberg, 1999). The 
M C 1 R w a s also found in Leydig cells of the testis, lutein cells of the corpus luteum and 
trophoblastic cells of the placenta (Wikberg et al., 2000). The localization of M C 1 R to 
macrophages and monocytes (Hartmeyer et al., 1997), neutrophils (Catania et al., 1996), 
endothelial cells, fibroblasts (Boston and Cone, 1996), keratinocytes (Luger et al., 1997) and 
microglial (Wong et al., 1997) cell types have recently been much discussed in relation to anti-
imflammatory actions of M S H peptides. In the CNS, M C 1 R is found to be located to only a few 
scattered neurons of the periaqueductal grey area in both rat and human brains and M C 1 R does 
not have a major role in the C N S (Xia Y et al., 1995). The M C 1 R contains substantial single 
nucleotide polymorphisms (SNP's ) in its coding region and it results in phenotypic variations in 
hair and skin colour. Increased risk of melanoma is also linked to some mutations in the MC1R 
(Wikberg et al, 2000) . MC1R binds a-, p - and y-MSH peptides, however a - M S H - M C l R binding 
is considered as predominant for many physiological effects, for instance, skin darkening, 
melanoma formation. 
2.2.3 Melanocortin receptor 2 ( M C 2 R ) 
Melanocort in receptor subtype 2 proved to be the receptor for the corticotropin (ACTH) binding, 
but not for the M S H s (Schioth et al., 1996). The MC2R is highly expressed in the adrenal cortex, 
where mos t of the expression occurs in the cells of zona glomerulosa and zona fasciculate and in 
a few scattered cells in the medulla, however, both the hypophysis and the hypothalamus proved 
to be negative (Xia and Wikberg, 1996). In the adrenal cortex M C 2 R is responsible for the 
A C T H mediated control of glucocorticoid and mineralocorticoid production (Mountjoy et al., 
1992). Natural mutations in the M C 2 R gene may be related to familial glucocortical deficiency 
(Weber et al., 1993). The M C 2 R has also been detected in mice (but not in human) adipocytes, 
where it may be responsible for stress-induced lipolysis mediated by A C T H released from the 
pituitary (Boston, 1999; Chhajlani, 1996). In the chicken, M C 2 R are expressed in both the spleen 
and the adrenal gland, indicating additional functions of the receptor in birds compared to 
mammals (Takcuchi et al., 1998). 
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The expression o f the M C 2 R w a s recently identified in the skin, thus indicating a possible novel 
role for this receptor and corticotropins in the physiology of the skin (Slominski et al, 1996). 
2.2.4 Melanocortin receptor 3 (MC3R) 
The M C 3 R was originally found as an orphan G-protein coupled receptor and was characterized 
as an unknown receptor useful as a polymorphic marker linked to non-insulin-dependent 
diabetes mellitus on human chromosome 20q (Bell et al., 1991; Yamada et al., 1991). MC3R 
w a s firstly identified, cloned, expressed and localized in the brain, placental and gut tissues by 
RT-PCR in 1993 (Gantz et al., 1993). Expression of M C 3 R was also found in the heart of 
mammals , in the adrenal gland of chicken and in the thymus and peritoneal macrophages of 
mouse (Chhajlani, 1996; Takeuchi and Takahashi, 1999; Getting et a l , 1999). M C 3 R is 
predominantly expressed in the CNS; hippocampus, ventral tegmental area (VTA), cortex, 
thalamus, nucleus arcuatus, septum, corpus amygdaloideum, substantia grisea centralis 
mesencephali, nucleus raphes, nucleus accumbens (NACC), hypothalamus (Gantz et al., 1993). 
Relatively high density of the M C 3 R is present in the N A C C and V T A (Lindblom et al., 1998). 
The much wider distribution of the M C 3 R protein compared to its m R N A and expression of the 
M C 3 R on the P O M C neurons of the arcuate nucleus, indicates the possibility that the central 
nervous system M C 3 R is a largely presynaptically located receptor. The M C 3 R are expressed on 
the cell bodies o f P O M C neurons of the posterior hypothalamus that form major projections to 
large parts of the CNS. So, the M C 3 R may function as an autoreceptor, regulating the release of 
M S H peptides from P O M C neurons. The melanocortins receptor expression during the 
development of the fetus shows that the rat M C 3 R expression appears only after birth (Xia and 
Wikberg, 1997). Recently it w a s showed that anabolic androgenic steroids cause a strong 
unregulat ion of M C 3 R at sites of the hypothalamus, where M S H peptides can also stimulate 
sexual behaviors (Wikberg et al., 2000). Nevertheless, the physiological functions of the MC3R 
are at present poorly understood. y-MSH peptides have a relatively high affinity to the MC3R 
(Table 4 ) . 
2.2.5 Melanocortin receptor 4 (MC4R) 
The ontogenesis of the mammalian M C 4 R expression showed that it is predominant during the 
whole fetal period (Kistler-Heer et al., 1998). The M C 4 R is widely distributed in the central 
nervous system and is represented in almost every brain region, including the cortex, thalamus, 
hypothalamus, brain stem, spinal cord, septum lateralis, tuberculum olfactorium and ventral 
tegmental area (Mountjoy et al., 1994). In a study covering 20 human peripheral organs, use of 
R T - P C R failed t o detect the M C 4 R in any of the organs studied (Chhajlani, 1996). Compared to 
mammals , the M C 4 R w a s expressed in many peripheral tissues of the chicken (Takeuchi and 
Takahashi , 1998). However, there is evidence that the M C 4 R may be present also in human 
adipose tissue (Chagnon et al., 1997). This is in line of the reported role of the M C 4 R in control 
of body weight. A number of mutations have been found in the coding region of the M C 4 R gene 
which link with dominant autosomally inherited forms of severe obesity. The M C 4 R of the 
hypothalamus and brain stem are believed to play an important role in the control of feeding 
behaviour. Direct injections of a - M S H or ACTH-( l -24 ) into hypothalamus or 
intracerebroventricularly (icv) caused a marked inhibition of food intake (Poggioli et al., 1986). 
A relationship between feeding control and melanocortin receptors was confirmed in 1994, when 
it was shown that endogenous agouti peptide acted as M C 4 R antagonist (Lu et al., 1994). Further 
it was strengthened by the discovery that M C 4 R knockout mice developed morbid obesity 
(Huszar et al., 1997). The selective MC4R antagonist HS014 induces overeating and severe 
obesity (Kask et al., 1998). 
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Many studies indicate that an M C 4 R agonist could be useful to treat obesity, while an MC4R 
antagonist might be of use to treat anorectic conditions. Chronic morphine and cocaine 
administration causes down-regulation of the M C 4 R expression in areas of the brain regions 
involved in opiate addiction, suggesting about M C 4 R role in drug addiction (Alvaro et al., 1996). 
Some studies show the MC4R involvement in the regulation of the cardiovascular system, since 
increase in mean arterial pressure by a - M S H or A C T H was blocked by icv administration of the 
natural M C 4 R antagonist agouti signaling peptide (Dunbar and Lu, 1999). There is also evidence 
that neurotrophic effect of a - M S H may be mediated by M C 4 R (Van Der Kraan et al., 1999). 
Activation of central M C 4 R may play a central role in the regulation of luteinising hormone and 
prolactin secretion (Wikberg et al., 2000). The main difference between the M C 4 R and the other 
melanocortin receptors is its particularly low affinity for the y-MSH peptides, and slightly higher 
affinity for (3-MSH than a - M S H and ACTH, see Table 4 (Schioth, 2000). 
2.2.6 Melanocortin receptor 5 (MC5R) 
The M C 5 R is ubiquitously expressed in many peripheral tissues (e.g., adrenal glands, fat cells, 
liver, kidneys, lung, lymph nodes, bone marrow, thymus, mammary glands, testis, ovary, 
pituitary, uterus, oesophagus, stomach, skin, skeletal muscle) and it is also present in the brain 
and spinal cord (Chhajlani et a l , 1993; Labbe et al., 1994). The receptor is richly expressed in 
the exocrine gland tissues (lacrimal, prostatic, seminal, pancreatic, preputial and Harderian) 
where it is present in the gland 's secretory epithelia (Wikberg et al., 2000). There is evidence 
suggesting that M C 5 R plays a role in regulation of functions of exocrine glands. M C 5 R in mice 
is involved in production of sebum from sebaceous glands resulted in water repulsion of their 
furs and thermoregulation (Wikberg, 2001). Lipolysis in adipocytes may be stimulated by a -
M S H peptides by activating MC5R. However, there are species differences in the stimulation of 
lipolysis in adipocytes, showing the rabbit and guinea pig as being considerably more sensitive 
to a - M S H than rodents and primates (Boston, 1999). a - M S H peptide has been shown to 
stimulate aldosterone secretion in the adrenal gland, and it is likely that the effect produced by a -
M S H is mediated via the MC5R. Interestingly, a - M S H stimulates inositol-trisposphate and 
protein kinase C (PKC) activity in g lomemlosa cells, indicating that the MC5R might be 
involved in signaling via the inositol-triphosphate pathway in the adrenal gland (Kapas et al., 
1996). The function of the M C 5 R expressed in the various tissues remains to be elucidated. 
Major sites of expression for different melanocortin receptor subtypes are summarized in Table 
2. 
Table 2. Tissue distribution of the M C receptor subtypes (Wikberg, 2001) 
M C R 
subtype 
Tissues reported with M C R subtypes 
M C 1 R melanocytes, melanoma cells, macrophages, brain, adipose tissue and testis 
M C 2 R adrenal gland and adipose tissue 
M C 3 R brain, placenta, duodenum, pancreas, stomach and heart 
M C 4 R different regions of the brain 
M C 5 R brain, adrenal gland, skin, spleen, thymus, testis, ovary, muscle, lung, adipose 
tissue, liver, uterus, stomach, bone marrow, leucocytes, pineal, mammary and 
thyroid gland 
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22.1 Structural characterization of the M C R and signal transduction pathways 
The melanocortin receptors belong to the class of G protein coupled 7-transmembrane (TM) 
region or heptahelix receptors. G-protein coupled receptors belong to the largest family of 
receptors with approximately 1000 members in mammals. The MC receptor family has the 
shortest amino acid sequence among the super famUy of G protein coupled receptors. The human 
MC1R, MC2R, MC3R, MC4R and MC5R are 317, 297, 361, 333 and 325 amino acids long, 
respectively. They are characterized by having short N-terminal (25-39 amino acids) and C-
terminal regions (17-21 amino acids) as well as very small second extracellular loop (9 amino 
acids). All the MCRs ave several potential N-glycosylidation sites in their N-terminal domains. 
The MCRs also have conserved cysteins in their C-termini, which may serve as sites for fatty 
acid acylation anchoring the C-terminus to the plasma membrane (Tatro, 1996). Insights into the 
structural organization of the MSH peptides binding to MCRs and their ligand pockets have been 
studied at the late 1990 t h . By using site-directed mutagenesis, there was initially identified two 
amino acid residues, Asp 1 1 7 (D117) in the third TM segment, or H i s 2 6 0 (H260) in the sixth TM 
segment of the human MC1R, that were involved in the binding of a-MSH (Frandberg et al., 
1994). All natural MSH peptides tested (which have an L-Phe in position 7) lost affinity for both 
mutants, whereas the D-Phe 7 containing NDP-MSH was not affected. Further studies indicated 
that actually these two amino acids rather participate in the maintenance of the over all structure 
of the MC1R and this conformational changes in the receptor is not linked to any specific amino 
acids in the MSH peptides (Schioth et aL 1997a). The linear MSH peptides are too flexible to 
allow accurate ligand locking. Therefore a novel series of small rigid cyclic MSH core peptides 
(for example [Cys 4, Cys 1 0]a-MSH(4-10) was synthesized to study the MC1R binding affinity, 
for the illustration see Fig 3). 
•m 
Ac-Cys- -His-:>Pr»-Arg-Trp-Cys-NMe 
I 1 
Fig. 3. Molecular 3 dimensional model represents interaction of die cyclic [Cys 4, Cys 1 0 ]a-
MSH(4-10) wit MC1R (Prusis et. al., 1997). 
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This model presented in Fig.3 indicates that the receptor binding site forms a binding pocket by 
involving most T M domains wi th exception of TM4 and TM5. Obviously all domains are 
necessary to arrange optimal protein conformation to provide high binding activity. 
The five melanocortin receptors exhibit sequence homologies ranging between 4 0 % and 60%. 
The identity is lowest between the M C 1 R and the M C 2 R ( 3 8 % identity) and highest between 
M C 4 R and the M C 5 R (60% identity), see Table 3. 
Table 3. Amino acid identity (in %) between the five cloned human M C receptor subtypes 
(Schioth et al., 1995; Schioth et al., 1997) 
M C 1 R M C 2 R M C 3 R M C 4 R M C 5 R 
M C 1 R 100 38 45 47 44 
M C 2 R 100 42 46 44 
M C 3 R 100 42 57 
M C 4 R 100 60 
M C 5 R 100 
It is interesting that the MC2R has a similar degree of homology to the M C 3 , M C 4 and MC5 
receptors, as to the MC1R, despite the dissimilarity among themselves. Generally, the MC 
receptor subtypes show lowest homology in t he intra- and extracellular loops and in T M 4 and 
T M 5 , and highest homology in T M 1 , TM3 and TM7. 
The ability of A C T H and different M S H peptides to bind to specific melanocortin receptor 
subtypes is showed in Table 4.The M C 2 R binds only A C T H and its fragments but not a , P, and 
y-MSH peptides. Moreover , although the other MC receptors bind A C T H and larger ACTH 
fragments, ACTH may be subjected to breakdown to shorter MSH peptides that generally show 
higher activity for the MSH-binding MC receptors (Schioth et al, 1995). Diacetylation lowers the 
affinity of a - M S H for all of the melanocortin receptors While the natural desacetylated form of 
ACTH and a - M S H favours the melanocortin 3 receptor even though the affinity between 
acetylated and desacetylated peptides are not very high. The M C 1 R and M C 5 R have more than 
30-fold and 2-fold higher affinity for a - M S H , respectively, compared to that of yi-MSH, 
whereas the MC3R has 2-3-fold higher affinity for y i -MSH than a - M S H . The M C 3 R shows a 
relative preference for y-MSH peptides. 
Table 4. Ligand preferences of the five mammalian M C receptor subtypes 
(Schioth et al., 1995; Schioth et al., 1996; Schioth et al., 1997) 
Melanocort in receptor 
subtype 
Potency order o f melanocortins to melanocortin 
receptors 
M C 1 R N D P - M S H > a - M S H > p - M S H > y i - M S H 
M C 2 R A K T H 
M C 3 R N D P - M S H > y , - M S H > y 3 - M S H > P - M S H > y 2 - M S H > a -
M S H > A K T H 
M C 4 R N D P - M S H » P - M S H > a - M S H > A K T H > y 1 - M S H 
M C 5 R N D P - M S H » a - M S H > P - M S H > A K T H > y , - M S H 
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The "/2-MSH has similar relative MCR affinity profile as yi-MSH, although it is somewhat less 
potent. The main difference between the MC4R and the other receptors is its particularly low 
affinity for the y-MSH peptides. So, the MC1R shows preference for a-MSH the MC3R for y-
MSH and the MC4R for P-MSH (Schioth et a l , 1995; Schioth et al., 1996; Schioth et al., 1997). 
All five melanocortin receptors subtypes are positively coupled in a stimulatory fashion, leading 
to the increase in intracellular cAMP after ligand activation (Gantz et al., 1993). The effect on 
cAMP production is rapid, reaching a maximum within 15 minutes. There are reports showing 
mat other signal pathways also may be involved, namely the phosphoinositol pathway for the 
MC3R (Konda et aL 1994), and the MC5R may additionally be linked to the Jak/STAT signaling 
pathway (Buggy, 1998). Pretreatment with a cAMP antagonist, abolished the decrease in IP3 
production at higher concentrations of a-MSH or ACTH and resulted in an increase in 
intracellular calcium levels, therefore indicating that MC3R may be coupled to two second 
messenger systems: PKA/cAMP and nyCa 2 + (see Fig. 4). The latter probably is under control of 
PICA The melanocortin receptors have consensus recognition sites for protein kinase C, and in 
some case also for protein kinase A, indicating that they may be subjected to regulation by 
phosphorylation (Wikberg et al., 2000). 
Fig 4. Overview of the possible signalling pathway induced by melanocortins through MCRs 
transduction AC, adenylate cyclase; cAMP, cyclic adenosine monophosphate; DAG, 
diacylglycerol; IP3, inositol 1,4,5-triphosphate; MC receptor, melanocortin receptor; PKA 
protein kinase A PKC, protein kinase C; PLC, phospholipase C (Frandberg, 1998). 
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23 The biological effects of MSH peptides 
23.1 Pigmentation 
Early observation in the 1960 t h showed that a-MSH increased skin darkening in humans (Eberle, 
1988). a-MSH and ACTH are both synthesized in human epidermis in response to ultraviolet 
radiation. Shortly after the cloning of the MC1R it was shown that the extension gene locus that 
controls coat color in mammals encodes the gene for the MC1R Population studies have 
revealed more than 20 allelic variants of the MC1R gene. The activation of the MC1R results in 
stimulation of cAMP formation, induction of pigmentation enzymes, including tyrosinase and 
leads to melanin synthesis. The human MC1R thus plays a central role in regulation of 
eumelanin (black/brown) and phaeomelanin (red/yellow) synthesis within the mammalian 
melanocyte (Schioth et al., 1999). 
a-MSH serves as a growth stimulator for normal melanocytes, when other synergistic mitogens 
are present, thus indicating that the MSH peptides and other factors are of importance for 
melanocyte cell proliferation in vivo (Halaban, 2000). Malignant transformation of melanocytes 
into melanoma leads to growth autonomy and is associated with the production of multiple 
growth factors and receptors by the tumour cells. High levels of a-MSH immunoreacrivity were 
detected in melanoma tumours and melanoma cell lines express up to 20-fold higher levels of 
MC1R mRNA compared to normal melanocytes (Loir et al., 1997). So, the most clarified 
function of MC1R is binding with a-MSH that leads to skin darkening and melanoma 
tumorogenesis. 
23 J. Inflammation 
The POMC can express melanocortins not only in pituitary gland but also in immune cells, 
indicating the role of MSH peptides in the regulation of the CNS, immune and endocrine system 
The POMC-derived peptides may be produced in immunocompetent cells when they receive 
non-cognitive (bacterial, viral) stimuli. The peptides then can be released to initiate 
glucocorticoid synthesis along the irnmuno-adrenal axis, hence induce immunosupression and 
anti-inflammatory action (Fig.5). 
• 
!>• ripr.froi or central 
n w v j g s system 
fffi 
i 
CRF 
Pituitary gtand 
.-. * C T H 
Adrenal Qtarxts, Negative r«tJoaci< 
Nnjatim? feedback • l 
Fig. 5. The POMC-derived peptides take part in the transduction of the information between 
CNS and immune system (Blalock et al., 1985). 
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It was noted in the early 1980 that administration of a - M S H and A C T H ( l - 2 4 ) caused 
hypothermia and reduced fever induced by a leukocytic pyrogen (Glyn and Lipton, 1981). a -
M S H seems to act both directly on inflammatory cells in the periphery and through central 
mechanisms. Many inflammatory processes, such as neurodegenerative diseases, stroke, closed 
head injury, encephalitis, and bacterial endotoxin-induced inflammation within the brain, are 
marked by a local increase in cytokines, particularly T N F - a . The effects of a - M S H include 
inhibition of production and activity of immunoregulatory and proinflammatory cytokines such 
as interleukin ( I L ) - l a and I L - i p , EL-2, interferon-y, and inflammatory cytokine tumor necrosis 
factor (TNF) -a (Luger et a l , 1997, 1998; Lipton and Catania, 1998). a - M S H is also found to 
produce by macrophages, monocytes, and mast cells. Elevated levels of a - M S H were also 
reported to be present in plasma from HIV infected patients and patients with sepsis (Airaghi et 
al., 1999; Catania et al., 2000). Melanocortin peptides significantly inhibit the release of both NO 
and T N P - a into cell-free supernatants from microglia cells. Melanocytes, keratinocytes, several 
other cutaneous cell and inflammatory cell types express the M C I R . The M C 1 R has received the 
most attention as the mediator of the effect of a - M S H on inflammatory processes. Recently it 
was found that not only a - M S H but also its shorter fragments ( a - M S H 1-10 and a - M S H 11-13) 
might considerably suppress NF-kB production in macrophage cell line expressing M C I R , when 
they are exposed to inflammatory agents such as LPS and interferon-y (Mandrika et al., 2001). y-
M S H immunoreactive material was demonstrated to be present in human neutrophil granulocytes 
(Johansson et al., 1991). 
2.3.3 Behavioural effects 
Melanocort in peptides induce a large array of behavioural effects which include improvement of 
attention, motor effects, facilitating actions of learning, modification of sexual and feeding 
behaviours (De Wied and Jolles, 1982). There is also evidence that the a - M S H and y-MSH 
peptides have quite disparate and sometimes even opposing actions on the central nervous 
system. In comparison to the quite well studied effects of a - M S H much less is known about the 
functional roles of the y-MSH peptides in CNS and peripheral tissues. Studies on the influence of 
y -MSH peptides on behaviour are one of the main tasks of the present PhD thesis. 
2.3.3.1 Grooming behaviour 
Grooming behaviour of mammals, such as rats, rabbits or cats, is a pattern of characteristic 
movements with readily definable components consisting of activities directed to the animal 's 
body surface, such as face washing, body grooming, licking, scratching and genital grooming. 
Novel environment is well known to induce excessive grooming behaviour in small mammals 
and birds. MSH and ACTH peptides can induce excessive grooming in the rat. Excessive 
grooming could be elicited by icv injections of a - M S H , synthetic M C R agonists Melanotan-II 
and N D P - M S H (Adan et al.. 1999) and also by y i -MSH (see results). The grooming responses of 
a - M S H and A C T H ( l - 2 4 ) were blocked by melanocortin receptor blockers HS014 and SHU9119 
(Schioth, 2000). There is evidence that the effects are mediated by the activation of MC4R 
subtype (Vergoni et al., 1998). a - M S H and ACTH injected directly into the V T A 
paraventricular nucleus of the hypothalamus, dorsomedial nucleus of the hypothalamus and 
anterior hypothalamus induce grooming behavior (Argiolas et al., 2000). M C R blockers can 
attenuate the effects of the melanocortic peptides. 
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2.3.3.2 Sexual behaviour 
ACTH and MSH peptides are known to effect sexual behaviour in both male and female rats. In 
male rats, rabbits and cats icv injections of A C T H ( l - 2 4 ) or a - M S H may elicit elements of 
copulatory behaviour such as erection, ejaculation, sexual postering and genital licking, even in 
the absence of a female partner (De Wied and Jolles, 1982). Both A C T H ( l - 2 4 ) and a - M S H 
induced similar increases in erection frequencies when injected directly into paraventricular 
nucleus of the hypothalamus (Argiolas et al., 2000). The three major kinds of neural autonomic 
control of erection are stimulatory adrenergic, inhibitory cholinergic and inhibitory mediated by 
nitric oxide (Argiolas, 1999). Peripheral administration of a - M S H or A C T H does not seem to 
induce erection. The synthetic M C R agonist Melanotan-II induced a marked increase in erection 
frequency in double-blind study in men with erectile dysfunction (Wessells et al., 1998). MC4R 
antagonist HS014 only marginally blocked the frequency of penile erections induced by a - M S H 
(Vergoni et al., 1998). It is thus apparent that the molecular mechanisms eliciting the changes in 
sexual behaviour by M S H and A C T H peptides are distinctly different from those eliciting the 
grooming behaviour. Today, it is not clear which receptor mediates the effects of melanocortins 
on erection, nor is it well established how this effect interacts with other central regulators (such 
as dopamine, serotonin, acetylcholine, nitric oxide, oxytocin and opioid peptides). 
2.3.3.3 Feeding behaviour 
Complex machinery is known to regulate feeding behaviour. Peripheral input to the central 
feeding systems is mediated by leptin, a hormone produced in the adipocytes. Inside the brain 
leptin may upregulate the a - M S H and downregulate the neuropeptide Y/agouti related peptide 
(AGRP). Within the central nervous system various regulatory factors are involved, which 
include neuropeptide Y, corticotropin-releasing hormone, galanin, orexin, catecholamine-
regulated transcript, melanin-concentrating hormone and monoamines. A role for melanocortins 
in the central control of appetite was described as early as the 1980 t h (Vergoni et al., 1986). The 
central melanocortin system effects on feeding seem to be mediated by the actions of a - M S H 
and AGRP on M C 4 R in hypothalamic areas and other regions of the CNS, such as in the 
brainstem. The reduction of food intake was still seen after 4 weeks of administration of a - M S H 
(Lim et al., 2000). Inactivation of the MC4R gene in mice results in marked increase in body 
weight and length (Huszar et al., 1997). The central administration of a - M S H , A C T H ( l - 2 4 ) and 
Melanotan-II induces anorexia, while the non-selective M C 4 receptor antagonist SHU9119, and 
the M C 4 receptor-selective antagonist HS014 induced marked orexigenic effects (Kask et al., 
1998). The anorectic effect of Melanotan-II is blocked by SHU9119, as well as the anorectic 
effect of a - M S H is blocked by HS014 (Vergoni et al., 1998). The relatively MC4-receptor-
selective agonist (3-MSH inhibits dose-dependently fasting-induced food intake, whereas the 
relatively M C 3 R selective agonist y i -MSH fails this effect. (Kask et al., 2000). Thus, there exists 
very strong support for the role of the MC4 receptor in regulation of feeding behaviour. 
2.3.4 Cardiovascular effects 
Melanocort ins have been described as having a variety of cardiovascular effects. a - M S H and 
ACTH are effective in prohibiting death in anesthetized rats in a volume-controlled model of 
hemorrhagic shock and during conditions of prolonged respiratory arrest (Ludbrook and 
Ventura, 1995). Studies on the mechanism of this anti-shock effect suggest that melanocortins 
inhibit the overproduction of T N F - a and nitric oxide seen in shock (Guarini et al., 1997). 
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HS014, a selective M C 4 R antagonist is able to block the reversal to shock induced by A C T H ( 1 -
24) after both icv and iv administration in rats (Guarini et al., 1999). 
Moreover, y -MSH peptides, which have a preference for the MC3R, produced no effect. 
Injection of a - M S H into the dorsal vagal complex of the medulla oblongata o f the rat elicited 
hypotensive and bradycardic effects that were blocked by the M C R antagonist SHU9119 (Li et 
al., 1996). However, the icv administration of a - M S H or ACTH leads to the increase in mean 
arterial pressure, concomitant with increase in the lumbar sympathetic nerve activity. The effect 
of a - M S H or A C T H was blocked by icv administration of the natural M C 4 R antagonist agouti 
signaling protein (ASIP) (Dunbar and LU, 1999). Intracerebroventricular injection of y-MSH 
produced prolonged pressor effects that could not be blocked by melanocortin receptor 
antagonist SHU9119. y i -MSH and y 2 - M S H peptides induce a dose-dependent, short-lasting 
increase in blood pressure, heart rate, and pulse amplitude following iv administration in 
normotensive and normovolemic rats. ACTH (1-24), a - M S H and y ^ M S H that are lacking Arg-
Phe sequence in the C-terminal, were to be found either inactive or much less active (Van 
Bergen et al., 1995, 1997). In generally, the regulation of cardiovascular system by melanocortic 
peptides is mediated by both melanocortin receptor and non-melanocortin receptor mediated 
mechanisms. 
2.3.5 Other functions of melanocortins 
Melanocortin peptides are reported to antagonize opiate dependence and tolerance and to induce 
opioid withdrawal effects (Szekely et al., 1979; Contreras et al., 1984). It was speculated that the 
antagonism of opiate self-administration, analgesic tolerance, and physical dependence caused 
by melanocortins could be mediated through the M C 4 R (Alvaro et al., 1997). Melanocortins ( a -
MSH) are known to improve axonal regeneration following peripheral nerve injury and stimulate 
neurite outgrowth from CNS neurons both in vitro and in vivo. 
Rat spinal cord, dorsal root ganglia, sciatic nerve, and soleus muscle were analyzed for the 
expression of the MC3R, MC4R, MC5R and P O M C . The only M C R found by RNAse protection 
assays was the M C 4 R in the lumbar spinal cord, indicating a possible role in neuroregeneration 
for the MC4R (Van der Kraan et al., 1999). Administration of a - M S H either centrally or 
peripherally inhibits fever induced by endotoxins (lipopolysaccharides), IL-1 , IL-6 or TNF-
a (Lipton and Catania, 1998). a - M S H also decreases ischemia/reperfusion injury after ischemia 
and inhibits both neutrophil accumulation and nitric oxide production. a - M S H decreases renal 
injury when neutrophil effects are minimal or absent, indicating that a - M S H inhibits neutrophil-
independent pathways of renal injury (Chiao et al., 1998). There is evidence that a - M S H 
increases release of luteinizing hormone (LH) in female but not in male rats (Limone, 1997). The 
physiological effects of the melanocortins are summarized in the Table 5. 
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Table 5. Effects of the melanotropins on the pituitary gland and various peripheral organs 
(Eberle, 1988) 
Peptide Target organ Effect 
a - M S H skin stimulates melanogenesis 
a - M S H adenohypophysis inhibits prolactin release 
modulates L H release 
stimulates h G H release 
a - M S H , 
p -LPH 
sebaceous glands stimulate sebum secretion 
a - M S H , 
p - M S H 
adipocytes (rabbit) stimulate lipolysis 
a - M S H , 
p - M S H 
ys-MSH 
adrenal cortex stimulate aldosterone secretion 
modulate ACTH effects 
a - M S H immune system inhibits IL-1 induced host-defence 
reactions (anti-inflammatory 
properties) 
a - M S H , 
y-MSH 
heart 
vessels 
increase heart rate 
increase blood pressure 
a - M S H , 
Y2-MSH 
kidneys increase natriuresis 
a - M S H eye stimulate permeability changes 
2.4 Synthetic M C R agonists and antagonists 
The important issues for the clarification of the functional roles of melanocortins in CNS and 
periphery will be the development of the selective agonists and antagonists on the five 
melanocortin receptors and evaluate the pharmacology, pharmacokinetics and toxicology of 
these compounds. Already in the past, quite large number of linear or cyclic M S H peptide 
analogues were designed and screened. Early seeking of new ligands was based mainly on their 
ability to cause the effects on skin darkening in amphibians or lizards. N o w most of these 
peptides have only historical interest however a few are still useful for studying the 
pharmacology of the five melanocortin receptor subtypes. There is intensive search for the new 
highly active M C R ligands. 
2.4.1 Agonists 
Linear peptide N D P - M S H ( [Nle 4 -D-Phe 7 ] a -MSH; Melanotan-I) is one the most useful synthetic 
agonists from the early studies (Table 6.). NDP-MSH shows high binding affinity for the all of 
MC receptors (Table 7 ) . Therefore NDP-MSH has been widely used in its radio-iodinated form 
for radioligand binding studies (Schioth et al., 1995). 
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Table 6. Al ignments of structures of useful ligands for melanocortin receptors 
(Schioth, 2001; Wikberg, 2001). 
Peptide Structures of ligands 
N D P - M S H Ac-Ser-Tyr-Ser-Nle-Glu-His-D-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH 2 
MTII Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lvs-NH? 
M S 0 5 Ser-Ser-Ile-Ile-Ser-His- L-Phe-Arg-L-Trp-Gly-Lys-Pro-Val- N H 2 
M S 0 9 Ser-Ser-Ile-Ile-Ser-His- D-Phe-Arg- L-Trp-Gly-Lys-Pro-Val- N H 2 
R 0 2 7 - 3 3 2 5 Buturyl-His-Phe-Arg-Trp-N-methyl glycine- N H 2 
HS131 (cyclo (S-S) -Ac-L-Cys 5 -Gly 6 -D-Nal 7 -L-Cys-NH 2 1 0 ) a - M S H 5 " 1 0 trifluoroacetate 
HS014 Ac-Cvs-Glu-His-D-Nal-Arg-L-Trp-Glv-Cvs-Pro-Pro-Lvs-Asp- N H 2 
SHU9119 Ac-Nle-Asp-His-D-Nal-Arg-Trp-Lvs-NH? 
HS024 Ac-Cvs-Nle-Are-His-D-Nal-Aj-g-Trp-Glv-Cvs-NH, 
HS028 A c - Cvs-Glu-His-dCl-D-Phe-Arg-Trp-Glv-Cvs-Pro-Pro-Lvs-Asp-NH 2 
Note. The amino acid residues which make up the ring closure in the cyclic compounds are shown underlined. Nle, 
norleucine; D-Nal. p-(-2-riaphmyl)-D-aiaiune: dCl-D-Phe. 3,4-dichloro-D-phenylalanine; D-Phe, D-phenylalanine; L-
Phe, L- phenylalanine. 
In 90 of the last century a series of 23 cyclic lactam peptides was claimed, all o f which were 
designed around a variant of the critical four amino acid pharmacophore (His-Phe-Arg-Trp) in 
M S H in which the L-Phe has been replaces by D-Phe. One o f this peptide that has been applied 
quite widely in assessment of t he physiological effects of the melanocortins is the metabolically 
stable M S H lactam analogue Melanotan-II (Hadley et al., 1989). The binding profile of 
Melanotan-II indicates that it is a fairly non-selective agonistic peptide at all the M S H binding 
M C R (Wikberg et al., 2000). Melanotan-II w a s used for stimulation of sexual responses and 
melanin synthesis in mammals . Central administration of Melanotan-II in rats inhibits food 
intake, this effect has believed to be exerted by stimulation of M C 4 R (Fan et al., 1997). 
Clinically, Melanotan-II has been evaluated for treatment of psychogenic erectile dysfunction 
(Wikberg et al, 2000) . M o r e recently a highly active and full selective M C I R agonist MS05 was 
synthesized. Another close analogue to MS05 is MS09 that is a more potent agonist than MS05 
on the M C I R , al though it is less selective compared to M S 0 5 (see Table 6). Both MS05 and 
M S 0 9 have shown to inhibit the production of the inflammatory mediator nitric oxide in 
macrophage cells (Szardenings et a l , 2000). T h e use of the MS05 and M S 0 9 may be considered 
as potential anti-inflammatory agents. Recently, were synthesized an interesting new MC4R 
agonistic peptide R027-3325 (Benoit et al., 2000). However, the R027-3325 showed low 
affinity for the human M C 4 R (Wikberg et al., 2000). The synthetic MCR agonist and antagonist 
used in different tests are shown in Table 7. 
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Table 7. Binding affinity (K t ) of synthetic peptides for human melanocortin M C I , M C 3 , MC4 
and M C 5 receptors (Wikberg et al., 2000) 
M C I R M C 3 R M C 4 R M C 5 R 
A g o n i s t s 
NDP-MSH 0.085 0.40 3.8 5.1 
Melanotan-II 0.67 34 6.6 46 
MS05 0.87 1100 >100 000 >100 000 
MS09 0.16 6.5 46 270 
R027-3325 33 000 340 000 250 000 >300 000 
A n t a g o n i s t s 
SHU9119 0.71 1.2 0.36 1.1 
HS014 110 54 3.2 690 
HS024 19 5.5 0.29 3.3 
2.4.2 Antagonists 
Various melanocortin receptor antagonistic peptides have also been developed. One of the first 
antagonists synthesized was a cyclic peptide, SHU9119, a full antagonist for the M C 3 R and 
M C 4 R and a partial agonist for the M C I R and MC5R. However, SHU9119 is not selective for 
any of these receptors and is likely to have a pronounced effect on all four M C R when injected 
into experimental animals. Thus the usefulness of SHU9119 as an experimental tool for M C -
receptor subtype classification seems to be limited. Further development of cyclic peptides leads 
to the discovery of the first selective MC4R antagonist HS014 (Schioth et al., 1998b). However 
HS014 similarly to SHTJ9119 is a partial agonist of M C I R and MC5R, it shows also antagonistic 
properties towards MC3R. Both, SHU9119 and HS014 have been found to increase food intake 
and body weight on their central administration to rats (Kask et al., 1999). Also M C 4 R blocker 
HS014 is capable of completely attenuating the loss of body weight induced by leptin in animals 
Other cyclic M S H peptide analogue HS024 shows about 10-fold more potent antagonism on the 
M C 4 R compared to HS014 (see Table 6). Unfortunately, HS024 appears to be antagonistic on all 
the MSH-binding MCRs . The HS024 causes a dose dependent increase in food intake in free 
feeding rats after its icv administration (Kask et al., 1998). Recently efforts have been made in 
search for non-peptide M C R agonist and antagonists. Intriguingly, a 1,4-dihydropiridine 
compound cerebrocrast showed highly selective affinity to MC4R (Jansone et al., in press) 
indicating that structure of this compound may conform M C 4 R optimally. 
Newly synthesized M C R ligands mostly serve for experimental studies as model-analogues of 
MSH peptides. In 2002-2003 have been designed and synthesized several highly selective 
agonists and antagonists for the M C 3 R and MC4R. Unfortunately, these compounds are not yet 
commercially available. Highly melanocortin-receptor-subtype-selective agonists and 
antagonists are needed to for better understand the mechanisms underlying the various effects of 
the melanocortins and the roles of the melanocortin receptors in the mediation of these effects. 
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3 . AIM A N D TASK S O F T H E STUDY 
T o study behavioural and neurochemical repertoire of natural melanocortins y i -MSH 
and y 2 -MSH, and at least in par t to clarify their functional role in the central nervous 
system. 
T A S K S 
1. To perform studies o f y-MSH peptides in comparison to reference peptide a - M S H 
in behavioural tests (rats and mice) and microdialysis experiments (rats) by peptide 
intra-VTA, ICV and intracisternal administration. 
2 . To study influence o f melanocortin receptor subtype 4 (MC4R) antagonists HS014, 
HS964 and HS131 on MSH-peptide induced central effects. 
3 . To examine central mechanisms o f a - M S H , y i -MSH and y 2 -MSH induced effects 
by use of different neurotransmitter receptor (dopamine, GABA, glutamate, opiate) 
agonists and antagonists as test-drugs. 
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4. M A T E R I A L A N D M E T H O D S 
The methods used have been described in details in the respective papers (I-VII). 
4.1 Animals 
Adult male Wistar rats (Breeding Facility of the Joint Stock Company GRINDEX, 
Riga, Latvia) and male Sprague-Dawley rats (Beco, Sweden) weighing 270-350g 
were used in the experiments (papers I, II and IV,VII). In analgesia experiments 
BALB/c male mice 20±2g were obtained from the Institute of Microbiology and 
Virusology, University of Latvia, Riga, Latvia (paper V) . In the study of assessment 
of locomotor activity, BALB/c male mice 19±lg came from the Breeding Facility of 
the Joint Stock Company GRINDEX, Riga, Latvia (paper III). The animals were 
housed in groups of 4 (rats) and 8 (mice) under standard laboratory conditions: 
temperature 21±1°C, relative humidity of 55±10% and artificial 12h dark-light cycle 
(lights on 07.00-19.00). Free access to standard rat or mice diet and tap water was 
available at all t imes. Experimental sessions were conducted between 09.00-14.00. 
Each experimental group consisted of 4-10 rats and 7-9 mice. The experimental set-
ups were approved by the local Ethics Committees on Laboratory Animal Use of 
Latvia and/or Sweden 
4.2 Drugs 
Y2-MSH peptide was purchased from B A C H E M , Switzerland. The HS964, H S 1 3 1 , 
HS014 (structures for synthetic peptides see in chapter 2.10.), a - M S H and y i -MSH 
were synthesized in the Department of Pharmaceutical Pharmacology, Uppsala 
University, Uppsala, Sweden. Synthesis of the peptides was done by using the solid 
phase approach applying a Fmoc-based Pioneer peptide synthesis system (PerSeptive 
Biosystems) and purified by HPLC. The correct molecular weights of the peptides 
were confirmed by mass spectrometry. The peptides were dissolved in water and 
stored frozen in aliquots until used. Prior to the experiments aliquots with peptides 
were unfrozen and dissolved until appropriate dose in sterile artificial cerebrospinal 
fluid (CSF) or saline. a - M S H was used as a reference peptide. 
Dopamine (DA) and 3,4-dihydroxyphenylacetic acid (DOPAC) were obtained from 
Sigma Chemicals (St Louise, USA). Stock solutions were made in sterile water and 
stored until use. Before experiments, the stock solutions were unfrozen and diluted 
until needed concentrations with artificial CSF, of the following composition: 8.65g/l 
NaCl; 201.31mg/l KC1; 176.42mg/l CaCl 2 ; 172.81mg/l M g C l 2 in sterile water 
(Apoteket, Produktion&Laboratorium, Umea, Sweden). Phencyclidine (PCP), L-
amphetamine (AMP), naloxone hydrochloride, bicuculline were purchased from 
Sigma Chemicals (St Louise, USA). Haloperidol (0 .5% solution) and diazepam ( 5 % 
solution) were from Gedeon Richter, Hungary. Muscimol was obtained from Fluka 
AG, Switzerland. 
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4.3 Behavioural studies ( I , 11, 111) 
4.3.1 In rats 
4.3.1.1 Intraventricular (ICV) and ventral tegmental area (VTA) cannulation and 
drug infusions ( I, II) 
Guide cannulas made from stainless steel syringes (15mm long, 0 .56mm OD) were 
slowly implanted stereotaxically under Nembutal ( C E V A Sanofi, France) anesthesia 
(60mg/kg i.p.) into t h e left V T A or left lateral ventricle (ICV) at the following co-
ordinates: -5.2mm caudal to bregma, 0.8mm lateral from midline, and - 8 . 0 m m ventral 
from dura mater or -1 .5mm, 1 .Omm, and - 3 . 6 m m , respectively (Paxinos and Watson, 
1982). The guide cannula w a s implanted 2 m m over the V T A for later insertion of a 
microinjection needle and kep t in place with dental cement (De Trey, Sevriton, 
Germany) and covered with duracryl ( S P O F A Dental, Czech Republic). To prevent 
c logging of the guide cannulas, a bent stylet of stainless steel was inserted into them, 
and removed only w h e n the injections took place. After implantation of intra-VTA or 
ICV cannulas animals were kept in individual cages for the following seven days in a 
recovery room. a - M S H , HS964, HS014, y ^ M S H or y 2 -MSH was given at the doses 
o f 0.3 and 3 n m o l in volume of 0.5u,l per rat . The control animal group received CSF 
in volume of 0.5pi p e r rat. F o r the combined treatments, HS964, HS014 , y 2 - M S H or 
saline (control group) were administrated 15min prior t o the a - M S H or yi-MSH. 
Drugs were injected manually into V T A or ICV via the guide cannula using a 75RN 
Hamil ton Microliter syringe (Hamilton-Bonadaz AG, Schwitzerland) and a very fine 
polyethylene tube (PE-10, Clay Adams, Sweden) attached to a 30-gauge 
microinjection needle that extended 1.2mm deeper than t h e guide cannula. The total 
volume injected for each substance was 0 .5 or \ \ \ \ and the speed of injection was 
0.25ul/min. T h e microinjection needle was left in place after injection for 5 min to 
limit d r u g efflux up t h e cannula shaft. 
4.3.1.2 Analysis of behavioural responses (I, II) 
The d a y before behavioural experiment, male Wistar rats (300-350g) and male 
Sprague-Dawley rats (270-3 40g) were transported to an observation room for 1 day of 
handling and habituating. O n the next day when experiments started, each ra t was 
placed for 30 min in to a Plexiglas observation cage (60x40x15cm 2 ) for adaptation to 
the novel environment . Registration of behavioural responses started o n the 5 t h min 
after t h e injection o f MSH peptide into V T A or IVC and continues for an hour for 
time-response studies by using a Psion Workabout microcomputer (Noldus, the 
Netherlands). Grooming behavior w a s expressed in seconds as the sum o f the separate 
grooming reactions, i.e. total grooming (face washing, body licking, scratching, ano-
genital grooming, head shakes and wet-dog shakes). T h e data were expressed in 
figures as four observation periods, like 0-15min, 16-30min, 31-45 min and 46-60min 
periods (paper II) o r summed as 0-15min, 0-30min, 0-45min and 0-60min periods 
(paper I). T h e following non-grooming behaviour events were registered: vertical 
activity (VA), horizontal activity (HA) and catalepsy V A and HA w e r e scored as 
incidences during t h e total observation period. Catalepsy w a s evaluated at the 
beginning and at the end o f experiment in three consecutive tests for max imum 10s 
each: (1) by placing the rat with i ts forepaws on a 7cm high bar, (2) placing the rat 
with t h e hind legs o n the s ame bar, and b y (3) placing the rat across two 7cm high 
bars distanced at 15 cm (Kobayashi et al., 1997). 
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Each of the catalepsy tests were given a weighting coefficient, respectively, 0.2, 0.3 
and 0.5 and the total catalepsy was scored as total t ime the animal spent in the 
separate tests multiplied by its corresponding coefficient (Sanberg et al., 1988). 
4.3.1.3 NMDA-toxicity test (unpublished data) 
Male Wistar rats (270-350g) received y 2 - M S H (at the dose of 0.3 nmol/0.5pl; intra-
V T A ) 5 min prior the injection of N M D A (10ug/0.5ul; intra-VTA). The dose of 
N M D A was appropriate for inducing tonic seizures. Rats of control group received 
intra-VTA injections of saline and NMDA. Following behaviour responses were 
observed: horizontal activity, vertical activity, ipsilateral and contralateral rotations. 
4.3.2 In mice 
4.3.2.1 Locomotor activity tests in mice ( HI) 
Locomotor activity tests were performed in BALB/c male mice (19-21g) after 
intracisternal (i.e.) injection of yi-MSH, y 2 - M S H or M C 4 receptor antagonist HS014 
at the dose of 0.3 nmol/mouse in a volume of 10u l Peptides were dissolved in saline. 
Phencyclidine (PCP) 5mg/kg intraperi toneal^ and L-amphetamine (AMP) 5mg/kg 
subcutaneously were administered 5min prior to peptide injections. Mice of control 
groups received saline i.e. in the volume of lOul/mouse. For the assessment of the 
locomotor activity, the mice were placed in the Activity Cage (Ugo Basile, Cat.7400, 
Italy). Locomotor activity was registered from the 3 0 t h to 6 0 t h min after PCP or AMP 
administration. 
4.3.2.2 Analgesia tail flick test (V) 
a - M S H , y , -MSH, y 2 -MSH and HS014 (all at the doses 0.3, 1 and 3 nmol/ lOu.1) were 
injected i.e. into the cisterna magna in conscious BALB/c male mice via a J-shape 
needle connected to a Hamilton syringe, as previously described by Takagi et al 
(1979). Naloxone hydrochloride (2 mg/kg), bicuculline (0.5 mg/kg), haloperidol (0.5 
un 1 mg/kg; 0 .5% solution), diazepam (10 mg/kg; 5 % solution), muscimol (1 mg/kg) 
and ethanol ( 1 0 % ethanol in water) were used as test-drugs and injected 
intraperitonelly in mice prior to i.e. injections of melanocortins. The tail flick test was 
a slightly modified version of that previously described by Dewey (1981). 
The tail of the mouse was placed on the photoelement window of a M O D E L DS20 
SOCREL tail flick apparatus (Ugo Basile, Italy) and an infrared beam was focused on 
the tail area 2cm from its basis. The latency for the mouse to react to the pain stimuli 
was recorded. Maximal exposure to the pain stimuli was to 15s. The tail flick latency 
test was performed at 30min, 60min, 90min, 90min, 2h, 3h and 24h after the 
following injections of melanocortins or test-drugs. 
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4.4 Neurochemical experiments - brain microdialysis in anaesthetized rats (IV, 
VII) 
4.4.1 Surgery procedure 
Microdialysis is an in vivo sampling technique, in which a hollow semi-permeable 
membrane is inserted into a particular brain area in the experimental animal and 
perfused with saline. For acute experiments, the rats were anaesthetized with inactin 
(80mg/kg, i.p.) and positioned in a Kopf stereotaxic frame (David Kopf Instruments, 
CA, USA) . The body temperature of the rats was kept at 37C° using a body HB 101/2 
temperature control unit (Letica, Scientific Instruments, Barcelona, Spain). A 
microdialysis probe (MAB, A g n Tho ' s AB, Lidingo, Sweden) was slowly implanted 
in the left nucleus accumbens (coordinates from bregma. B+2.2, L-1.5, V-7 .1 ; 
Paxinos and Watson, 1982) and used to collect extracellular dopamine (DA) and its 
metaboli te DOPAC. The outer diameter of the microdialysis probe was 0.6mm, the 
length 2mm and it had a 15 000 Daltons 's cutoff P E S (Polyethen Sulphone) 
membrane . T h e probe was constantly perfused with artificial cerebrospinal fluid 
(CSF; Apoteket , Produktion & Laboratorium, Umea, Sweden) at a flow rate 2ul/min 
(infusion pump, Univentor 684 Syringe pump, Bulebel Industrial Estate, Malta). Two 
hours after the implantation o f the probe, dialysates were collected every 20 min from 
the outlet line in the Microsampler (Univentor 810 Microsampler, Bulebel Industrial 
Estate, Malta) into polyethylene microcentrifuge tubes and analyzed immediately by 
high-performance liquid chromatography wi th electrochemical detection (see below). 
Three basal samples were collected with less than 15% variation of the D A and 
D O P A C levels before drug administration started. Figure 6. illustrates the 
experimental set-up of the brain microdialysis. 
Fig.6. Brain microdialysis: schematic illustration of the experimental set-up. (1) 
Microdialysis pump; (2) syringe selector; (3) body temperature support; (4) 
microdialysis collector; (5) temperature controller (6) stereotaxic holder with a 
microdialysis probe implanted into a rat brain: (a) inlet tubing; (b) microdialysis 
holder (c) outlet tubing. 
31 
The guide cannula was implanted into the left V T A (coordinates from bregma: B-
5.0mm, L-0.9mm, V-7.2mm; Paxinos and Watson, 1982) as was described above in 
section 4.3.1 (VTA cannulation) for later administration of a - M S H , y i -MSH, Y2-MSH 
and HS131 at the doses of 10, 3, 3 and 1 nmol/0.5ul per rat, respectively. For the 
combined treatments, Y2-MSH or HS131 were administered 40min prior to the 
injections of y i -MSH or a - M S H , respectively. Control animals receive CSF into the 
VTA. 
4.4.2 Estimation of extracellular concentration of dopamine and D O P A C using 
high-performance liquid chromatography (HPLC) 
Neurotransmitter D A and its metabolite D O P A C in collected brain nucleus 
accumbens dialysate were determined using H P L C technique with electrochemical 
detection (Gamache et al., 1993). For the separation of biogenic amines each 40p,l 
sample of dialysate was injected onto a reversed-phase column (ReproSil-Pur C-18-
A Q 150x3mm, particle size 5p.m) using a Rheodyne injection valve equipped with a 
100ml loop. Coulometric-electrochemical detection system (ESA Inc, Chelmsford, 
M A , USA) utilizing two electrodes were used to oxidize the amines. Preinjection part 
guard electrode voltage was +0.4V (ESA, Guard Cell Model 5020) and the working 
electrode voltage was +0.34V ( E S A Analytical cell Model 5011). The recycled 
mobile phase consisted of a mixture of 2g/l C F L C O O N a ^ ^ O , 38.75mg 1-
octanesulfonic acid, 3.7mg E D T A and 100ml/l methanol at pH 4. The flow rate of the 
H P L C pump (LKB 2150 HPLC pump, Bromma, Sweden) was 0.6ml/min. 
Chromatograms were recorded using a M E G A series integrator (Carlo E R B A 
Strumentazione, USA). The limit of detection was 0.4nM for both DA and DOPAC. 
4.4 .3 Histological examination (TV, VH) 
The histological examination was performed at the end of microdialysis experiments 
to convince the correct positioning of the microdialysis probe in the nucleus 
accumbens and guide cannula directly above the V T A Rats were decapitated and the 
brains were removed, frozen in cold (between - 2 0 ° and - 3 0 ° ) 2-methylbutane. The 
frozen brains were mounted on a cryostat microtome (MJ.CROM H M 500 OMV, 
Laborgerate G m b H Walldorf, Germany) and sectioned (35pm). 
The sections were mounted on gelatin coated glass slides and stained with Mayer 
hematoxyll ine (Histolab Products AB, Sweden). The stained sections were digitized 
in a video camera (CCD-72, Dage-MTI, Michigan City, IN, USA) and the placement 
of microdialysis probe and the guide cannula were verified using NTH-Image software 
(NTH Image 1.54, NIMH, Bethesda, M D ) and the brain atlas of Paxinos and Watson 
(Fig.7). Only animals with a correctly implanted probe and cannula were further 
included in the statistic analysis. 
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Fig.7. The rat brain sections showing the position of the t ips of the microdialysis 
probe in t he nucleus accumbens [a] and the guide cannula into the V T A [b] (the atlas 
of Paxinos and Watson, 1982). 
4.5 Statistical analysis 
Data for t he behavioral and analgesia studies (I, II, V) were analyzed by one-way 
AN OVA followed by the Bonferroni 's multiple comparison or Newman-Keuls tests 
as a post hoc. Results a re expressed as the m e a n ±SEM. Statistics o f the locomotor 
activity da ta (III) was calculated as mean values +SEM and significance w a s 
evaluated by A N O V A followed by Student 's t test. In the microdialysis studies (IV, 
VII) the average concentration of three baseline samples w a s considered as control 
values and expressed as 100%. The statistical evaluation of microdialysis data (VII) 
was carried out using one-way A N O V A followed by the Newman-Keuls multiple 
comparison test and paired / test . Data were analyzed using the statistical program 
Prism 3.0 (graph Pad). Inter-group comparisons (VI) were made with a factorial 
A N O V A test followed b y Fisher 's PLSD test where appropriate. Then statistics were 
performed using the Stat View 4.51 software for Macintosh. P-values equal and lower 
than 0.05 were considered to be significant. 
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5. RESULTS 
5.1 Behavioural effects of centrally administered melanocortins and their analogues in rats 
(LII) 
5.1.1 Effects of a-MSH, yi-MSH and y 2 -MSH (If) 
Peptides were administered intra-VTA and/or intracerebroventricularly (ICV) and tested in the 
open field test in rats. First of all we found the optimal dose of peptides. a -MSH Yi-MSH Y2-
MSH were administrated into the VTA at the doses 0.3 and 3 nmol. Total grooming and vertical 
activity were estimated for 15 minutes in the open field. At the smaller dose only a-MSH 
showed significant grooming activity in rats. So, the higher dose showed the more pronounced 
effects than 0.3 nmol. Thus, for studies of time-dependent effects the dose of 3nmol was chosen 
and total grooming (Fig. 8) and vertical activity (Fig. 9) were observed. Data with a dose of 
0.3nmol are not presented in figures. Figures 8, 9 and 10 represent the data four consecutive 15 
min observation intervals, 0-15min, 16-30min, 31-45min and 46-60rnin. 
Both a-MSH and yi-MSH at the dose of 3 nmol caused significant and marked increase in total 
grooming at the first 15 minutes and it lasted throughout the 1 -h observation period (Fig.8). 
By contrast, neither 0.3 nor 3 nmol of y 2-MSH affected the total grooming behavior in rats 
compared with the saline control (Fig 8). 
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• Saline 
• a-MSH 
• yi-MSH 
• Y2-MSH 
0-15min 16-30min 31^5min 46-60min 
Fig.8. The influence of a -MSH Yi-MSH and y 2-MSH (each peptide of 3 nmol/0.5pl into the rat 
left VTA) on grooming responses during 1 h after injections. n=8. 
*p< 0.05 vs saline control. 
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With respect to the vertical activity the MSH peptides show the same considerable difference: 
Yi-MSH (0.3 and 3 nmol) and a-MSH (3 nmol) increased the vertical activity, but only during 
the first 15 minutes period. However none of doses of Y2-MSH influenced vertical activity at any 
of the time periods studied (Fig.9). 
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Fig.9. The influence of a-MSH, yi-MSH and y 2-MSH (each peptide of 3 nmol/0.5ul into the rat 
left VTA) on vertical activity during 1 h after injections. n=8 
* p< 0.05 vs saline control. 
5.1.2 Effects of combined administration of yrMSH and yi-MSH 
In order to assess the behavioural effect o f combined administration of yi-MSH and y 2-MSH, the 
rats were pre-treated with either saline or y 2-MSH at the dose of 3 nmol 15 min prior to intra-
VTA administration of yi-MSH at the dose of 3 nmol. The yi-MSH given to the saline-pre-
treated rats caused a significant increase in vertical activity and total grooming in rats during 1 h 
observation. Pretreatment with y 2-MSH significantiy attenuated the yj-MSH induced groorning 
behaviour (Fig. 10) and vertical activity in rats (not shown in figure) during lh observation. 
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F i g 10. Effect of pre-treatment with y 2-MSH or saline on the effect of yi-MSH (both peptides of 
3 nmol/0.5ul into the rat left VTA) on grooming responses during 1 h after injections. n=8. 
*p< 0.05 vs saline control, °p< 0.05 vs saline+yi-MSH. 
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After 15 min and lh following injection the animals were tested for catalepsy. In these tests it 
was revealed that only Y2-MSH at both doses (0.3 and 3 nmol) caused catalepsy, whereas a-MSH 
and yi-MSH lacked this effect. After 15min following Y2-MSH administration the catalepsy was 
4-5 scores from the maximum 10 and after an hour - 4.9 scores. The animals that received the 
combined treatment (Y2-MSH+71-MSH) showed 3.1 score catalepsy. 
5 .13 Effects of MC4R antagonists HS964 and HS014 and their influence on a-MSH (I) 
The aim of the study was to obtain behavioural effects (grooming horizontal and vertical 
activity) induced by MC4R antagonists HS964 and HS014 administered either intra-VTA or ICV 
in rats. a-MSH was used as a reference substance. The results show that a-MSH caused 
considerable and significant (vs saline control) grooming activity already after 15 min following 
both intra-VTA and ICV injections (Fig 11). (jtooming activity was sustained for 60 min in a 
slightly gradually increasing manner. 
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Fig 11. Effect of a -MSH HS964, HS014 or pre-treatment with HS014 or saline on the effect of 
a-MSH (all peptides at the dose of 3 nmol/0.5ul) administered into the VTA or ICV on 
grooming responses in male rats. n=6-10. 
*p< 0.05 vs saline control, + p< 0.05 vs saline+a-MSH. 
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Intriguingly, that also HS964 and HS014 caused an increase in grooming activity after both ICV 
and intra-VTA administration. Both HS964 and HS014 administered into the VTA induced small 
increase of the grooming activity that contrasted with intensive grooming behaviour caused by 
the injection of a-MSH. Intracerebroventricular injection of HS014 but not HS964 induced more 
pronounced grooming behaviour in rats than its intra-VTA administration. This high grooming 
activity was sirrular to degree caused by the ICV injection of a-MSH. HS014 injection bom ICV 
and intra-VTA 15 min prior to the administration of a-MSH blocked grooming behavior in rats 
(Figl 1). This blocking effect is more pronounced after the intra-VTA injection. HS964 did also 
block the a-MSH induced grooming after intra-VTA administration at 15 min time period (data 
not shown in fig.). a-MSH showed the increase in vertical activity only after intra-VTA 
administration, but not after ICV injections (not shown in figure). Intra-VTA administration of 
HS014 elevated the vertical activity in manner comparable to that of a-MSH. Horizontal activity 
was not influenced by a-MSH or HS964. Horizontal activity was slightly increased only after 
ICV injections of HS014 (locomotor activity data not shown in figure). 
52 Influence of Yi-MSH and Y2-MSH on hyperlocomotion induced by psychoactivating 
drugs 
5.2.1 Phencyclidine (PCP) and amphetamine (AMP) hyperlocomotion tests in mice (III) 
PCP dose of 5mg/kg intraperitoneally caused a hyperlocomotion in mice. MSH peptides 
administered intracistemally acted differentially: yi-MSH potentiated the PCP-induced effects, 
whereas y 2-MSH antagonized the PCP effects (Fig. 12). Moreover, pre-treatment with Y2-MSH 
reduced the yi-MSH-induced potentiating influence on PCP. Similar antagonizing effect against 
Yi-MSH+PCP was observed in HS014-pre-treated mice (Fig. 12). 
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Fig.12. Influence of y r M S H and Y2-MSH (each of 0.3 nmol/lOul, i.e.) on the PCP- induced 
hyperlocomotion in BALB/c mice. PCP (5 mg/kg) was administrated intraperitoneally 5 min 
prior to peptide injections. Locomotor activity was registered from 30 t h to 60 t h min after PCP 
administration. n=9. 
* p< 0.05 vs saline, °p< 0.05 vs PCP," p<0.05 vs yi-MSH+ PCP 
Both yi-MSH and y 2-MSH injected intracistemally in BALB/c male mice reduced AMP-induced 
(5mg/kg, subcutaneously, 5min prior to peptide injections) hyperlocomotion (data not shown in 
figure). 
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5.2.2 Influence of Y2-MSH on the NMDA-induced behavior in rats (unpublished data) 
Administration of NMDA (10 ug) into the ventral tegmental area in rats caused dramatic 
changes in behavior: increased locomotor activity and induced rotations (Fig. 13). Intra-VTA 
injection of y 2 -MSH 5 min prior the NMDA completely antagonized the NMDA-caused 
neurotoxic behaviour responses in rats (Fig. 13). 
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I Saline+NMDA (control) 
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F i g 13. Effects of the Y2-MSH (0.3 nmol/0.5 ul, intra-VTA) pre-treatment (5 min prior the 
injection of NMDA) on NMDA (10 ug/0.5 pL intra-VTA) induced locomotor activity. n=4. 
HA, horizontal activity; V A vertical activity; I-Rot, ipsilateral rotations; C-Rot, contralateral 
rotations. 
*p< 0.05 vs saline+NMDA (control group). 
S3 Examination of analgesic effects of melanocortins (V) 
5.3.1 Studies of a-, y i - , y 2 -MSH and HS014 
In these studies a - M S H Yi-MSH Y2-MSH and MC4R antagonist HS014 were injected 
intracisternally in mice. Besides, the effects of different test-drugs (haloperidol, naloxone, 
bicuculline, muscimol, ethanol and diazepam) were used for the determination of mechanisms of 
analgesic action. Test-drugs were injected peripherally. Analgesic effects were estimated as tail-
flick responses. The results obtained shows that i.e. (inrracistemal) injection of y 2 -MSH at the all 
three doses (0.3, 1 and 3 nmol) significantly increased the tail-flick latencies in mice. Analgesic 
effect was stable and lasted until 90min following the injections (Fig. 14). 
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The peak response for y 2-MSH was at 60 min with an approximately 70% increase compared to 
the baseline (Fig. 14). 
Fig. 14. Effects of the Y2-MSH (0.3,1 and 3 nmoL i.e.) on tail flick latencies in BALB/c mice. 
n=7-9. 
*p< 0.05 vs saline. 
Yi-MSH gave a short increase in tail flick latencies at 60-90 min and only at the smaller, 0.3 
nmoL dose (Fig 15). 
• Saline 
• 0.3 nmol 
• 1 nmol 
o 3 nmol 
Baseline 30min 60min 90min 2h 3h 24h 
Fig 15. Effects of the yi-MSH (0.3, 1 and 3 nmol, i.e.) on tail flick latencies in BALB/c mice. 
n=7-9. 
*p< 0.05 vs saline. 
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Completely different picture was showed by the all three doses o f a-MSH that caused at 30min 
hyperalgesia with maximum decrease being about 35% from the baseline level (Fig. 16). 
7 -i -
Baseline 30min 60min 90min 2h 3h 24h 
Fig. 16. Effects of the a-MSH (0.3, 1 and 3 nmoL i.e.) on tail flick latencies in BALB/c mice 
n=7-9. 
*p< 0.05 vs saline. 
H i e MC4R antagonist HS014 injected i.e. at the doses of 0.3, 1 and 3 nmol did not influence the 
tad-flick latencies in analgesia study (data not shown in figure). 
5.3.2 Studies of the influence of the test-drug-pretreatments on Y2-MSH-induced analgesia 
Intracisternal administration of HS014 or yi-MSH (both at the dose of 1 nmol) 30 min prior to 
the injection of 1 nmol o f Y2-MSH have shown that neither HS014 nor yi-MSH pre-treatment 
affected tail-flick response induced by Y2-MSH. The dopamine receptor antagonist haloperidol 
(0.5 and 1 mg/kg; Lp.) per se induced a clear and significant increase in the tad-flick latency. 
There were no significant differences between the haloperidol pre-treated animals (haloperidol 
injected 30 min prior the La injection of Y2-MSH), y 2-MSH treated and the animals receiving 
combined treatment (haloperidol+y2-MSH) on tad flick latency responses. 
The opiate receptor antagonist naloxone (2 mg/kg i.p.) caused no effect on the tail-flick latencies. 
Similarly as haloperidol, naloxone administered 30 min prior to the i.e. administration of y 2-
MSH at the dose of 1 nmol did not alter the increase in tail-flick latency induced by the i.e. 
injection o f y 2-MSH. 
Intraperitonal injection o f ethanol (4 g/kg) per se caused significant increase in tail-flick 
latencies. For the combined treatment ethanol (4 g/kg; Lp.) were given 10 min prior to Lc. 
injections o f a-, yi- or y 2-MSH (all at the dose of lnmol). The a-MSH did not significantly affect 
the ethanol response, whereas yi-MSH significantly attenuated the ethanol response. By contrast, 
Y2-MSH significantly potentiated the ethanol-induced increase in tad-flick latencies (Fig. 17). 
The GABA A receptor antagonist bicuculline (0.5 mg/kg; i.p.)per se did not show any significant 
effects on the tad-flick latencies in mice. For the combined treatment bicuculline (0.5 mg/kg; 
i.p.) was injected 5 min prior to Lc. injections of a-, Yi- or y 2-MSH (each of lnmol). 
Pretreatment with bicuculline completely attenuated the increase in tail-flick latency induced by 
y 2-MSH. However bicuculline did not affect response of a- or yi-MSH (Fig. 17). 
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The GABA receptor agonist muscimol (1 mg/kg; i.p.) per se induced a significant increase in 
tad-flick latency at 30min observation time. For the combined treatment muscimol (1 mg/kg; 
i.p.) was administered 5 min prior to Lc. injections of a-, yi- or y 2-MSH (all peptides at the dose 
of 1 nmol). Neither a-MSH nor yi-MSH gave any significant alterations of the tad flick latency 
response induced by muscimol. The muscimol significantly potentiated the Y2-MSH induced 
analgesic effect. Figure 17 summarizes the data obtained with yi-MSH, y 2-MSH and pretreated 
with test-drugs in analgesia test in mice. 
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Fig. 17. Effects of yi-MSH and y 2-MSH (both at the dose of 1 nmoL i.e.), bicuculline (0.5 mg/kg, 
i.p.), muscimol (1 mg/kg, Lp.), ethanol (4 g/kg Lp.) and diazepam (10 mg/kg, Lp.) on tad flick 
latencies in BALB/c mice. n=7-9. 
*p< 0.05 vs saline, #p<0.05 vs Y2-MSH, Ap<0.05 vs muscimol+saline, °p<0.05 vs ethanol+saline, 
+ p<0.05 vs diazepam+saline. 
G A B A a receptor hgand at the benzodiazepines site, diazepam, at the dose of 10 mg/kg Lp. per se 
caused a significant analgesic effect. For the combined treatment diazepam was injected 5 min 
prior to i.e. injections of a-, yi- or Y2-MSH (1 nmol each) in mice. Both the a-MSH and yi-MSH 
treatments significantly attenuated the increase in tail-flick latency caused by diazepam 
However, the combined treatment of diazepam and y 2-MSH did not affect significantly the tad-
flick response, compared to any of these treatments given alone. 
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5.4 Influence of melanocortins on extracellular dopamine and DOPAC concentrations in 
anaesthetized rat nucleus accumbens in microdialysis study (TV, VII) 
5.4.1 Effects of yi-MSH and y 2 -MSH (VTI) 
Yi-MSH or Y2-MSH (both at the dose of 3 nrnol/0.5ul) were injected into the rat brain left VTA 
and extracellular dopamine and its metabolite DOPAC concentrations in the left NACC in 
anaesthetized rats were determined by brain microdialysis study. Injection of CSF served as 
controL For the combined administration, Y2-MSH was injected 2 samples or 40mm prior to the 
injection of y r MSH. The dose of 3 nmol/0.5pl for MSH peptides was selected in accordance 
with the doses known to elicit maximal behavioral responses. Baseline dialysate levels of DA 
and DOPAC were 32.3±0.3 fmol/40ul and 24.6±lnmol/40pL respectively. Injection of CSF did 
not induce any changes in the NACC extracellular DA and DOPAC level. In anaesthetized rats 
the intra-VTA injections of y-MSH peptides had different effects on nucleus accumbens 
extracellular concentrations of D A and its metabohte DOPAC. 
Adniinistration o f yi-MSH resulted in a significant increase in the extracellular DA release in the 
NACC. By contrast to the increase induced by Yi-MSH, the intra-VTA injection of Y2-MSH 
caused a marked decrease in the DA levels on the NACC microdialysates. Intra-VTA pre-
treatment with Y2-MSH abolished the influence of yi-MSH on dopamine concentration (Fig. 18.) 
CSF Y2-MSH y r M S H y 2 -MSH+y r M S H 
Fig. 18. Average levels of extracellular dopamine in the anaesthetized rats nucleus accumbens 
measured by microdialysis following intra-VTA administration of artificial CSF, yi-MSH Y2-
MSH (each peptide in 3nmol), and influence o f the pre-treatment of Y 2 -MSH on the effect of yr 
MSH. Changes are expressed as percentages (±SEM) from basal levels of dopamine (calculated 
as the mean of the three samples before the treatment of MSH peptides). n=7. 
*p<0.05 vs CSF (control group), +p< 0.05 vs y,-MSH. 
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Results from the measurements of DOPAC by brain microdialysis technique are shown in Fig. 
19. Administration of yi-MSH into the left VTA gave a increase also in the extracellular DOPAC 
level. Moreover, the intensity of the increase of extracellular DOPAC induced by the intra-VTA 
injection of yi-MSH was markedly higher than that of the extracellular DA level in the NACC 
(Fig. 18 and Fig. 19). yrMSH caused a decrease in the DOPAC levels in NACC microdialysates. 
Pretreatment of Y2-MSH (y2-MSH injected 40min prior yi-MSH) significantly attenuated yi-
•MSH-induced increase in DOPAC content (Fig. 19). 
So, in vivo microdialysis results similarly as in the behavioral studies results confirm that both y-
MSH peptides may act in an opposite manner. 
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CSF y r M S H y r M S H y 2 -MSH+y r M S H 
Fig. 19. Average levels of extracellular DOPAC in the anaesthetized rats nucleus accumbens 
measured by microdialysis following administration of artificial CSF, yi-MSH, y 2-MSH 
(peptides each of 3nmol) and influence of the pre-treatment of yrMSH on the effect of yi-MSH. 
Changes are expressed as percentages (±SEM) of basal pretreatment levels of DOPAC 
(calculated as the mean of the three samples before the treatment of MSH peptides). n=7. 
*p<0.05 vs CSF (control group), #p<0.05 vs y r MSH. 
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5.4.2 Effects of MC4R antagonist HS131 in microdialysis study (TV) 
The study reveals the effects induced by the intra-VTA administration of a-MSH (10 
nmol/0.5ul) and the MC4R selective antagonist HS131 (1 nmol/0.5u.l) on the level of 
extracellular D A and DOPAC in the anaesthetized rat nucleus accumbens. Injection of CSF 
served as control. Administration of MC4R antagonist HS131 into the VTA did not affected the 
extracellular level of both D A and DOPAC in NACC. Instead, injection of a-MSH into the left 
VTA caused a significant increase in the levels of both DA and DOPAC. This increase was 
blocked by pretreatment of HS131 injected 40min prior a-MSH (Fig.20). 
Fig. 20. Average levels of extracellular D A and DOPAC in the anaesthetized rats nucleus 
accumbens measured by microdialysis following intra-VTA administration of artificial CSF, 
lOnmol a - M S H lnmol HS131 or the influence of the pre-treatment of lnmol HS131 on the 
effect of lOnmol a-MSH. The results are presented as mean +SEM of DA and DOPAC 60 min 
after administration relative to basal levels. n=4-6. 
***p<0.05 vs CSF (control group), HS131 and HS131+ a-MSH. 
44 
6. DISCUSSION 
Melanocort ins were the first peptide hormones among these discovered in the beginning of the 
last century (Eberle, 1988). Despite many years of investigation, mechanisms underlying the 
broad array of physiological effects of melanocortins in the brain and the whole body were 
poorly understood. In comparison to such melanocortin peptides, as A C T H and a -MSH, 
remarkably less is known about the functional roles of y i -MSH and y 2 - M S H peptides in the 
brain. 
The last five-ten year studies have shed a light in clarifying the central role of melanocortin 
peptides. This substantial progress was made in the 1992-1993 when identifying, cloning and 
characterizing of five different types of melanocortin receptors, termed M C I R , MC2R, MC3R, 
M C 4 R and M C 5 R were performed separately in two scientific centers - the Uppsala University, 
Sweden (Chhajlani and Wikberg, 1992; Chhajlani et al., 1993) and the Oregon University, USA 
(Mountjoy et al., 1992; Gantz et al., 1993). M C R s are widely expressed in different tissues of the 
body whereas in the brain mostly are present M C 3 R and MC4R. Resent autoradiographic studies 
also confirmed that MC3R protein dominates in many areas of the brain, such as the nucleus 
accumbens N A C C , ventral tegmental area (VTA), medial pre-optic area and ventromedial 
nucleus of the hypothalamus. In the V T A area, not only M C 3 R expression but also M C 4 R has 
been determined (Lindblom et al., 1998). Since the discovery of MCRs, the melanocortinergic 
effects have been discussed in context of recently discovered neural melanocortin receptors. 
Melanocort ins show specific affinities for each o f the M C R subtype in the brain. Binding studies 
using recombinant human M C R indicate that y i -MSH has about 3-fold higher affinity for the 
M C 3 R than a - M S H , whereas a - M S H peptide shows 45-fold higher potency for the M C 4 R than 
Yi-MSH (Schioth et al., 1995, 1996). The y 2 - M S H has demonstrated a similar to y i -MSH affinity 
profile for human melanocortin receptors; however the binding affinities of y 2 - M S H for MCR 
are about 2- to 3-fold lower than these for the y i -MSH (Schioth et al., 1996). Unfortunately, none 
of the natural melanocortins show selective binding activity for the M C 3 R and MC4R. 
Therefore, it might be of value to look for synthetic specific antagonists on the different M C R 
subtypes in order to clarify effects caused by natural melanocortins. Presently for the 
experimental use are only non-selective M C 3 R / M C 4 R antagonists, for instance HS014 , HS964 
and HS131 (Schioth et a l , 1998b). In 2002-2003 are synthesized selective antagonists for the 
MC3R, M C 4 R and M C 5 R antagonists (Grieco et al., 2002; Balse-Srinivasan et al., 2003), 
unfortunately they are not yet available commercially. 
We have focused our interests on the effects induced by yi- and y 2 -MSH, taking into account that 
they show a high affinity for M C 3 R (Schioth et al., 1995) o n the one hand, and the abundant 
expression of the M C 3 R in the VTA, on the other hand. The V T A is the site of origin of 
mesolimbic dopaminergic A10 neurons that innervate the NACC, the major terminal area for 
these neurons. W h e n the biologically active substances stimulate dopamine cells, the dopamine 
release in the N A C C is increased, and that coincides with hyperlocomotion and stereotypical 
behavioral responses (e.g. exploring, grooming behaviour) in laboratory animals. Release of 
dopamine in the N A C C is regarded as crucial factor in the mediat ion of cognitive, rewarding, 
motivational and affective functions (Spanagel et al., 1992). It is assumed that in schizophrenic 
patients or drug addicted persons, dopaminergic hyperactivity in the V T A - N A C C pathways may 
lead t o psychoses, paranoid delutions etc. 
The cytoarchitectony of the VTA is very complicate showing that V T A dopamine neurons are 
influenced by many other systems, for instance, GABA, glutamate, opiate and cholinergic ones 
(Fig. 21). V T A A10 dopaminergic neurons receive a lot of interneurons that may modulate 
dopamine release in the NACC (Spanagel and Zieglgansberger, 1997), for instance, the 
inhibitory amino acids (e.g. GABA) acting on the G A B A A receptors and the excitatory amino 
acids (e.g. glutamate) acting on the N M D A or non -NMDA receptors. 
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Fig. 21. The mesolimbic dopaminergic system activity of VTA DA neuron and DA release in 
the NACC are modulated by different neurotransmitters, released from both inhibitory and 
excitatory interneurons (Rommelspacher H, 1997). 
In our experiments, y^MSH, y 2-MSH as well as MC4R antagonists mostly were administered 
into the VTA to evaluate behavioral responses induced by these peptides. a-MSH served as 
reference peptide. 
6.1 Behavioral repertoire of MSH peptides 
Our results have shown that a-MSH injected into the VTA induced marked grooming responses 
in rats. Grooming is a partem of behavioral condition which has been described as readdy 
definable components consisting of activities directed to the animal's body surface, such as 
ticking face washing body grooming and genital grooming. As it has been reported earlier, the 
ICV administration of a-MSH induced an excessive grooming activity in rodents (Gispen et al., 
1975; Torre and Cellis, 1988). Our present data confirm that intra-VTA injection of a-MSH also 
showed a stable grooming effect. It is intriguing that grooming behaviour was increased to a 
much greater degree when a-MSH was injected into the VTA than after TVC administration We 
have found that the intra-VTA administration of MC4R antagonist HS014 may cause a potent 
inhibition of the a-MSH induced grooming activity, indicating that a-MSH grooming effects 
may be provided via MC4R. Another support for this suggestion is that the MC4R antagonistic 
ACTH(4-10) analogues also are capable to block the grooming response induce by ICV 
administered a-MSH (Adan et al., 1997). That is in line with our data that shows the abdity of 
MC4R antagonist HS014 to inhibit the a-MSH induced grooming response also following its 
IVC injection. 
Surprisingly, that MC4R antagonists (HS014 and HS964) may also cause some increase in 
grooming behaviour, vertical and horizontal activity following their injections into the VTA or 
ICV. The grooming responses of MC4R antagonists HS014 and HS964 are more pronounced 
when MC4R antagonists are injected into ICV than after intra-VTA injection. 
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Yi-MSH showed a slightly less potent grooming effect in comparison to a - M S H . Both a - M S H 
and y i -MSH increased not only grooming but also vertical activity. In contrast t o a - M S H and yi-
MSH, intra-VTA administration of y 2 -MSH showed strikingly different effect: the y 2 - M S H was 
practically ineffective in inducing grooming behavior and vertical activity in rats. Moreover, 
intra-VTA injection o f y 2 - M S H peptide induced even a slight long-lasting catalepsy. Our data are 
in line with previously reported data indicating that y 2 -MSH is not capable to cause increase in 
grooming responses following intra-cerebroventricular administration (Van Ree et al., 1981). 
Furthermore, for the first t ime we have shown that in case of combined treatment, y 2 - M S H may 
at tenuate the g rooming response and the vertical activity induced by yi-MSH. 
These data are very intriguing, since both yi-and y 2 - M S H structurally differs by the only an extra 
C-terminal glycine residue in the y 2 -MSH molecule. It is possible that this additional glycine 
residue, which is expected to b e flexible as a 'moving tail ' , could change the peptide 
conformation quite different and thus may influence its pharmacological properties. One might 
speculate that therefore y 2 - M S H could become antagonistic, or it might even be capable of rapid 
br inging a M C R into a desensitized state. 
Thus, o u r data confidentially show a distinct difference in the behavioral repertoire of intra-VTA 
administered M S H peptides and also the possible role of these peptides in the regulation of 
activity of the mesolimbic dopaminergic system: a - M S H and y i -MSH may act as activating 
peptide, whereas y 2 - M S H as inhibitory one. The y-MSH peptides showed not only the opposite 
spectra of behavioral effects; moreover y 2 - M S H also may attenuate the grooming response and 
the vertical activity caused by the y i -MSH Since y , -MSH acted similarly to some central 
st imulants (amphetamine), which are capable to induce hyperlocomotion stereotype, one may 
suggest that y i - M S H acts as psychoactivating peptide where as y 2 - M S H as anti-psychotic one. 
Their opposi te action may serve for the balancing of psychoactivating state, possible via the 
mesol imbic system 
W e can not yet explain for sure which of the M C R s exactly play the role in the behaviour effects 
caused by M S H peptides, either there is yet another unknown M C R or melanocortins are 
exert ing their behavioral effects via another pathway distinct from the melanocortins receptors. 
There a r e data describing that y r , y 2 - and y 3 - M S H , but not the a - M S H are capable to prevent the 
binding of [ 3 H]-naloxone to opiate receptors of the brain (Oki et al., 1980). For the [ 3 H]-
na loxone sites, the y 2 - M S H expresses the lower affinity than y r M S H peptide (Oki et al., 1980). 
Howeve r , y-MSH peptides have shown an about 1000-fold lower affinity to opiate receptors 
when compared with the affinities for an MC3R. So, it seems unlikely that opiate receptors are 
involved in t he y - M S H peptides induced behavior responses when administrated intra-VTA. 
Recent ly , the autoradiographic studies in the Biomedical Center of Uppsala (Lindblom et al., 
1998) pointed out the intriguing fact: the peculiar binding properties o f M S H peptides in the 
V T A seemingly indicating the presence of yet another M C R in this area. 
T h e da ta obtained in t h e behavioral study indicated us to clarify the mechanisms of action of the 
different behavioral effects induced by melanocortins. Some answers w e have obtained from 
further neurochemical studies 
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6.2 Neurochemical basis of the dopaminergic component 
To find the direct arguments for the MSH peptides influence on the mesolimbic dopaminergic 
system w e used in vivo brain microdialysis method in anaesthetized rats. The concentrations of 
extracellular dopamine (DA) and D O P A C were measure in the rat nucleus accumbens (NACC) 
following the y i -MSH, y 2 -MSH, a - M S H and M C 4 R antagonist HS131 injections into the VTA. 
Intra-VTA injections of a - M S H and y i -MSH caused a considerable increase in the extracellular 
DA and DOPAC release in the NACC. However , a - M S H caused slightly higher influence on 
D A level than that on metabolite DOPAC. Interestingly that y i -MSH (which similarly to a - M S H 
is capable of inducing marked grooming) demonstrated a more pronounced ability to intensify 
the release of D O P A C than that of DA, indicating a strong and prolonged D A metabolism 
caused by this peptide. In contrast to both a - M S H and yi -MSH, the intra-VTA administration of 
y 2 - M S H caused a decrease in the extracellular D A and D O P A C contents in the rat NACC 
dialysates. The lowering of extracellular D A level was more pronounced than that of DOPAC. 
For the combined treatment, y 2 - M S H was injected prior to yi-MSH, and the same antagonizing 
phenomenon between both peptides which was obtained in the behavioral studies was noted: y 2 -
M S H abolished the yi-MSH-induced increase of extracellular D A and D O P A C contents in the 
rat N A C C . These data indicate that DAergic system directly or indirectly may be modulated by 
a- , yi- and y 2 - M S H peptides. The neurochemical data, showing that y i -MSH and a - M S H cause 
an increase in the extracellular D A and D O P A C release, are in good line with those 
demonstrated in behavioral experiments: a - M S H - and yi-MSH-induced hyperactivity (an 
excessive grooming and increase in vertical locomotor activity) can be attributed to intensified 
activity of the DAergic mesolimbic system. At the same time, depressed DAergic processes in 
the N A C C may give some explanation for the cataleptic state caused by y 2 -MSH. The opposite 
action of y 2 - M S H and y i - M S H , a strong antagonism of y 2 - M S H towards the effects induced by 
t h e y i - M S H , suggest that the relationships between both y-MSHs may be considered, perhaps, as 
functional antagonism based on their opposite influence at least on the mesolimbic dopaminergic 
system, particularly on their ability to influence D A metabolism. 
The intra-VTA injection of M C 4 R selective antagonist HS131 did not cause any changes the D A 
and D O P A C contents in the rat NACC; however the pre-treatment with HS131 completely 
abolished the effect of a - M S H . One may suggest that a - M S H caused effect on the increase of 
N A C C dopamine and DOPAC levels is mediated by activating melanocortin receptors, 
particularly; it might be M C 4 R subtype. 
For the further dopaminergic system involvement in the effects of the melanocort ins we use 
AMP-induced hyperlocomotion model in mice. Amphetamine (AMP) may act as 
psychostimulant, which induces dopamine release from the presynaptic nerve terminals. The 
further dopamine accumulation in the synaptic cleft leads to enhanced postsynaptic reception. In 
experimental animals this causes behavioral hyperlocomotion (Segal, 1975). Our data show that 
in model animals both y i - M S H and y 2 - M S H intracistemally reduced the AMP-induced 
hyperlocomotion in mice. Naturally, w e expected that y i -MSH will potentate A M P 
hyperlocomotion, and y 2 - M S H will antagonize AMP effects. Since both peptides attenuated 
AMP-induced effects, one may suggest that dopaminergic mechanisms are not the unique non-
melanocortinergic component for these peptides; however dopamine system may play an 
essential role for their action. 
Still, it is difficult to define precisely whether the MSH peptides are capable to affect the NACC 
DAergic system directly, or. that is most likely, indirectly. Our further studies were devoted to 
clarify the mechanisms of M S H peptides in behavioral and neurochemical experiments by use of 
test-drugs as analogues for different neurotransmitter systems. 
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6.3 Glutamatergic component 
T h e data obtained in phencyclidine (PCP) model-animals, show that y -MSH peptides might 
affect not only DAerg ic but also activity of t he glutamatergic system. PCP is a model-compound 
used to obtain a 'schizophrenic state ' in laboratory animals. This drug is known to induce 
behavioral hyperactivation by increasing locomotion. PCP is a non-competi t ive antagonist of 
glutamate N M D A receptors. Similarly to the data obtained in open field studies, y -MSH peptides 
also showed different effects in PCP-model-animals: intracisternal injection of y i -MSH 
potentiated the PCP-hyperlocomotion effects, whereas Y2-MSH antagonized the PCP effects. 
Moreover , Y2-MSH reduced the mentioned y i -MSH potentiating effect (y i -MSH+PCP) . These 
data show that y i -MSH may act as phychoactivating peptide with an ability to enhance the action 
of glutamate receptor antagonist PCP, whereas Y2-MSH showed anti-phychotic action. 
Interestingly, that M C 4 R antagonist HS014 also was capable to antagonize y i -MSH+PCP 
effects. Similarity in the effects of Y2-MSH and M C 4 R antagonist HS014 (antagonism against 
bo th y i -MSH and y i - M S H - P C P ) indicates that they may act somehow in similar manner on the 
glutamatergic processes. Since the influence o f PCP on the mesolimbic system via DA release in 
the N A C C has been already proved, the modulation of the P C P effects by y i -MSH, Y2-MSH and 
HS014 allows suggesting their ability to alter this system activity probably via glutamate-DA 
receptor cross-talk mechanisms. 
Another evidence suggesting y-MSHs involvement in the modulat ion of glutamatergic processes 
in the brain comes from NMDA-seizure (increased locomotor activity and contra lateral 
rotations) test. W e have shown that in t ra-VTA pretreatment with Y2-MSH 5 min prior to intra-
V T A administration of NMDA, completely antagonized the NMDA-caused neurotoxic 
behaviour responses in rats 
6 .4 GABAerg ic component 
Behavioral and microdialysis studies indicated that t he central effects induced by the 
melanocortin peptides and their synthetic analogues at least in part can be attributed to the 
dopaminergic and glutamatergic processes. Further, analgesic studies showed one another 
neurotransmitterergic system - GABAergic one - crucial for melanocortin actions. MSH 
peptides (OL,J\- and Y2-MSH) were injected intracisternal in mice and examined on pain 
perception by use of tail flick method. Analgesia study has shown that only Y2-MSH (at all three 
doses 0 .3 , 1 and 3 nmol, i.e.) was capable t o cause central analgesic effect This effect was 
pronounced and lasted for 90 min. T h e y 2 -MSH has shown stronger analgesia in comparison 
even to opiate peptide enkephaline that caused central analgesic effect only for about 5 min 
(Klusa, 1984) Opiate receptor antagonist naloxone did not affected y 2 - M S H induced analgesia, 
indicating that opiate receptors are not essential for y 2 - M S H induced analgesia. y2-MSH-induced 
analgesia also w a s not altered by M C 4 R antagonist HS014 or by y i -MSH peptide, suggesting 
tha t melanocortinergic system do not play an important role in analgesic effect of Y2-MSH. The 
s ame was with t he dopamine receptor antagonist haloperidol that did not influence the Y2-MSH 
analgesia effect 
Surprisingly, only G A B A . \ receptor ligands affected the Y2-MSH induced analgesia. 
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Agonist muscimol potentiated the y 2-MSH analgesic effect, while antagonist bicuculline 
completely abolished it. At the same time, yrMSH effect was not influenced by GABA receptor 
benzodiazepine site ligand diazepam Intriguingly, yi-MSH and also a-MSH significantly 
reduced analgesic effect caused by diazepam Thus, y 2-MSH analgesic effect can be altered only 
by GABA A receptor GABA site ligands. The ethanol-induced analgesia was not influenced by 
a -MSH however yi-MSH reduced and yrMSH increased the ethanol effect. Ethanol is a known 
modulator of GABAA-receptor (Davies and Alkana, 1998). 
Therefore, mere is a strict evidence of the diverse interaction shown by MSH peptides on various 
sites of G A B A A receptor: y 2-MSH influenced the GABA site ligands muscimol and bicuculline, 
a-and yi-MSH by benzodiazepine site ligand diazepam and both y-MSHs influenced in opposite 
manner the ethanol site (Fig.22) 
Fig. 22. GABAA-receptor sites: receptor protein organization (A) and cross-section (B). 
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The short-term hyperalgesia caused by the all three dose of a - M S H must be mention to the 
central analgesic effects induced by the melanocortins. This effect induced by the intracisternal 
injection of a - M S H in mice is in line wi th a previous report where ICV administration of a -
M S H caused hyperalgesia in rats (Sandman and Kastin, 1981) 
We can conclude that Y2-MSH induces central analgesia via a mechanism that does not involve 
either melanocortin receptors or opioid receptors. Our data indicate that Y2-MSH analgesic effect 
is mediated via direct and/or indirect stimulation of GAB A A receptor G A B A site. 
The data of present studies indicate that central effects of melanocortin peptides involve not only 
melanocortinergic (which was tested by other authors as y-MSH peptides express high affinity to 
M C 3 R or MC4R) but a lso non-melanocortinergic - DAergic, GABAergic and glutamatergic 
pathways in the central nervous system. 
Moreover our studies showed that y i -MSH and Y2-MSH almost in all (the only exception was 
AMP-induced hyperlocomotion study) demonstrated opposite action: if y i -MSH induced 
pronounced grooming behaviour and increased vertical activity in rats, increased both dopamine 
and D O P A C levels in the rat NACC, potentiated PCP-induced hyperlocomotion, the y 2 - M S H did 
not influence grooming behaviour, caused a moderate catalepsy, reduced both dopamine and 
DOPAC levels in the rat NACC, antagonized PCP-induced hyperlocomotion, abolished N M D A -
caused neurotoxic behavior responses in rats, caused a stable analgesic effect mediated via 
G A B A A receptor. The most interesting phenomenon in many studies was a demonstrated y 2 -
M S H antagonism towards the effects induced by y i -MSH: y 2 - M S H antagonized the y i -MSH-
induced grooming behavior, abolished the yi-MSH-caused increase in dopamine and D O P A C 
levels and inhibited yi-MSH-induced potentiation of the PCP-hyperlocomotion. These 
behavioral and neurochemical data allow us to suggest that y i -MSH acts as psychoactivating 
whereas y 2 - M S H as antipsychotic peptide. 
The functional role o f b o t h y-MSH peptides might be in the maintenance of balanced 
psychoactivating state regulated either by their possible functional antagonism or their different 
interaction with melanocortinergic and/or other neurotransmitterergic systems. Hence, present 
studies have revealed some new aspects of the multifunctional influence of y -MSH peptides on 
the various processes of the central nervous system; one may suggest that Y l - M S H and y 2 - M S H 
can regulate the mesolimbic dopaminergic system, which is responsible for the development of 
drug dependence and motivational processes, manifestation of schizophrenic hyperactivation and 
emotions. Results of our studies may indicate new pharmacotherapeutic strategies in the 
treatment of drug dependence and other pathological processes associated with a functioning of 
the reward system. 
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7. C O N C L U S I O N S 
1. Yi- and Y2-MSH injected into the VTA induced an opposite behavioral repertoire in 
rats: y i -MSH caused the increased grooming responses and vertical activity, whereas 
Y2-MSH lacked these activities (it caused a moderate catalepsy). Neurochemical data 
obtained in microdialysis studies also revealed distinct effects, since peptides 
influenced in different manner the DA and its metabolite content in the rat nucleus 
accumbens after peptide intra-VTA administration: y i -MSH increased D A and 
D O P A C levels whereas y 2 - M S H caused a decrease of both monoamine levels in the 
rats NACC. These data indicate eventual psychoactivatory role of y i -MSH and 
antipsychotic one of the y 2 - M S H 
2. In both experimental setups in rats (behavioral and microdialysis), y 2 - M S H acted as 
an antagonist of y i -MSH indicating that these peptides may play a role of functional 
antagonists at the level of the dopaminergic mesolimbic system. 
3. Data obtained in the schizophrenia model-mice and NMDA-toxici ty tests in rats 
showed that both y-MSHs might modulate glutamatergic system. y i -MSH potentiated 
the phencyclidine (PCP)-induced hyperlocomotion, whereas Y2-MSH significantly 
reduced the PCP effects (peptides injected intracisternally). In these experiments y 2 -
M S H antagonized the y r M S H - i n d u c e d potentiation of the PCP-hyperlocomotion 
effects. Int ra-VTA injection of y 2 -MSH completely antagonized the NMDA-caused 
neurotoxic behavioural responses in rats. 
4. y-MSH peptides have a possibility to regulate also GABAergic processes. In 
analgesia test (tail flick in mice) Y2-MSH caused a long-lasting central analgesia that 
was potentiated by muscimol (GABA site agonist of the G A B A A receptor) and 
completely reduced by bicuculline ( G A B A site antagonist of the G A B A A receptor) 
but not altered by other test-drugs like, M C 3 / M C 4 receptor antagonist HS014, opiate 
receptor antagonist naloxone, y i -MSH, and D A receptor antagonist haloperidol. These 
data indicate GABAergic pathway involved in y 2 - M S H caused central analgesia. 
Moreover, y i -MSH considerably decreased diazepam (benzodiazepine site agonist of 
the G A B A A receotor) induced analgesia indicating ability of y i -MSH to affect 
benzodiazepine site of G A B A A receptor. Both y-MSH peptides differentially affected 
analgesia caused by ethanol, a modulatory site of the G A B A A receptor: y i -MSH 
reduced, whereas y 2 -MSH potentiated the ethanol effect. 
5. The data obtained in the present behavioral and neurochemical studies which have 
shown distinct action of j \ - and y 2 - M S H , allow to suggest that y -MSHs play a 
functional role in regulat ing^alancing the brain psycho activating state (mostly the 
mesolimbic system) by acting not only via melanocortin receptors but also by 
involving non-melanocortinergic mechanisms, at least in part, dopamin-, glutamat-
and GABAergic components 
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Evaluat ion of behavioura l e f f e c t s of 
neural m e l a n o c o r t i n r e c e p t o r 
a n t a g o n i s t s i n j e c t e d ICV a n d in VTA 
in rats 
V. K L U S A 1 , S . S V I R S K I S 1 , B . O P M A N E 1 , R . M U C E N I E C E 1 2 , A . S K U J I N S 1 , F . M U T U L I S 2 , J . E . S . 
W I K B E R G 2 , H . B . S C H I O T H 2 
'Laboratory of Pharmacology, Latvian Institute of Organic Synthesis, Riga, Latvia 
department of Pharmaceutical Pharmacology, Uppsala University, Uppsala, Sweden 
SUMMARY. The natural melanocortic peptides are known to exert a variety of effects after central administration. 
Recently, we discovered the first potent and selective substances for the MC4 receptor, i.e. HS964 and HS014. We 
found HS964 to be an antagonist for the MC1, MC3, MC4 and MC5 receptors in vitro. HS014 is an antagonist for the 
MC3 and MC4 receptors and a partial antagonist for the MC1 and MC5 receptors. We injected a-MSH and these 
substances, both intracerebroventricular (ICV) and in the ventral tegmental area (VTA) in rats and scored several 
behavioural effects. The results show that a-MSH caused intensive grooming which was antagonized by pre-treatment 
of both HS014 and HS964. The data give further support to the hypothesis that it is the MC4 receptor which mediates 
grooming in rodents. The grooming effects of a-MSH were more pronounced after intra-VTA administration compared 
to the ICV administration. Both a-MSH, HS014 and HS964 caused an increase in vertical activity of the rats after intra-
VTA administration but not after ICV administration. Horizontal activity was virtually not affected by the administration of 
the peptides. The data indicate that the neural MC3 and MC4 receptors are not likely to be an important mediators of 
locomotor activity in rats. 
I N T R O D U C T I O N 
Pro-opiomelanocortin (POMC) is post-translationally 
cleaved into a variety of peripheral and neuroactive sub-
stances including adrenocorticotropin (ACTH) and the a, 
p-, ^-melanocyte stimulating hormone (MSH). These pep-
tides are commonly termed Tnelanocortins'. ACTH stimu-
lates steroidogenesis in the adrenal gland, whereas a-MSH 
stimulates melanogenesis in melanocytes. Besides these 
well-known effects, the melanocortins are reported to have 
a broad array of other effects, e.g. being neurotrophic, 
induce grooming in rodents, anti-inflammatory, antipyretic, 
and affecting pain perception, memory, learning, behav-
iour, blood pressure and events surrounding parturition.1-2 
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Five receptors for the melanocortic peptides are 
c loned. 3 - 7 The MCI receptor is expressed in melanocytes 3 
and it has a role for pigmentation in several species of 
vertebrates. ' The MC2 (or ACTH) receptor is exclusively 
expressed in the adrenal g l and 4 8 and binds ACTH with 
high affinity but not the MSH peptides. 9 The MC3 recep-
tor is expressed in the brain (predominantly in the VTA, 
and in few regions of the brain stem), as well as in the 
periphery where it has been found in the placenta, gut 
t i s s u e s . 5 1 0 " The MC4 receptor is predominantly found in 
the central nervous system, where it is represented in 
almost every brain region, including the cortex, thala-
mus , hypothalamus, brain stem and spinal cord. 7 1 2 The 
MC4 receptor has recently been knocked out and subse-
quently related to control of weight homeostasis. 1 3 The 
MC5 receptor has widespread peripheral tissue distri-
bution but can also be found in the brain. It is believed 
tha t the MC5 receptor plays a role for exocrine gland 
function. 1 4 
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The natural melanocortic peptides (a-MSH, p-MSH, y-
MSH and ACTH) have a specific affinity profile for each of 
the MC receptor subtypes although they are not exclu-
sively selective for the different subtypes, with the excep-
tion that a-MSH is selective for the MCI receptor and 
ACTH is selective for the MC2 receptor. ' 5- 1 7 The MC2 
receptor is distinguishable from the other MC receptors as 
it does not bind the MSH peptides. The lack of selective 
compounds have hampered the clarification of the physi-
ological roles especially of the MC3, MC4 and MC5 recep-
tors. SHU9119 was the first potent MC3 and MC4 receptor 
antagonist. 1 8 However, SHU9119 is not selective for any of 
the MC receptors . 1 8 1 9 We have recently developed the first 
selective MC4 receptor substances: HS964 and HS014. 2 0 
The aim of the present study was to investigate the 
effects of the new selective MC4 receptor substances 
HS964 and HS014 on behaviour after both injection into 
the ventral tegmental area (VTA) and intracerebroven-
tricular (ICV) in rats. 
M A T E R I A L S A N D M E T H O D S 
Chemicals 
Chemicals a-MSH were purchased from Neosystem S.A., 
France. The HS964 and HS014 were synthesized using 
the solid phase approach applying a Fmoc based Pioneer 
peptide synthesis system (PerSeptive Biosystems) and 
purified by HPLC as earlier described. 2 0 The correct mol-
ecular weights of the peptides were confirmed by mass 
spectrometry. Peptides were dissolved in water and 
stored frozen in aliquots until used. 
Expression of receptor clones 
The human M C I 3 and human MC5 7 receptor had earlier 
been cloned by us into the expression vector pRc/CMV 
(In Vitrogen). The human MC3 and human MC4 receptor 
DNAs, cloned into the expression vector pCMV/neo, were 
gifts from Dr Ira Gantz. 5 6 For receptor expression, COS-1 
(CV-1 Origin, SV40) cells were grown in Dulbecco's modi-
fied Eagle's medium with 10% foetal calf serum. Eighty 
percent confluent cultures were transfected on 100 mm 
cell culture dishes with the DNA (approximately 1 |ig 
DNA for every 1 x 10* cells) mixed with liposomes in 
serum free medium. After transfection, the serum-free 
medium was replaced with growth medium and the cells 
were cultivated for approximately 48 h. Cells were then 
scraped off, centrifuged, and used for radioligand binding. 
cAMP assay 
The transfected cells were harvested and incubated for 
30 min at 37°C with 0.05 ml serum free Dulbecco's 
modified Eagles medium in each tube, containing 0.5 mM 
IBMX (isobutymiethylxantine) and appropriate concen-
trations of a-MSH or HS964. After incubation with the 
indicated drugs, cAMP (adenosine 3':5'-cyclic mono-
phosphate) was extracted with perchloric acid at a final 
concentration of 0.4 M. After centrifugation, the protein 
free supernatants were neutralized with 5 M KOH/1 M 
Tris (tris-(hydroxymethyl)aminomethane). 0.05 ml of the 
neutralised cAMP extract or a cAMP standard (dissolved 
in distilled water) was added to a 96 well microtiter plate. 
The content of cAMP was then estimated essentially 
according to Nordstedt & Fredholm, 2 1 1990, by adding to 
each well pHjcAMP (0.14pmol, approximately 11,000 
cpm, specific activity 54 Ci/mmol, Amersham) and 
bovine adrenal binding protein and incubating at 4°C for 
150 min. Standards containing non-labelled cAMP were 
also assayed concomitantly with the samples. The incu-
bates were thereafter harvested by filtration on 
Whatman GF/B filters using a semiautomatic Brandel cell 
harvester. Each filter was rinsed with 3 ml 50 mM 
Tris/HCl pH 7.4. The filters were punched out and put 
into scintillation vials with scintillation fluid and 
counted. The cAMP assays were performed in duplicate 
wells and repeated three times. 
Animals 
Male Wistar rats were bred at the Breeding House of the 
Joint Stock Company GRINDEX, Riga, Latvia, and used at 
weights 300-350 g. The animals were housed in groups 
of five in a light-dark cycle of 12 h (lights off 19.00-700). 
Surgical procedures 
Cannulas, made from stainless steel needles (15 mm 
long, 0.56 m m OD), were implanted stereotaxicariy under 
Nembutal (CEVA, Sanofi, France) anaesthesia (60 mg/kg 
i.p.) into the left VTA or left lateral ventricle (ICV) at the 
following co-ordinates: -5 .2 caudal to bregma, 0.8 mm 
lateral from midline, and -8 .0 ventral from dura mater or 
-1 .5 , 1.0, and -3.6, respectively (Paxinos and Watson, 
1982). Cannulas were kept in place with dental cement 
(SPOFA Dental) and covered with duracryl (SPOFA 
Dental). To prevent the clogging of the cannulas, a bent 
stylet of stainless steel was inserted into each of them, 
and removed only when the injection took place. After 
the surgery, the rats were individually housed, given 
food and water ad libitum and allowed to recover for the 
following 7 days in a recovery room. 
Injections 
Drugs were injected into the VTA by means of a 75RN 
Hamilton Digital Syringe and a very fine polyethylene 
tube (Clay Adams, PE-10) attached to a 30-gauge needle 
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which was inserted into the implanted cannula. On the 
day of experiment an MSH-peptide aliquot was thawed 
and dissolved in saline to provide 0.3 and 3 nmol/rat for 
injections into the VTA or ICV. The total volume injected 
for each substance was 1 ill and the speed of injection 
was 0.25 ul m i n - 1 . For the combined treatments 
(HS964/HS014/saline + a-MSH), HS964/HS014/saline 
was administered 15 min prior to the a-MSH injection. 
Behavioural analysis 
On day 7 after surgery, the rats were transported from 
the recovering room to an observation room for 1-day of 
handling and habituating. Each rat was placed into a 
Plexiglas observation cage (60 x 40 x 15) and left for at 
least 1 h to diminish stress reactions to t h e novel envi-
ronment. The rat was then placed onto an injection plat-
form for 5 min before drug aclmrnistration. Immediately 
after the injection, the rats were placed into observation 
cage. Observation started on the 5th min after the onset 
of the injection and continued for 1 h for time-response 
studies by using a Psion Workabout microcomputer 
(Noldus, the Netherlands). Grooming activity was 
expressed in seconds as total duration of the separate 
grooming reactions (face washing, body licking, scratch-
ing, ano-genital grooming, head and wet-dog shakes) for 
each observation period (0-15 min, 0-30 min, 0 -45 min 
and 0-60 min). Following non-groorning, behavioural 
events were registered as rearing or vertical activity (VA) 
and horizontal activity (HA). VA and HA were scored as 
incidences during all observation periods. In the case of 
combined drug treatments, the injection schedule was: 
HS014/saline was injected 15 min prior to a-MSH for 
both intra-VTA or ICV administration, and the behaviour 
was observed during 1 h after the last injection. However, 
with respect to HS964+a-MSH was observed only after 
intra-VTA administration and during the first 15 min 
period. The observation sessions were performed 
between 10.00 and 14.00 Each experimental group con-
sisted of at least six rats. 
Statistics 
Statistical analysis was done using independent samples 
t-test or one-way ANOVA with Newman-Keuls test as a 
post-hoc. Data are expressed as the mean ± S.E.M. 
Animal ethics 
Experimental procedures were carried out in accordance 
with guidelines of the European Community, local laws 
and policies and were approved by Ethics Committee of 
Animal Experimentation at the Latvian Research Council. 
R E S U L T S 
We have earlier characterized how HS014 influences 
cAMP levels in cells expressing the MC 1, MC3, MC4 and 
MC5 receptors. 2 0 However, a possible cAMP response 
after stimulation by HS964 had not been tested. We 
expressed the DNAs for the above mentioned receptors 
and measured the cAMP accumulation after addition of 
a-MSH and HS964. As can be seen in Figure 1, a-MSH 
stimulated accumulation of cAMP in all the cell types. 
COS-1 cells which had not been transfected by any of the 
MC receptors did not respond to a-MSH (data not 
shown). HS964, in concentrations up to 1 )xM, did not 
affect the cAMP levels of any of the MC receptor express-
ing cells. Instead, 0.1 \iM HS964 was found to completely 
block the cAMP increase induced by a-MSH for all the 
four MC receptors. 
We then used both these MC4 selective antagonist 
(HS964 and HS014) for behavioural studies in rats. We 
injected both of the substances either intra-VTA or ICV in 
rats and scored grooming behaviour, horizontal and ver-
tical (or rearing) locomotor activities. a-MSH was 
injected alone as well as with prior treatment with saline, 
HS964 or HS014. The complete results are shown in 
Table 1 and Table 2. 
The results on grooming behaviour are shown in 
Figure 2. The results show that a-MSH induced consid-
erable and significant (vs saline control) grooming activ-
ities already after 15 min following b o t h intra-VTA and 
ICV injections, which were sustained for 60 min in a 
slighdy gradually increasing manner. The intensity of 
the grooming (duration and number of incidences) was 
more pronounced after intra-VTA administration that 
after ICV a<iministration. HS964 and HS014 also caused 
some increase in duration of grooming activity after 
both intra-VTA and ICV administration. When HS014 
was administrated prior to the administration of a-MSH 
it blocked grooming behaviour, bo th after ICV and intra-
VTA administration. As can be read out of Figure 2, this 
blocking effect is most pronounced after the intra-VTA 
administration. HS964 did also block a-MSH induced 
grooming after intra-VTA administration at 15 min 
which was the only time period scored for this peptide in 
this study. 
a-MSH caused an approximately two-fold increase (vs 
saline control) in vertical activity at the 30, 45 and 60 
min observation periods after intra-VTA injection, but not 
after ICV administration. HS014 also caused an increase 
in vertical activity after intra-VTA adiiiinistrauon but not 
after ICV administration. This increase in vertical activity 
caused by HS014 was comparable to that of a-MSH. The 
same pattern was observed for HS964 as for HS014 and 
a-MSH even though the vertical activity after intra-VTA 
aclministration of this peptide was not pronounced. 
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Compound log (M) Compound log (M) 
Fig. 1 Generation of cAMP in response to a-MSH (•), HS964 (•) or a-MSH + 1 nM HS964 (A) for the MC1, MC3, MC4 and MC5 
receptors in transfected COS-1 cells. Each point represents the average±SEM (n=6). 
No significant alterations in horizontal activity was 
observed when a-MSH was administrated in either of the 
routes used. Horizontal activity was not influenced by 
HS014 after intra-VTA application, however, this activity 
was slightly (approximately 30-40%) increased during 
the 15 and 30 min observation periods after ICV injec-
tion. Locomotor activities after intra-VTA and ICV injec-
tions of HS964 did not differ from the activity of the 
control rats, with the exception that a delayed (at the 45 
and 60 min observation periods) more than two-fold 
increase in horizontal activity was observed at both 
adrninistration routes. 
D I S C U S S I O N 
The MSH peptides were among the first peptide hor-
mones that were discovered. 1 There is a broad array of 
physiological effects related to them which underlying 
mechanisms are not well understood. After the cloning of 
the genes for the MC receptor subtypes and specific 
binding characterization of each of the subtypes in vitro, 
it became clear that none of the natural MSH peptides 
are selective for the newly discovered MC3, MC4 or MC5 
receptors. It has therefore not been possible to delineate 
each of the different physiological effects presumed to be 
exerted by these receptors by using the natural MSH 
peptides. Recent discovery of non-selective antagonists 
for the MC3 and MC4 receptors 1 8 and the first selective 
antagonist for the MC4 receptors 2 0 (HS964 and HS014) 
have opened new possibilities to explore the underlying 
mechanism behind the effects of the MSH peptides. 
HS964, and its more potent and more selective analogue 
HSO14, would therefore be interesting tools to probe the 
specific effects of the MC receptors in the central nervous 
system. HSO 14 has also recendy been shown to be highly 
effective in inducing food intake in free feeding rats, an 
effect related to the MC4 receptor. 2 2 " 2 3 HSO 14 has earlier 
been shown to be potent antagonist for the neural MC3 
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Table 1 intra-VTA injections in rats 
A) Total grooming, duration, sec 
Observation periods 
0-15' 0-30' 0-45' 0-60' 
saline 
a-MSH 
HS964 
HS014 
saline+a-MSH 
HS964+a-MSH 
HS014+a-MSH 
56.2 ±8.4 
230.2 1 37.0* 
118.8 ±22.4* 
97.3 ±14.7* 
236.0 ± 42.0* 
17.7110.1* 
66.7 ± 44.0* 
57.317.0 
424.61 108.4* 
123.7120.6* 
134.3125.3* 
468.41 123.8* 
103.6165.0* 
69 .2123 .0 
564.21167.6* 
169.319.6* 
141.1+ 21.2* 
665.01 189.7* 
118.7161.3* 
77.9 1 27.9 
655 .51 173.6* 
210^5 ±20.7* 
186.2 + 38.7' 
780.7 + 205.2* 
135.0154.9* 
B) Vertical activity (or rearing), incidences 
0-15' 
Observation periods 
0-30' 0-45' 0-60' 
saline 
a-MSH 
HS964 
HS014 
saline+a-MSH 
HS964+a-MSH 
HS014+a-MSH 
16.212.1 
20.5 1 4.9 
19 .312 .7 
30.3 1 6.7 
30.3 + 5.5" 
6.0 + 2.1* 
15 .315 .8 
12.813.0 
28.2 1 5.9" 
23.5 ± 6.3" 
36.3 ±9.1* 
44.0 ± 8.3* 
23.5 ± 10.5 
13.012.7 
29.2 1 5.8* 
30 .518 .0 
37.8 1 8.3* 
48 .4110 .4 
33.8 ± 16.8 
15.514.5 
30.9 1 5.3" 
33 .819 .8 
41.016.8* 
52.1 112.5* 
41.5122.9 
C) Horizontal activity, incidences 
0-15' 
Observation periods 
0-30' 0-45' 0-60' 
saline 
a-MSH 
HS964 
HS014 
saline+a-MSH 
HS964+a-MSH 
HS014+a-MSH 
18 .612 .3 
22.5 1 4.0 
16 .012 .0 
28.4 ± 4.5 
27.7 ± 4.7 
9.5 1 4.3* 
17 .015 .5 
19.5 ±6.2 
30.8 ±6.2 
22.3 1 6.0 
33.3 ± 8.0 
37.3 + 6.1 
21 .018.0 
19.516.2 
31.616.1 
42 .6112 .5 
34.8 1 8.6 
39 .716 .6 
25 .319 .3 
21 .016 .3 
32 .815 .8 
51 .3115.4 
38 .518 .5 
41.4 17 .3 
32.0114.0 
*p<0.05 vs saline one-way ANOVA and post-hoc Bonferroni's multiple comparison test, nonparametric Mann-
Whitney test 
+ p<0.05 vs saline+aMSH 
of a-MSH. 2 5 Our present data confirm the grooming 
effect of a-MSH. The selective MC4 receptor antagonists 
HS964 and HSO 14 seem to be potent inhibitors of the a-
MSH induced grooming which may indicate that it is 
indeed the MC4 receptor which mediates the a-MSH 
induced grooming. This falls in line with earlier data 
which indicate that the low affinity analogue of 
ACTH(4-10), stated to be selective for the MC4 receptor, 
also inhibited a-MSH induced grooming. 2 6 We have 
shown earlier tha t y-MSH has very low affinity for the 
MC4 receptor 1 6 a n d previous observations indicating that 
Y-MSH is not capable of causing grooming activity when 
injected ICV 2 7 are thus also in line with our present 
observations. A recent study, using the non-selective 
analogue SHU9119 and some low affinity ACTH(4-10) 
and MC4 receptors and our present data show that also 
HS964 is a potent antagonist for these receptors in vitro. 
However, as HSO 14 were found to be a partial agonist for 
the MCI and MC5 receptors, 2 0 HS964 proved in the pre-
sent study to be a antagonist for also these two MC 
receptors. 
Grooming is a pattern of behavioural condition which 
has been described as 'scratching', 'preening', "rubbing 
against objects and dust, sand, m u d and sun bathing'. 
This behaviour may seem to be directed to outer body 
surface but may be more related to the na ture of the 
situation than to the condition of the skin. 2 4 Grooming is 
known to be influenced by several central stimulants 
such as opioids and it has been known for long time that 
grooming behaviour is induced by central administration 
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Table 2 ICV injections in rats 
A) Total grooming, duration, sec 
Observation periods 
0-15' 0-30' 0-45' 0-60' 
saline 17 .8±3.6 36.1 ±6.9 40 .0±9 .3 41 .5±10.6 
a-MSH 188.5 ±34.4* 229.3 ± 29.1* 229.7 ± 29.2* 280.9 + 42.1* 
saline+a-MSH 194.3 ±64.7* 244.1 ±62.5* 255.6 ±57.9* 292.2 ± 46.7* 
HS964 93.8 ±8.5* 116.8 ±8.9* 148.3 ±33.9* 193.5 ±71.3* 
HS014 114.8 ±29.2* 224.5 ±78.7* 237.7 ± 85.0* 283.5 ± 76.3* 
HS014+a-MSH 41.7 ±23.2* 58.4 ±23.7* 78.9 ± 26.8* 100.3 ±23.7* 
B) Vertical activity (or rearing), incidences 
Observation periods 
0-15' 0-30' 0-45' 0-60' 
saline 18.3 ±2 .4 33.0 ±5.3 38.3 ±6.6 41.3 ±8 .7 
a-MSH 15.3 ±3 .2 19.4 ±2.5 21.3 ±7 .3 25.4 ± 4.9 
saline+a-MSH 22.8 ± 6 . 3 27.3 ± 7.7 27.3 ±7 .7 29.4 ±8 .7 
HS964 24.3 ± 11.5 37.8 ±13.1 45.3 ± 14.9 55.9 ±17.7 
HS014 29.5 ±6 .6 33.7 ±7.3 34.8 ± 7.8 36.0 ± 8.2 
HS014+a-MSH 15 .515 .7 29.0 ±12.9 39.5 ± 19.0 40.5 ± 20.0 
C) Horizontal activity, incidences 
0-15' 
Observation periods 
0-30' 0-45' 0-60' 
saline 15 .812.9 25.012.7 30.3 ± 3.8 35.9 ±3.1 
a-MSH 14.1 ± 1.8 18.2 ±2.3 20.1 ±2.1 26.6 ±2.5 
saline+a-MSH 19.8 ±4 .7 28.315.5 28.9 ±5.1 32.9 ±6 .7 
HS964 32.3 ± 14.9 52.4 ±14.9 63.6 ± 10.4* 72.4 ± 11.5* 
HS014 30.8 1 3.5* 37.3 ±3.5* 39.5 ±4.5 46.8 ± 5 . 3 
HS014+a-MSH 19.318.1 30.0 ±8.1 36.3 116.4 38.3 ± 18.3 
*p<0.05 vs saline one-way ANOVA and post-hoc Bonferroni's multiple comparison test, nonparametric Mann-
Whitney test 
+ p<0.05 vs saline+aMSH 
analogues as well as analogues of y-MSH may also sup-
port tha t it might by the MC4 receptor which mediates 
grooming. 2 8 
We have not been able to find any earlier reports relat-
ing any melanocortic peptides to vertical or horizontal 
activity. Our data show that there is some increase in ver-
tical activity after intra-VTA administration of a-MSH. 
However, both HS014 and HS964 show also some 
increase in vertical activity after administration in this 
area indicating that there is not any specific activity of a-
MSH on the MC3 or MC4 receptors of which these pep-
tides should act as antagonist. It is likely therefore that 
this effect is non-specific and not mediated through the 
MC receptor, or alternatively it is mediated through the 
MCI or MC5 receptors. There are only two reports about 
expression of the MCI receptor in the CNS3?-0 whose 
data suggest that the expression of the MCI receptor is 
very limited and seemingly related to only the periaqual 
gray area. The MC5 receptor has been found to be pre-
sent in the brain by several research groups, but is seems 
that the expression of this receptor is also comparatively 
l imited. 3 ' - 3 5 Our present data can therefore not exclude 
that the effect of a-MSH on locomotor activity was medi-
ated through any of these receptors. 
It is intriguing that our data show that grooming 
behaviour is increased to a much greater degree when a-
MSH is injected intra-VTA in the midbrain than after a 
ICV administration. The VTA_grea shows an abundant 
expression of the MC3 r e c e p t o r 5 - ^ bu t expression of the 
MC4 receptor is also present in this a r e a ^ , Moreover, it 
seems that the effects of these MSH peptides on locomo-
tor activity seem to be more pronounced after the intra-
VTA adrninistration than after the ICV administration. It 
cannot be concluded that the effects after intra-VTA 
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0-15 min 0-30 min 0-45 min 0-60 min 
Fig. 2 Effect of the administration of 
A) the left VTA or B) ICV on grooming 
during different observation times. 
different MSH peptides into 
behaviour of male rats 
adrninistration are exclusively due to interactions with 
MC receptors in this particular area, but it is likely that 
the activity of MSH peptide administration is, in general, 
more effective in this area or in adjacent areas in the mid-
brain. 
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B e h a v i o u r a l r e s p o n s e s o f y - M S H p e p t i d e s a d m i n i s t e r e d 
i n t o t h e r a t v e n t r a l t e g m e n t a l a r e a 
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A B S T R A C T 
The behavioural effects induced by z-. yi - and y2-MSH peptides (0.3 and 3 nmole per rat) injected into 
the left ventral tegmental area (VTA) of rats were compared, y- and yi-MSH caused grooming of 
comparable magnitude, and also additional vertical activity (rearing). By contrast y2-MSH caused a 
moderate but stable catalepsy, and practically no grooming. Moreover, intra-VTA pre-treatment 
with y2-MSH, 15 min prior to intra-VTA yi-MSH, markedly attenuated both the y1 -induced 
grooming and vertical activities. The differences in the behavioural response of the MSH peptides 
indicate that they act differentially on MC receptors in the VTA. 
K e y w o r d s behavioural effect. MSH, ventral tegmental area. 
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Despite many years of investigations, the mechanisms 
underlying the central effects of melanocort ins (i.e. 
A C T H and z.-, />'- a n d y-MSH peptides) are still poorly 
unders tood . However, substantial progress was made 
with the cloning o t rive different types of melanocortin 
receptors, termed M C I , MC2. MC3, MC4 and MC5 
(Chhajlani & Wikberg 1092, Mountjoy ET AL. 1992, 
Chhajlani ET AL. 1993, Gantz H AL. 1993a, b). Using IN SITU 
hybridization the distributions of m R N A s for the 
different M C receptors have been mapped. Thus , MCI 
receptor mRNA was detected only in some discrete 
neurones or the periaqueductal grey (PAG) area (Xia 
E! TIL. 1995). MC2 receptor mRNA seems no t to be 
expressed in the central nervous system, although it is 
abundant ly expressed in cells o f the adrenal cortex (Xia 
& Wikberg 1996). The M C 3 receptors are distinctly 
expressed in several regions of the h\pothalamus, 
thalamus and mesencephalon. In particular neurones of 
the ventral tegmental area (YTA) of the midbrain show 
abundant expression of M C 3 receptor m R N A (Low 
ET AL. 1904, Xta & Wikberg 199 - ) . T h e MC4 receptor is 
widely expressed in many regions oh the CNS although 
at varying levels (Low ET AL. 1994). T h e localization o t 
the MC5 receptor in the central nervous system has 
hitherto nor been mapped with bistochemical tech-
niques, although Nor the rn blot and RT-PCR analysis 
indicate that it is present in the brain (Chhajlani ET AL. 
1993, Gantz ET AL. 1994, Fathi ET AL. 1993). 
A C T H and the X-, /?- and y-MSH peptides are 
formed from the P O M C (pro-opio melanocortin) 
precursor, and POMC-immunoreact ive neurones from 
two neural systems of the brain, of which one originates 
in cell bodies localized in the posterior hypothalamus, 
and the other in cell bodies o f the brain stem. These 
neurones project to distinct regions of the central 
nervous svstem including the telencephalon, dien-
cephalon, mesencephalon, brainstem and spinal cord 
(see Low ETA/. 1994). The functions of the y-MSH 
peptide family are not well unders tood. Evidence exists 
that the acetylated melanocort in (a-MSH) and the des-
acetylated melanocort ins (y-MSH and ACTH) are 
bioprocessed in different ways in different POMC" 
neurones (Mezey ET AL. 1985). Moreover , in contrast to 
the acetvlated-MSH produced in the pituitary, the 
hvpothalamic 2-MSH is not acetylated (Eberle 1988). 
The pharmacological properties of a- and y-MSH differ. 
Using radioligand binding Schioth ET AL. (1996) found 
a-MSH to show about 40-fold higher affinity for the 
human MC4 receptor affinity than y l - M S H , while 
y l - M S H showed abou t 4-fold higher affinity for the 
MC3 receptor than a-MSH. In this study the y2-MSH 
was found to show a similar affinity profile as y l - M S H 
' .' >m-sp< . r u l c - n c c : |.tr Y\ i k h c t L ' . PlKimi.KX-utx.'.l pharm.icoli > p . B'»N * ' - 7 l . 1L\IC S-~51 2.A L'pp^iln, S w e d e n 
Behavioural responses of y-MSH • V Kkisa t! al. 
although it showed all over slightly (about 3-fold) lower 
affinities than y l - M S H for the different MC receptor 
subtypes. 
In the present stuclv we have focused on the 
behavioural effects induced by 7.-, y l - and )'2-MSH 
peptides injected into the VTA of rats, which is an area 
where the m R N A for both MC3 and MC4 receptors 
have been reported (Gantz et al. 1993a, Mountjoy et al. 
I«)94, Xia & Wikberg 1997). O u r present data indicate 
that the pharmacology of the 2-, y l - and "/2-MSH 
peptides differs significantly. In the case of y l - and 
•/2-MSH these differences are intriguing as y2-MSH 
differs only bv the extra C-cerxninal Glv residue 
compared with y l -MSH. This is the first time such 
pharmacological differences of y l - and y2-MSH were 
reported upon their injection into the CNS. 
M A T E R I A L S A N D M E T H O D S 
. llliwilli 
Male Wistar rats were bred at the Breeding House of 
the State Pharmaceutical Company G R I N D E X , Riga, 
Latvia, and used at weights 300-350 g. The animals 
were housed in groups of five in a light—dark cycle of 
12 h dights off 19.(10-7.0(1 hours). 
Survival procedures 
Cannulas made from stainless steel needles (15-mm 
long, 0 .56-mm O D ) were implanted stereotaxicallv 
under Nembutal (CEYA, Sanoh, France) anaesthesia 
(60 mg k g - ' i.p.) into the left YTA at the following 
co-ordinates: —5.2 caudal to bregma, 0.8 mm lateral 
from midline, and —8.0 ventral from dura mater 
(Paxinos & Watson 1982). Cannulas were kept in place 
with dental cement (SPOFA Dental) covered with 
duracrvl (SPOFA Dental). To prevent clogging of the 
cannulas a bent stylet of stainless steel was inserted into 
them, and removed only when the injection took place. 
After surgery rats were individually housed and given 
food and water ad libitum and allowed to recover for the 
following 7 clays in a recovery room. 
Peptides 
a-MSH (:Y-Acetyl-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-
Trp-Gly-Lys-Pro-Val-NHo), y l -MSH (H,N-Tyr-Val-
Met-Glv His-Phe-Arg-Trp-Asp-Arg-Phe-NH 2 ) , and 
/2 -MSH (H,N-Tyr-Val-Met-Gly-His-Phe-Arg-Trp-
Asp-Arg-Phe-Gly O H ) peptides were from BACHEM. 
The peptides were stored frozen in aliquots until used. 
Injections 
Drugs were injected into the VTA bv means of a T 5 R N 
Hamilton Digital Syringe and a very tine polyethylene 
Acta l'hysi..l Sea ml I W ) . 167. »<MiM 
aibe (Clav Adams , PH-10) attached to a 3()-gauge 
needle which was inserted into the implanted cannula. 
On the day of the experiment an MSH-peptide aliquot 
was thawed and dissolved in saline to provide 0.3 or 
3 nmole per rat. T h e total volume injected was for each 
substance I / /L at a speed of 0.25 m i n - 1 . For the 
combined t reatments (i.e. y2-MSH + yl -MSH), the 
•/2-MSH was administered 15 min prior to the yl-MSH 
injection. In the control groups y2-MSH was substi-
tuted with saline (i.e. saline + yl -MSH). 
Beharinnral analysis 
On day 7 after surgery the rats were transported from 
the recovering room to an observation room for 1 day 
of handling and habituating. Each rat was placed into a 
Plexiglas observation cage (60 X 40 X 15 c m ' ) and left 
for 30 min to diminish stress reactions to the novel 
environment. T h e rat was then placed onto an injection 
platform for 5 min before drug administration. 
Immediately after the injection the rat was placed in an 
observation cage. Observat ion started at the fifth 
minute after the onset of the injection and continued 
for up to I h using a Psion Workabout microcomputer 
(Noldus, the Netherlands) . Grooming activity (i.e. total 
grooming) was expressed in seconds as the sum ot the 
durations of the separate grooming reactions (face 
washing, body licking, scratching, ano-genital 
grooming, head and wet-dog shakes) recorded during a 
15-min period. T h e following non-grooming behav-
ioural events were registered: vertical activity (i.e. 
rearing) and catalepsy. Vertical activity was scored as 
incidences during the total ot each observation period. 
The tests were performed either for one 15-min period, 
or for four 15-min periods for a total of 60 min. At the 
start and at the end of, respectively, 15 and 60 min the 
rats were tested individually for catalepsy in three 
consecutive tests tor maximum 10 s each by: (I) placing 
the rat with its torepaws on a 7-cm high bar, (2) placing 
the rat with the hind legs on the same bar, and bv (3) 
placing the rat across two 7-cm high bars distanced at 
15 cm. Each ot the catalepsy tests 1-3 were given a 
weighting coefficient, respectively, 0.2, 0.3 and 0.5, and 
the total catalepsy was scored as total time the animal 
spent in the separate tests multiplied by its corre-
sponding coefficient. Thus the maximal score for a rat 
is 10 X 0.2 + 10 X 0.3 + 10 X 0.5 = 10 (see Sanberg 
et al. 1988). Tl ic observation sessions were performed 
between 10.00 and 14.00 hours. Each experimental 
group consisted of at least six rats. 
Statistics 
Statistical analysis was done using independent samples 
/-test or one-wav \\< >v.\ and Bonfcrroni's multiple 
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comparison test as a post hoc. Results are expressed as 
the mean ± SF!M. 
Animal ethics 
Experimental procedures were carried out in accor-
dance with guidelines of the European Community , 
local laws and policies and were approved bv the Ethics 
Commit tee of Animal Experimentation at the Iranian 
Research Council. 
R E S U L T S 
Before the onset o f the experiments the rats were 
handled and habituated to the experimental environ-
ment in order to minimize the novelty factors as much 
as possible. We first studied the effect of intra-VTA 
administration of a-, y l - and ",'2-MSH at the doses 0.3 
and 3 nmole during the first 1 5-min observat ion period 
(Fig. la). As can be seen 3 nmoles of both z-MSH and 
y l -MSH caused significant grooming. However, at the 
dose it.3 nmole the effect was significant onlv for 
y-MSH. Bv contrast, neither (1.3 nor 3 nmoles of 
','2-MSH affected the total grooming compared with the 
saline control . 
In Fig. 1(b) is shown the vertical activity recorded in 
the experiment shown in Fig. 1(a). As can be seen 1.1.3 
and 3 nmoles <<T y l -MSH significantly increased the 
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vertical activity. Also x-MSH increased vertical activity, 
although this was significant onlv at the 3 nmole dose. 
Bv contrast, none of the doses of y2-.MSH increased 
vertical activity. In Fig. l c is shown the catalepsv scores 
recorded at the end ot the experiment. As can be seen 
both (1.3 and 3 nmoles of "/2-MSH caused catalepsv 
(4—5 scores from die maximum 10), whereas 1- and 
y l -MSH did not. 
Time—effect relations were then assessed by 
administering 3 nmole of each of the peptides and 
observing m o t o r activities at four consecutive 15-min 
observation intervals. The data collected lor total 
grooming are represented in Fig. 2a. As can be seen 
from the figure the intra-VTA injection of either 
a-MSH or y l - M S H caused a marked and significant 
increase in total grooming throughout the l-h obser-
vation period. Bv contrast the i n t r a - \ T A administration 
of y2-MSH did not cause anv significant increase in the 
grooming during the first two, or during the last 
observation period. However , during the third 
(30—45 min) period y2-MSH did seem to cause a small, 
but significant increase of g rooming compared with the 
saline control (P < 0.05). With respect to vertical 
activity a- and y l - M S H induced a marked increase, but 
onlv during the first 15 min (Fig. 2b). ",'2-MSH did not 
cause vertical activity at anv ot the time periods studied 
(Fig. 2b). 
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In order to assess the effect of combined treatment 
of y l - and "/2-MSH the rats were pre-rreated with either 
3 nmoles ot intra-VTA "/2-MSH or saline (serving as 
control) 15 min prior to intra-VTA administration of 
3 nmole y l -MSH. T h e results are shown in Fig. 2. As 
can be seen in Fig. 2a the y l -MSH given to the saline-
treated rats caused a significant increase in total 
grooming at all rime periods studied. For the rats prc-
treated with / 2 - M S H significant attenuations of the 
y l - M S H grooming response were seen for the first and 
the two last time periods studied. T h e vertical activity 
was also increased in the saline pre-rreated animals 
receiving y l -MSH, and this increase was attenuated bv 
the "/2-MSH pre-trcarment, the effects being significant 
at the second and third 15-min period (Fig. 2B). In 
order to further assess the inhibitory effect of "/2-MSH 
on the y l -MSH, the grooming scores of the experiment 
shown in Fig. 2 were summed for the whole 60-min 
period. For the saline + y l -MSH and y2-MSH + y l -
MSH-treated groups these sums of scores were 
501 ± 96 and 205 + 45, respectively, a difference being 
statistically significant (P < 0.05). T h e corresponding 
numbers for vertical activity were 36.4 ± 4.5 and 
19.9 ± 6.6 (P < 0.05). 
At the end of the experiment shown in Fig. 2 the 
animals were tested for catalepsy. In these tests it was 
revealed that only the "/2-MSH treatments induced 
catalepsy. Thus for the group receiving "/2-MSH alone 
the catalepsy score was 4.9 ± 0 .1, while for the 
/2 -MSH pre-treated group (i.e. the group that was also 
given y l -MSH) the score was 3.1 ± 1.0. (In the former 
case the time point for recording catalepsy was 65 min 
after the injection of "/2-MSH, whereas in the latter case 
the recording was 80 min after the injection of 
' /2-MSH, and thus 65 min after the injection of 
y l -MSH) . 
D I S C U S S I O N 
We have here shown that left intra-VTA administration 
of 2- and y l -MSH induces marked grooming activity ot 
a similar maximal magnitude, although the y l -MSH 
appears to be slightly less potent than 2-MSH. The 
observed grooming activity is typical for the a-MSH 
induced behavioural repertoire earlier reported (see 
Gispen et al. 1975). In addition both ot- and y l -MSH 
increased vertical activity. 
The 2-MSH and y l -MSH show considerable 
sequence differences although they share a common 
core (His-Phe-Arg-Trp), a core which is found in all 
natural melanocortic peptides. Binding studies using 
recombinant human MC receptors indicate that y l -
MSH is 3-fold more potent than a-MSH on an MC3-
receptor, whereas on an MC4-receptor 2-MSH shows 
45-fold higher potency than y l -MSH (Schioth el al. 
i n : 
1995, 1996). In the present study we found that 2-MSH 
was more po ten t than y l - M S H . Thus, our present 
results would speak in favour ot the notion that the 
grooming effect by MSH-peptides is mediated via 
the MC4 receptor. \ \ e have earlier also shown that the 
intra-VTA administrations o t our MC4-receptor 
blocking c o m p o u n d HSO 14 lead to attenuation of the 
grooming responses induced bv intra-VTA adminis-
tration of a - M S H (Klusa et al. 1998), an observation 
which also suppor ts the role of the MC4 receptor in 
grooming. Suppor t for this contention also comes from 
observations bv Adan et al. (1997) demonstrating that 
MC4-receptor antagonistic ACTH(4—10) analogues are-
capable of blocking the grooming response of i.c.v. 
a-MSH. However , functional results from the /;/ rim 
administration of a peptide might not entirely reflect its 
potencies at the receptors as factors such as differential 
susceptibility to breakdown bv peptidase, diffusion or 
other process leading to elimination from the site of 
injection mav affect its concentration. Moreover, the 
receptor selectivities o t presently used peptides arc-
quite low. In this context we would also like to mention 
that we recently found receptor autoradiographic evi-
dence that there are MSH-binding sites in the VTA 
which are distinct from the MC3 and MC4 receptors 
(Lindblom et al. 1998). Fur ther studies are warranted 
before one definitely ascribes a role for the MC4 
receptor in the mediation of the grooming responses 
induced by MSH-pept ides . 
The results obtained with '/2-MSH were strikingly 
different from those obtained with 2- and y l -MSH. 
Thus , the ' /2-MSH peptide was practically ineffective in 
inducing g rooming and vertical activity; instead it 
induced a long-lasting cataleptic state. Our observations 
are somewhat in line with a previous observation 
indicating that ' /2-MSH is not capable of causing 
grooming when injected intra-cerebroventricularlv (Van 
Ree et al. 1981). However, besides the capability of 
"/2-MSH to induce a long-lasting cataleptic state, we 
have in the present study in addition shown that the 
peptide is capable of attenuating the grooming 
responses and the vertical activity induced by y l -MSH. 
O u r earlier binding studies suggest that y2-MSH 
shows an affinity profile for the human MC receptors 
which is similar to that of y l -MSH, although the 
binding affinities of y2-MSH for human MC receptors 
are about 2- to 3-fold lower than thev are for y l -MSH 
(Schioth ei at. 1996). It has earlier been hypothesized 
that "/2-MSH can act as an endogenous opioid antag-
onist (Van Ree et al. 1981), and opiate-induced cata-
lepsy is reported to be comparable with those induced 
by neuroleptics (Costall &. Naylor 1973). Moreover, Oki 
el al. (1980) reported that y l , y2 and "/3-MSH, but not 
a-MSH, prevented the binding ['H]-naloxone to opiate 
receptors of the rat brain. However, quite high 
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concentrations were needed (in the / ( M range) which 
corresponds to an about 1000-fold lower affinity when 
compared with the affinities for e.g. an MC3-receptor. 
The 7'2-MSH shows also lower affinity for the 
[ : ,H]-nalo.xone sites than does y l - M S H (Oki et al. 1980). 
In view of the low affinities of }'2-MSH for the opiate 
receptors it seems unlikely that these receptors are 
involved in the "/2-MSH effects of the present study. 
Perhaps the / 2 - M S H is exerting its effect via another 
pathway that is also distinct from the melancortin 
receptors. 
T h e only difference between y l - and "/2-MSH is an 
extra C-terminal Gly in the "/2-MSH. It is possible that 
this additional residue, which is expected to be flexible 
as a 'moving tail', could render the pept ide conforma-
tion quite different and change its pharmacological 
properties. For example the y2-MSH could become 
antagonistic, or it might even be capable of rapidly 
bringing an MC receptor into a desensitized state. 
However, further studies will be required to clarify 
these issues. In these smdies it might be o f value to use 
specific antagonists of the different M C receptors, 
something which is presently available only for the 
MC4-receptor (see Schioth et al. 1998). 
Lastly, it should also be ment ioned that we w-ere 
recently able to delineate between M C 3 and MC4 
receptors in the rat brain by using an autoradiographic 
approach (Ltndblom et al. 1998). O u r studies seem to 
indicate that the MC3 receptor protein dominates in 
many areas of the C N S such as the nucleus accumbens, 
medial pre-optic area and ventromedial nucleus of the 
hypothalamus, whereas in many other areas there are 
both MC3 and MC4 receptors present . However, 
interestingly in our study we found peculiar binding 
properties of MSH-peptides in the V T A seemingly 
indicating the presence o t vet another M C receptor in 
this area. These data seem to add to the complexity in 
the inteqxetat ion of the present data and should 
p rompt further investigations to clarify the functional 
roles of MC receptors in the VTA. 
In summary we have here shown that distinct 
differences exist in the behavioural effects caused by 
intra-VTA injections of a, y l - and y2-MSH. No t only do 
these peptides cause different spectra of behavioural 
effects, but we have also found y2-MSH to be capable of 
attenuating the g rooming responses caused bv y l -MSH. 
Supported bv Howard Hughes Medical Institute (HHM1 75195-
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M E L A N O C O R T I N S A N D T H E I R R E C E P T O R S : 
B E H A V I O U R A N D N E U R O C H E M I S T R Y 
Introduction 
During bioprocessing of the proopiomelanocortin (POMC) molecule 
several melanocortin peptides (ACTH, a-, (3-, and y-MSH) have been 
formed [5]. Afunctional role is well established for ACTH (stimulation 
of steroidogenesis in the adrenals) and a-MSH (melanogenesis in the 
melanocytes), whereas (J- and y-MSH still remain as mystery. In the 90th 
an intense identification and cloning of the melanocortin receptors 
(MCR) have been started. At present five MCR subtypes are described: 
MCIR, MC2R, MC3R, MC4R and MC5R [2,3,8,9,20,25]. The MCIR 
mRNA expression is limited in melanocytes and melanoma tumors [3], 
and M C I R is considered as crucial for a - M S H - r r i e d i a t e d effects 
(pigmentation). More strongly limited (only in the adrenal tissues) is 
MC2R mRNA express ion; this subtype mediates the ACTH corticotropic 
effects [20,23,28]. Wide expression of the MC3R mRNA is detected in 
the brain and peripheral tissues (e.g. placenta, pancreas) [5,9,22]; this 
receptor subtype binds y,- a n d ^ - M S H peptides, however a functional 
role for both peptides and Their receptors is still unclear. 
MC4R mRNA expression is found in brain tissues and this receptor 
subtype is capable to bind P-MSH (but not y-MSH) [2.9,19,24], 
Expression of the MC5R mRNA is distributed in many central and 
peripheral tissues and its overlapping with MC3R, MC4R and MC5R 
mRNA expressions is detected [7,10]. 
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In a framework of collaboration between the Uppsala University and 
the Latvian Institute of Organic synthesis, the studies were focused on 
Y^MSH and Y t - M S H to clarify their pharmacological and neurochemical 
effects, possible functional role of these peptides and their receptors. 
Since MC3R mRNA expression is detected to'a greater extent in the 
ventral tegmental area (VTA) [22,29], the peptides were microinjected 
in this brain structure. The first data were striking: although the chemical 
s t ructures of both y-MSHs are very s imilar ( y , - M S H : H , N -
YVMGHFRWDRF-OH; y :-MSH: H 2N-YVMGHFRWDRFG-OH)"and 
they differ by only one extra amino acid (Gly) residue at the C-terminal 
of Y , - M S H . these peptides showed different behaviour spectrum. [ 1 6 ] . 
If y,-MSH injected intra-VTA in rats induced excessive grooming and 
intensification of vertical activity, y^-MSH in opposi te , caused 
hypoactivation, even moderate catalepsy. Moreover, Y-.-MSH acted as 
antagonist by reducing the y,-MSH-induced grooming responses. 
Therefore the question can be arisen whether these opposite effects of 
Y,-MSH and Y t - M S H are mediated via the same specific MC3R and its 
different activation, or other receptor subtype - M C 4 R - which 
expression is recently detected in the VTA, is also involved in peptide 
actions. Besides, one should be taken into account that the VTA belongs 
to one of the major dopaminergic pathways - the mesolimbic system -
which transfers signals from the VTA to the nucleus accumbens (N AAC). 
This system is considered as "reward system" and intense dopamine 
release in the NACC is taken as crucial neurochemical basis which 
explain motivation of chronic opiate, alcohol use and development of 
the drug dependence [ 1 7 ] . Dopamine over-release in the NACC and 
behavioural hyperactivation/hyperlocomotion is found in schizophrenic 
patients during psychotic states [6 ] . 
The present study analyses the influence of Y , - M S H and y 2-MSH on 
"psychotic states" in schizophrenic model animals. Psychoactivation was 
induced by phencyclidine and amphetamine, which may intensify 
dopaminergic system and cause an increase in locomotor activity. 
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Methods 
Animals 
The experiments were performed in BALB/c male mice (19—21 g) 
obtained from the Breeding Facility of the Joint Stock Company 
GRINDEX (Riga, Latvia). Mice were kept at +21 t, conditioned air. 
humidity 60 ± 10%, light cycle from 6.00 a.m to 6.00 p.m.. standard 
diet (Akromin Standard Diets 1320), water ad libitum. 
Drugs and injection procedure 
Y,-MSH and y 2-MSH (BACHEM), MC4R antagonist HSO 14 from 
the University of Uppsala [26], were injected intracistemally (ic) in mice 
at a dose of 0.3 nmole/mouse (in a volume 10 u.1). 
Phencyclidine (PCP) synthesized at the Latvian Institute of Organic 
Synthesis; L-amphetamine (AMP) purchased from SIGMA; both drugs 
were administered peripherally 5 min prior to peptide injections: PCP 5 
mg/kg intraperitoneally, AMP 5 mg/kg subcutaneously. Peptides were 
dissolved in saline. Mice of the control groups received saline ic in the 
volume of 10 ml/mouse. 
Assessment of the locomotor activity 
The mice were placed in the Activity Cage (Ugo Basile, Cat.7400) 
and locomotor activity was registered from the 30th to 60th min after 
PCP or AMP administration. 
Statistics 
The results are calculated as mean values ± SEM and significance 
was evaluated at p<0.05 (Student's t test). Inter-group statistics was 
evaluated by ANOVA followed by Student's t test). 
Ethics 
The experimental procedures were carried out in accordance to the 
EU recommendations and accepted by the Ethics Committee on 
laboratory animal use at the Latvian Science Council. 
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Results and discussion 
In model animals which have received AMP as psychoactivation-
roirnicV.ing drug, both y-MSH reduced the AMP induced hyperloco-
motion. As it is well-known, AMP acts as dopamine releaser from the 
presynaptic nerve terminals resulting in dopamine accumulation in the 
synaptic cleft, which in turn leads to enhanced postsynaptic reception. 
This manifests as behavioural hyperactivation and increased locomotion 
[27]. 
In case of PCP-model the peptides acted differentially: y,-MSH 
potentiated the PCP-effects, whereas y 2 -MSH antagonized the PCP-
effects. Moreover, y,-MSH reduced the mentioned y,-MSH potentiating 
effect (y,-MSH+PCP). 
These data indicate that y,-MSH may act as psychoactivating, 
whereas y,-MSH as anti-psychotic peptide. However, there is no clear 
unders tand ing of their mechan i sms of act ion, s ince PCP is a 
representative of the opiate sigma receptor ligand [18], either a non-
competitive N M D A receptor antagonist [1]. The question of the 
participation of melanocortin receptors in y-MSH-induced influence on 
PCP effects, could had be solved by using selective MCR antagonists. 
Unfortunately, there is a problem to design selective MC3R antagonist, 
however HS014 was found [26] as effective MC4R antagonist [13.14]. 
It seems that detection of MC4R mRNA in the VTA has a great 
importance, although MC4R has lower affinity to y-MSHs in comparison 
to that of MC3R. Recently we have shown that MC4R antagonist HSO14 
acted as strong antagonist towards the a-MSH-induced grooming [14]. 
In light of these results there is surprisingly novel data from the present 
experiments: similarly to y,-MSH, HSO 14 was capable also to antagonise 
Y[-MSH-t-PCP effects (Fig.). One may suggest whether MCRs can 
mutually interact (cross-talk?) or y-MSHs and HSO 14 may affect 
mesolimbic dopaminergic processes. Our previous neurochemical data 
[15] are in line of that suggestion, as y^MSH and y,-MSH injected intra-
VTA in rats considerably influenced dopaminergic processes in the 
mesolimbic system (NACC and tuberculum olfactorium), particularly 
by intensifying dopamine metabolism (elevation of DOPAC concentra-
tion) in 15 min after administration. Despite short half-life of the pep-
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tides, their neurochemical effects were long-lasting that manifested as 
a propagation (in 1 h after injection) of the alterations also in other adja-
cent structures (nigrostriatal) and other neurotransmitter contents (e. g. 
sharp reduction of serotonin in the striatum). 
Thus, the data obtained show that y-MSHs are capable to interfere 
with various neurotransmitter systems. Obviously that may explain a 
variety of different central effects caused by y-MSH peptides, e.g. 
influence on blood pressure, pain perception, memory [15. 21]. So, in 
our experiments y,-MSH enhanced the activity of glutamate receptor 
antagonist PCP, on one hand, and antagonised effects of the dopamine 
releaser AMP, on the other hand. Besides one can be taken into 
consideration that y,-MSH has high affinity to MC3R. In turn, similarity 
in the effects of y 2 -MSH and MC4R antagonist HSO 14 (antagonism 
against both y r M S H and y,-MSH+PCP) indicates that they may act in 
similar manner on the glutamatergic processes. It remains as mystery 
how one C-terminal residue which makes y 2 -MSH structure longer than 
that of y ,-MSH may cause so great difference in their behavioural 
activities and probably in modifying the melanocor t inergic and 
glutamatergic systems. Since PCP influence on the mesolimbic system 
(stimulation of DA release in the NACC) can be taken as proved [14], 
the modulating influence of the PCP effects by y,-, y 2 -MSH and HSO 14 
may indicate their ability to alter effectively this reward .system and 
appropriate processes. The effectiveness of HSO 14 in the stimulation of 
feeding behaviour [12] allows to suggest food intake as reward process. 
One may expect that y 2-MSH will be capable to express similar to HSO 14 
activity but opposite (anorexic) from yj-MSH. The elucidation of the 
roles of melanocortins and their receptors are under intense studying. 
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Strong evidence suggests a functional link between the 
melanocortin and dopamine systems. a-Melanocyte stimulating 
hormone (a-MSH) induced grooming behaviour, which can be 
blocked by dopamine receptor antagonists, is associated with 
increased dopaminergic transmission in the striatal regions. 
Whether this effect is mediated specifically by melanocortin 
(MC) receptors has not previously been established. Using in 
vivo microdialysis on anesthesized rats we have shown that a-
K e y words: Dopamine; HS131; MC-t-receptor; Microdialysis; a-MSH 
MSH administered into the ventral tegmental area induced a 
significant increase in dopamine and DOPAC levels in the 
nucleus accumbens. This increase was completely blocked by 
pre-treatment with the MC< receptor selective antagonist 
HS 131. indicating that the effects of a-MSH on dopamine 
transmission may be mediated by the MC4 receptor. Neuro-
Report 12:2155-2158 © 2001 Lippincott Williams & Wilkins. 
I N T R O D U C T I O N 
Melanocortin peptides, such as a-melanocyte stimulating 
hormone (a-MSH) and adrenocorticotropic hormone 
(ACTH), are derived from the pro-hormone pro-opiomela-
nocortin (POMC). Central POMC containing neurons pro-
ject from areas in the hypothalamus and brain stem to 
many areas of the central nervous system. The melanocor-
tin peptides are known to act on five subtypes of the 
melanocortin receptors. Two of them, the MC3 and MQ 
receptors, are claimed to be dominant in the CNS [1]. The 
behavioural effects of the melanocortin peptides are well 
documented, and include avoidance, feeding, stretching-
yawning and grooming [2]. In some recent studies we used 
the MQ receptor selective antagonist HS014 and showed 
that it could block the grooming behaviour elicited by a-
MSH, indicating that melanocortin induced grooming may 
be mediated by the M Q receptor [3,4]. 
There are several reports suggesting the existence of a 
functional link between the melanocortin and dopamine 
systems [1]. The two systems are anatomically overlapping, 
and some dopamine synthesizing regions, such as the VTA 
[5], also express melanocortin receptors [6]. Intracerebro-
ventricular administration of melanocortin receptor ago-
nists not only induce excessive grooming, but also causes 
elevated concentrations of caudate nucleus dopamine 
levels [7]. Elevations in DOPAC/DA ratios in the caudate 
putamen and nucleus accumbens have also been observed 
after administration of a-MSH into the ventral tegmental 
area (VTA) [8]. Grooming may also be induced by admin-
istration of dopamine Dj agonists [9]. Moreover, the 
dopamine Di-receptor selective antagonist SCH 23390 
inhibits the grooming behaviour induced by ACTH, sug-
gesting that melanocortin induced grooming, and perhaps 
other behaviours, are at least partially mediated by central 
dopamine [9,10]. 
Whether the effects of melanocortin peptides on striatal 
dopamine levels is specifically mediated by melanocortin 
receptors has not been established. The aim of this study 
was to test the hypothesis that MQ-receptors in the VTA 
causes increased release of dopamine in the nucleus 
accumbens. 
MATERIALS A N D METHODS 
a-MSH (Ac-Ser-Tyr-Ser-Met-Clu-His-L-Phe-Arg-L-Trp-Gly-
Lys-Pro-Val-NH2) and HS131 (cyclo (S-S)-Ac-L-Cys5, 
GIy6,r>Nal7,L-Cys-NH2 1 0)a-MSH5-1 0 trifluoroacetate [11]) 
were synthesized using the solid phase approach applying 
a Fmoc-based ^'oneer peptide synthesis system (PerSeptive 
Biosystems) ar.a purified by HPLC. The correct molecular 
weights of the peptides were confirmed by mass spectro-
metry. Dopamine and DOPAC (3,4-dihydroxyphenylacetic 
acid) were obtained from Sigma-Aldrich, Tyreso, Sweden. 
The rat MC3 and MCi receptor clones were generously 
provided by Dr RD Cone, Vollum Institute, USA and Dr R 
Duman, Yale University, USA, respectively. The receptor 
clones were transiently expressed in COS cells [12] and 
competition curves were made for HS131 with a constant 
concentration of [ 1 2 5I][Nle\ D-Phe7]a-MSH as described 
previously [13]. The radioligand binding assays were 
performed in duplicate and repeated 3 -4 times. 
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In order to establish the antagonistic/agonistic proper-
ties of HS131 on the rat MCi-receptor, a cAMP assay was 
performed by applying eight different concentrations of o-
MSH alone or in the presence of 30 nM HS131 to COS cells 
transiently expressing the rat M Q receptor. Incubations 
with ligands were performed for 20 min before quenching 
the cells with perchloric atid/Tris-KOH and assaying 
cAMP using a protein binding assay essentially as de-
scribed [14]. 
Male Sprague-Dawley rats (Beco, Sweden; n = 21, 270-
340 g) were housed in groups of four at a temperature of 
20-22°C and a relative humidity of 55% under an artificial 
lighfcdark cycle (lights on 07.00-19.00 h). The animals had 
unlimited acess to food (R36 food pellets, Labfor, I^ctimin, 
Vadstena, Sweden) and water. The study was approved by 
the local ethical committee. 
The animals were divided into four groups; saline 
(n=6), a-MSH (n = 6), HS131 (n = 5) and a-MSH+ HS131 
(n = 4). They were anaesthetized with inactin (80 mg/kg, 
Lp.) and positioned in a Kopf stereotaxic frame. Body 
temperature was kept at 37°C using a HB 101/2 tempera-
ture control unit (Letica Scientific Instruments, Barcelona, 
Spain). The skull was exposed and two holes were drilled 
for the placement of a MAB microdialysis probe (cut-off 
20kDa PES; AgnTho's AB, Lidingo, Sweden) in the left 
nucleus accumbens (coordinates from bregma: B +2.2, L 
—1.5, V —7.1) and for a guide cannulae (made from 
stainless steel syringes, length 15 mm, o.d. 0.56 mm) into 
the left VTA (B -5.0, L -0.9, V -7.2). The guide cannula 
was implanted 2 mm over the VTA for later insertion of a 
microinjection needle and kept in place with dental cement 
(De Trey, Sevriton, Germany). 
The microdialysis probe was perfused with artificial 
cerebrospinal fluid (CSF; Apoteket Produktion and Labor-
atorier, Umea, Sweden) and inserted slowly into the 
nucleus accumbens in order to rrunimize tissue damage 
caused by penetration of the probe. The implanted probe 
was used to deliver extracellular dopamine and DOPAC. A 
constant flow of 2 ul/min was maintained with a micro-
dialysis pump (Univentor 684 Syringe pump, Bulebel 
Industrial Estate, Malta). Two hours after implantation of 
the probe, 20 min dialysate samples were collected from 
the outlet line in the Microsampler (Univentor 810 Micro-
sampler, Bulebel Industrial Estate, Malta) into polyethylene 
microcentrifuge tubes. Three basal samples were collected 
with <15% variation in DA and DOPAC levels before 
drug administration. 
a-MSH and HS131 were respectively dissolved in sterile 
artificial CSF. CSF (0.5 ul), a-MSH (lOnmol/0.5 ul) and 
HS131 (1 nmol/0.5 ul), respectively, were injected manually 
into the VTA via the guide cannula using a Hamilton 
Mirolitre syringe (Hamilton-Bonadaz AG, Switzerland) and 
a fine polyethylene tube (Clay Adams, PE-10) attached to a 
30-gauge microinjection needle that extended 1.2 mm dee-
per than the guide cannula, i.e. 0.8 mm over the VTA. For 
the combined treatments HS 131 was administered 40 min 
prior to the injection of a-MSH. The microinjection needle 
was left in place after injection to limit drug efflux up the 
cannula shaft. Sampling was continued for 4h. 
The concentrations of DA and DOPAC were determined 
using HPLC with electrochemical detection. A reversed-
phase column (ReproSil-Pur C-18-AQ, 150 X3mm, particle 
size 5 urn) was used to separate the biogenic amines, and a 
coulometric-electrochemical detection system (ESA Inc, 
Chelmsford, MA, USA) utilizing two electrodes was used 
to oxidize the amines. Preinjection part guard electrode 
voltage was +0.4 V (ESA, guard cell Model 5020) and 
working electrode voltage was +0.34 V (ESA, analytical cell 
Model 5011). The mobile phase consisted of 2g / l 
CH 3COONa.H 20, 38.75 mg/1 1-octanesulfonic acid, 
3.7mg/l EDTA and 100 ml/1 methanol at pH 4. The HPLC 
pump (LKB 2150 HPLC pump, Bromma, Sweden) was 
0.6rru/min. Chromatograms were recorded using a MEGA 
series integrator (Carlo ERBA, Strumentazione, USA). The 
limit of detection was 0.4 nM for both dopamine and 
DOPAC. 
After the experiment, the animals were killed by decap-
itation. The brains were removed, frozen in cold (between 
—20 and —30°C) 2-methyIbutane, mounted on a cryostat 
microtome and sectioned (35 pm). The sections were col-
lected on gelatine coated slides and stained with Mayer 
hematoxylin (Histolab Products AB, Sweden). The stained 
sections were digitized in a video camera (CCD-72, Dage-
MTI, Michigan City, IN), and the positioning of the micro-
dialysis probe and the guide cannula was confirmed using 
NTH-Image software (NTH Image 1.54, NIMH, Bethesda, 
MD) and a brain atlas as a reference [15]. Only animals 
with correctly implanted probe and cannula were included 
in the statistics. 
For statistical analysis, cAMP data were tested with a 
repeated measurements ANOVA, followed by Fisher's 
protected least significant difference (PLSD) test where 
appropriate. Changes in DA and DOPAC levels were 
represented as a mean of the three post-injectional sam-
plings relative to the three pre-injection samplings. Inter-
group comparisons were made with a factorial ANOVA 
test followed by Fisher's PLSD test where appropriate. All 
statistics were performed using the StatView 4.51 software 
for Macintosh, p < 0.05 was used as the criterion of 
statistical significance. 
RESULTS 
The results from the radioligand binding experiment are 
shown in Table 1. HS131 displayed a 150-fold selectivity 
for the recombinant rat MGt receptor over the recombinant 
rat MC3 receptor. Measurements of cAMP indicated that 
30 nM HS131 blocked the increase of intracellular cAMP 
levels induced by a-MSH in cells expressing the recombi-
nant rat MC; receptor (Fig. 1). Repeated measurements 
ANOVA analysis indicated that HS131 significantly 
(F(l,6) = 14.1, p< 0.001) blocked the a-MSH effect Post-
hoc analysis (Fischer's PLSD) showed that the effect was 
T a b l e t . Binding constants (pKj, mean ± s.e.m.. and K* values) of 
HSI3I for the rat M C j and MC4 receptors determined by radioligand 
binding on receptors expressed in COS cells and using [ l 2 5 l]-NPD-MSH 
as radioligand 
HSI3I rMC] rMC, 
pK 6.5 ±0.1 8 7 ±0.3 
K (nM) 331 2.12 
n 3 4 
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Fig. I . Generation of cAMP in COS-1 cells expressing the rat M Q 
recepcor in response to a-MSH (n = 5) and a-MSH + HS 131 (n = 3). 
Each point represents mean ± s.ejn. * p < 0.0S. 
significant at the two highest concentrations of a-MSH 
tested, i.e. 1 and 10 uM (F(l,6) = 9.413, p<0.05 and 
F(l,6) = 7.184, p < 0.05). 
Baseline dialysate levels of D A and DOPAC were 
0.67 ± 0.05 and 369 ± 29 nM, respectively. The results from 
the measurements of DA (F(3,17) = 12.63, p < 0.0001) and 
DOPAC (F(3,17) = 9.40, p< 0.001) by microdialysis are 
shown in Fig. 2. Post hoc analysis (Fischer's PLSD) indi-
cated that a-MSH injected into the VTA caused a signifi-
cant increase in the levels of DA ( p < 0.001) and DOPAC 
(p < 0.005) in the nucleus accumbens during the 60 min-
utes following the injection. Pre-treatment with HS131 into 
the VTA completely abolished the effect of a-MSH on both 
DA and DOPAC. HS131 administered alone into the VTA 
did not induce any effect on DA or DOPAC levels. 
DISCUSSION 
In this study we investigated the involvement of melano-
cortin receptors in the VTA for the melanocortin induced 
release of D a in the nucleus accumbens. We used in vivo 
microdialysis to measure the levels of extracellular DA and 
DOPAC in the nucleus accumbens following the intra-VTA 
injections of the MCR agonist a-MSH and the MQ-
selective antagonist HS131. In agreement with previous 
findings [7,8], a-MSH caused an increase in the levels of 
DA and DOPAC in the nucleus accumbens. The effect of 
HS131 was similar to that of CSF alone, but pre-treatment 
with HS131 completely abolished the effect of a-MSH. This 
is in support of the hypothesis that a-MSH mediates its 
effect on nucleus accumbens dopamine by activating mela-
nocortin receptors. 
a-MSH is a non-selective agonist for both the rat MC3 
and MC4 receptors, showing a Ki of about 10 nM for each 
of these receptors in binding assays [16]. Our present 
results, on the other hand, show that the MCR antagonist 
HS131 has a 150-fold binding preference for the MQ 
receptor compared to the rat M Q receptor. Moreover, our 
present results show that HS131 is a blocker to the 
i 1.5-1 
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Q 
I -
0.5-
CSF a-MSH HSI3I HSI3l/a-MSH 
2.5-1 (b) 
a. 
o 
Q 
0.5-
CSF a-MSH HSI3I HSI3lta-MSH 
Fig. 2. Average levels of DA (a) and DOPAC (b) in the nucleus 
accumbens measured by microdialysis after administration of artificial 
CSF. lOnmol a-MSH. I nmol HSI3I or lOnmol a-MSH after pretreat-
ment with I nmol HSI3I into the VTA. The results are presented as 
mean ± s.e.m. of DA and DOPAC 60 min after administration relative to 
baseline levels. * * * p < 0.005 « CSF. HS 13 I and HS 131 /a-MSH. 
agonistic activity of a-MSH on the rat M Q receptor. It 
seems thus likely that the quenching effect of HS131 on the 
a-MSH induced release of dopamine is due to blockade of 
MQ receptors, but due to the fact that the concentration of 
HS131 at the site of action in the VTA is unknown, it 
cannot be rigorously excluded that some other subtype of 
MC receptor is blocked. 
Previous evidence indicate that stimulation of central 
MQ receptors may induce grooming behaviour [3,4]. 
Moreover, earlier studies show that ACTH-induced groom-
ing may be blocked by doparnine receptor antagonists [10]. 
Therefore, it is reasonable to suggest that MQ receptor 
mediated release of dopamine might be a causative event 
in the induction of grooming behaviour by the melanocor-
hhs. 
The mesolimbic dopamine system originates in the 
ventral tegmental area (VTA) and project axons to the 
limbic system, including the nucleus accumbens. The role 
of the mesolimbic dopamine system is supposedly that of a 
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mediator of rewards; hence it is often referred to as the 
reward system. The reward system is believed to be 
involved not only in the hedonic impact of natural stimuli 
(such as food), but also in the development of drug 
addiction [17]. In a recent study, the availability of dopa-
mine D2 receptors were shown to be reduced in the 
striatum of obese patients, suggesting a role of the central 
dopamine system in the pathology of obesity [18]. Dopa-
mine is also essential for the hyperphagia in leptin-defi-
cient mice [19]. The melanocortin system is strongly 
implicated in the regulation of energy homeostasis, and the 
mechanism of action of melanocortin peptides on food 
intake involves the complex signaling of several hypotha-
lamic nuclei [20]. However, the observed action of melano-
cortins on the mesolimbic dopamine system suggests that 
some of the effect of melanocortin peptides on food intake 
may be attributed to alterations in the subjective value of 
food (for a discussion on possible involvements of dopa-
mine in feeding effects of the melanocortins see [21]). 
Moreover, the melanocortin system appears to have a role 
as a functional antagonist to opiate action [22]. Although 
this may seem somewhat paradoxical, due to the fact that 
opiates, in a similar fashion as the melanocortins, stimulate 
the release of nucleus accumbens dopamine [23], it may 
nevertheless provide yet a link between the melanocortic 
and reward systems. Interestingly, several of the other 
behaviours elicited by melanocortins, e.g. passive avoid-
ance [24] and stretching-yawning [25] may also involve the 
central dopamine system. It is thus possible that these 
melanocortin induced actions are also, at least partly, 
mediated by dopamine release. 
CONCLUSION 
We have here provided evidence that melanocortin recep-
tors, with the MC4 receptor being a likely candidate, may 
mediate the elevated release of dopamine seen in the 
nucleus accumbens after administration of a-MSH into the 
VTA. It is likely that MC receptor-mediated dopamine 
transmission is responsible for melanocortin-induced 
grooming behaviour, and possibly also in other melanocor-
tin effects, such as feeding behaviour, passive avoidance 
and stretching-yawning. 
REFERENCES 
1. Adan RA and Gispen WH. Peptides 18, 1279-1287(1997) 
2. de Wied D. Eur / Pharmacol 37S, 1-11 (1999). 
3. Klusa V, Svirskis S, Opmane B et al. Neuropeptides 32, 573-580. (1998). 
4. Vergoni AV, Bertolini A, Mutulis F et at. Eur } Pharmacol 362. 95-101 
(1998). 
5. )aber M, Robinson SW, Missale C el al. Neuropharmacology 35, 1503-1519 
(1996). 
6. Mountjoy KG, Mortrud MT, Low MJ et al. Mol Endocrinol 8. 1298-1308. 
(1994). 
7. Florijn WJ, Holtmaat AJ, de Lang H et al. Brain Res 625, 169-172 (1993). 
8. Torre E and Cells ME. Life Sci 42, 1651-1657 (1988). 
9. Van Wimerrma Greidanus TB, Maigret C, Tom M et al. Eur j Pharmacol 
173, 227-231 (1989). 
10. Wiegant VM, Cools AR and Gispen WH. Eur [ Pharmacol 41. 343-345 
(1977). 
11. Wikberg JES. Exp Opin Ther Patents 11, 1-16 (2001). 
12. Schioth HB, Muceniece R, Wikberg JE el al. Eur ] Pharmacol 288. 311-317 
(1995). 
13. Lindblom J, Schioth HB, Ursson A et al. Brain Res 810, 161-171 (1998). 
14. Nordstedt C and Fredholm BB. Anal Biochem 189, 231-234 (1990). 
15. Paxinos G and Watson C The Rat Brain in Stereotaxic Coordinates. Mew 
York: Academic Press; 1997. 
16. Adan RA, Szklarczyk AW, Oosterom J et al. Eur / Pharmacol 378, 
249-258 (1999). 
17. Koob GF. Trends Pharmacol Sci 13, 177-184 (1992). 
18. Wang G-J, Volkow ND; Logan J cl al. Lancet 357, 354-357 (2001). 
19. Szczypka MS, Rainey MA and Palmiter RD. Nature Genet 25, 102-104 
(2000). 
20. Cone RD. Trends Endocrinol Metab 10, 211 -216 (1999). 
21. Wikberg JE, Muceniece R, Mandrika I et al. Pharmacol Res 42. 393-420 
(2000). 
22. Alvaro JD, Tatro JB and Duman RS. Life Sci 61, 1-9 (1997). 
23. Di Chiara G and Imperato A. Proc Natl Acad Sci USA 85, 5274-5278 
(1988). 
24. Stewart MG, Kabai P, Harrison E et al. Neuroscience 70, 7-14 (1996). 
25. Ferrari F and Giuliani D. Neuropharmacology 36, 769-777 (1997). 
Acknowledgements: This research was supported by grants from the Swedish MCR (04X-05957), the Wiberg fund and Melacure 
Therapeutics. Baiba Opmane was supported by a stipend from the Swedish Sstitute under the Visby Programme. 
2158 Vol 12 No 10 20 July 2001 

Neuropeptides (2001) 35 (1). 50-57 
O 2001 Harcourt Publishers Lid 
doi: 10.1054/npep.2000.0843. available online at http://www.idealibrary.corn on 
The 72~MSH peptide mediates a central 
analgesic effect via a GABA-ergic 
mechanism that is independent from 
activation of melanocortin receptors 
V . K L U S A , 1 , 2 S . G E R M A N E , 2 S . S V I R S K I S , 1 ' 2 B . O P M A N E , 2 
J . E . S . W I K B E R G 3 
'Department of Pharmacology, Faculty of Medicine, University of Latvia, Riga, Latvia 
laboratory of Pharmacology, Latvian Institute of Organic Synthesis, Riga. Latvia 
department of Pharmaceutical Pharmacology, Uppsala University, Uppsala, Sweden 
S U M M A R Y U s i n g t h e l a t e n c y for tail-flick after t h e r m a l s t i m u l a t i o n w e h a v e a s s e s s e d t h e e f f e c t s of a-, y r a n d y 2 - M S H 
on n o c i c e p t i v e t h r e s h o l d in t h e m i c e . I n t r a c i s t e r n a l i n j e c t i o n s of y 2 - M S H i n d u c e d a d i s t i n c t a n a l g e s i a , w h i l e y , - M S H in 
t h e s a m e d o s e s g a v e o n l y a m i n o r a n a l g e s i a . I n t r a c i s t e r n a l a - M S H i n s t e a d g a v e a s h o r t - t e r m h y p e r a l g e s i a . T h e effect 
of y 2 - M S H w a s not b l o c k e d by a n y of t h e M C 4 / M C 3 r e c e p t o r a n t a g o n i s t H S 0 1 4 , n a l o x o n e or b y t h e prior i n t r a c i s t e r n a l 
a d m i n i s t r a t i o n s of Y r M S H . H o w e v e r , t h e y 2 - M S H a n a l g e s i c r e s p o n s e w a s c o m p l e t e l y a t t e n u a t e d by t r e a t i n g a n i m a l s 
with t h e G A B A A a n t a g o n i s t b i c u c u l l i n e . T h e y 2 - M S H a n a l g e s i c effect w a s m o r e o v e r a d d i t i v e to t h e a n a l g e s i a a f f o r d e d 
by m u s c i m o l a n d e t h a n o l , but not to t h a t a f f o r d e d b y d i a z e p a m . In a d d i t i o n b o t h y r a n d y 2 - M S H i n d u c e d m o d e r a t e 
c a t a l e p s y , b u t c o u l d a t the s a m e t i m e a t t e n u a t e h a l o p e r i d o l i n d u c e d c a t a l e p s i a . W e c o n c l u d e that y 2 - M S H m e d i a t e s a 
c e n t r a l a n a l g e s i c e f f e c t v ia G A B A - r e c e p t o r d e p e n d e n t p a t h w a y that is d i s t i n c t f r o m m e l a n o c o r t i c - a n d o p i o i d - r e c e p t o r s . 
M o r e o v e r , t h e m e c h a n i s m for y 2 - M S H ' s a n a l g e s i c e f f e c t a p p e a r s to b e d i s t i n c t from t h a t c a u s i n g m o d e r a t e c a t a l e p s i a 
by y - M S H ' s . © 2 0 0 1 H a r c o u r t P u b l i s h e r s Ltd 
INTRODUCTION 
The melanocortic peptides (ACTH and the a-, p- and y-MSH 
peptides) are derived from the POMC (pro-opio melano-
cortin) precursor and have a wide-spread distribution in 
the body. In the central nervous system POMC-immunor-
eactive neurones form essentially two neural systems: one 
originates in cell bodies localised in the posterior hypotha-
lamus, and the other in cell bodies of the brain stem. These 
neurones project to distinct regions of the central nervous 
system including t h e telencephalon, diencephalon, me-
sencephalon, brainstem and spinal cord (Eberle, 1 9 8 8 ) . 
Received 23 August 2000 
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Correspondence to: Jarl Wikberg, Pharmaceutical Pharmacology, 
Box 591. BMC. S-751 24 Uppsala, Sweden; Tel.: +46 18 4714238; 
Fax: +46 18 559718; E-mail: Jarl.Wikberg@farmbio.uu.se 
Over the last few years the mode of central actions of the 
melanocortins have started to become increasingly under-
stood. Five different types of melanocortin receptors, 
M C ! _ 5 , that are responsive to the melanocortic peptides 
have been cloned (Wikberg, 1 9 9 9 ) . Using in situ hybrid-
ization the distribution of mRNAs for the different MC 
receptors were mapped. The M C i receptor mRNA was 
detected only in some discrete neurones of the periaqu-
eductal gray (PAG) area (Xia et al., 1 9 9 5 ) . M C 2 receptor 
mRNA seems not to be expressed in the central nervous 
system, al though it is abundant ly expressed in cells of the 
adrenal cortex (Xia and Wikberg, 1 9 9 6 ) . The M C 3 receptors 
are distinctly expressed in several regions of the hypo-
thalamus, thalamus and mesencephalon. In particular 
neurones of the ventral tegmental area (VTA) of the mid-
brain show abundan t expression of M C 3 receptor mRNA 
(Low et al., 1 9 9 4 ; Xia and Wikberg, 1997). The M C 4 re-
ceptor is widely expressed in many regions of the CNS 
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Fig. 1 A-C Effects of y2-, y,- and a-MSH peptides on tail-flick 
latencies in BALB/c mice. Peptides were administered intracister-
nally at doses 0.3, 1 or 3 nmol and the tail-flick latencies were 
recorded for up to 24 h. Saline indicates controls injected with the 
same volume (10 ul) of solvent used for peptides (saline). Baseline 
represent tail flick responses recorded 30 min prior to administration 
of saline or peptides. Each bar represents the mean + S.E.M from 
measurements of 7-9 different animals. * indicates P < 0.05 vs 
saline. 
of Animal Experimentation at the Latvian Research 
Council. 
RESULTS 
Comparison of the effects of 7 2 -MSHs, 71-MSH and 
a-MSH on tail-flick latencies 
Results for the effect of intracisternal injections of 0.3, 1 
and 3 nmol of, respectively, y2-MSH, y ^  -MSH and a-MSH on 
tail-flick latencies are shown in Fig. 1 All three doses of 
72-MSH significantly increased the tail-flick latencies 
during the 3 0 - 9 0 min following the injections; the peak 
response being seen at 60 min and maximally amounting 
to an approximately 70% increase compared to the base-
line level (Fig. 1 A). By contrast, only the 0.3 nmol dose of y,-
MSH gave a significant increase of the tail flick latencies at 
60-90 min following its intracisternal injection, while at 
other time points, or at the 1 or 3 nmol doses no significant 
effects were seen (Fig. IB). a-MSH gave a completely differ-
ent picture as it caused hyperalgesia. Thus, 30 min after the 
injection of a-MSH all three tested doses reduced signific-
andy the tail flick latencies, the maximal decrease being 
about 35% from the baseline level (Fig. 1Q. 
Effect of HS014 on tail-flick latencies 
The possible effect of the MC4/MC3 blocker HSO 14 on tail-
flick latencies was assessed after intracisternal injections of 
0.3, 1 or 3 nmol of the compound (Fig. 2A). As seen the 
HSO 14 induced no or only very minor effects. Only at 
60 min and 24 h after its injection minor significant effects 
were seen at 1 and 3 nmol, respectively. These minor 
effects may presumably be regarded as spurious responses. 
Thus, HSO 14 appears to be essentially devoid of effects on 
tail-flick latency. 
Effects of HS014 and VT-MSH pre-treatments on the 
effect of 72 -MSH on tail-flick responses 
Animals were pre-treated by intracisternal acirninistration 
of either 1 nmol of HSO 14 or 1 nmol y} -MSH 30 min prior to 
the administration of 1 nmol of y2-MSH, and the tail-flick 
latencies were assessed (Fig. 2B). As can be seen from the 
figure the HSO 14 per-se did not affect tail-flick latencies, 
while yl-MSH caused a minor significant increase 30min 
after its injection. The y 2-MSH, on the other hand, caused 
the expected increase in tail-flick latencies; its effect being 
significant 30 -90 min following its injection. However, 
neither the HSO 14 nor the y,-MSH pre-treatment affected 
the response induced by y2-MSH (Fig. 2B). 
Effect of haloperidol and 72 -MSH on tail-flick responses 
Animals were pre-treated by i.p. administration of 1 mg/kg 
mg of haloperidol 30 min prior to the intracisternal admin-
istration of 1 nmol of y2-MSH, and the effects on tail-flick 
latencies were assessed (Fig. 3A). Controls were injected 
with saline via the appropriate route. The haloperidol pre-
treatment, per-se, induced a clear and significant increase 
in the tail-flick latency already at the start of the assess-
ment period (i.e. 30 min after haloperidol administration, 
corresponding to the zero time point recorded just before 
the saline/y 2-MSH injection) (Fig. 3A). The tail-flick laten-
cies then remained significantly increased up until 90 min, 
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although at varying levels (Low et al., 1994). The localisa-
tion of the M C 5 receptor in the central nervous system has 
hitherto not been mapped with histochemical techniques, 
although Northern blot and RT-PCR analysis indicate its 
presence in the brain (Chhajlani et al., 1993; Gantz et al., 
1994;Fathi et al., 1995). 
The melanocortic peptides induce a variety of central 
effects, which include alterations in motor and sexual 
behaviour, analgesia, improvement of memory, anti-
pyretic effects, and regulation of feeding behaviour 
(Wikberg, 1999). Some of these effects have been possible 
to tie to distinct sub-types of the MC-receptors. Thus, the 
MC 4 receptor appears to have a prominent role in the con-
trol of feeding homeostasis (Wikberg, 1999). The excessive 
grooming behaviour induced upon central administration 
by a-MSH is also mediated by MC-receptors as it is blocked 
by MC-receptor selective antagonists (Klusa et al., 1998), 
but the exact receptor(s) involved is still not entirely clear. 
In a recent s tudy we found that y-MSH's showed quite 
distinct differences on motor behaviours induced upon 
its injection into the ventral tegmental area of the rat, 
when compared with a-MSH (Klusa et al., 1999). Thus, y 2 -
MSH produced slight catalepsy and hypoactivation while 
a-MSH (and y r MSH) induced excessive grooming. More-
over, y2-MSH was capable to antagonise the y r M S H induc-
tion of grooming. These, results prompted us to investigate 
further the behavioural pharmacology of y-MSH peptides. 
In the course of these studies we found that the y2-MSH 
peptide is capable of inducing a powerful analgesic effect 
on its central administration to the mice. In the present 
study we set forth to characterise these effects. The most 
prominent result emerging from our s tudy is that, while the 
analgesic effect of y2-MSH remains completely untouched 
by administration of the MC-receptor blocker HSO 14 or the 
opioid-receptor blocker naloxone, it is completely attenu-
ated by the GABAA-receptor antagonist bicuculline, as well 
as augmented by the GABAA agonist muscimol. 
MATERIALS AND METHODS 
Animals 
Male BALB/c mice were bred at the Breeding House of the 
A. Kirhenstein Institute of Microbiology and Virusology, 
University of Latvia, Riga, Latvia, and used at weights 20 + 
2 g. The animals were housed in groups of five, using a 
l ight-dark cycle of 12 h (lights off 19.00-7.00). At the time 
of experiments the animals were arranged in groups con-
sisting of 6-10 mice. 
Drugs 
a-MSH (N-Acetyl-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-
Trp-GIy-Lys-Pro-Val-NH2), y,-MSH (H2N-Tyr-Val-Met-
Gly-His-Phe-Arg-Trp-Asp-Arg-Phe-NH2), and y2-MSH 
(H2N-Tyr-Val-Met-Gly-His-Phe-Arg-Trp-Asp-Arg-Phe-Gly-
OH) peptides were from BACHEM. The HSO 14 peptide was 
synthesised as described (Schioth et al., 1998). Peptides 
were stored frozen in aliquots until used. Naloxone hydro-
chloride (substance) was from Sigma Chemicals Co, 
USA; haloperidol (0.5% solution) from Gedeon Richter, 
Hungary; ( + )bicucialline (substance) from Sigma 
Chemicals Co, USA; muscimol (substance) from Fluka 
AG, Switzerland; diazepam (5% solution) from Gedeon 
Richter, Hungary. 
Drug administrations 
Peptides were dissolved in saline and injected intracistern-
ally (ic) into the cistema magna in conscious mice via 
a J-shape needle connected to a Hamilton syringe, as 
described (Takagi et al., 1979). Intracisternal injection 
volumes never exceeded 10 ul. Drugs were dissolved in 
saline and ethanol in water (10% ethanol), and injected 
intraperitoneally. 
Tail flick test 
Tail flick tests were carried out in accordance to the 
method described elsewhere (Dewey, 1981), with minor 
modifications. In brief, the tail of the mouse was placed 
on the photoelement window of a MODEL DS20 SOCREL 
tail flick apparatus (Ugo Basile, Italy) and an infrared beam 
was focused on the tail area, 2 c m from its basis. The 
latency for the m o u s e to react to the pain stimuli was 
recorded. To avoid tissue damages, maximal exposure to 
the pain stimuli was restricted to 15 s. 
Catalepsy test 
Test of catalepsy was carried out essentially as described 
(Kobayashi et al., 1997). In brief, catalepsy was evaluated 
by placing both forepaws of the mouse over a horizontal 
bar (diameter 0.2 cm), elevated 15 cm from floor, and the 
time (in s) during which the animal maintained this posi-
tion was recorded. 
Statistics 
Statistical analysis was done using independent samples 
r-test or one-way ANOVA and Bonferroni's multiple com-
parison test as a post-hoc. Results are expressed as the 
mean ± S.E.M. 
Animal ethics 
Experimental procedures were carried out in accordance 
with guidelines of the European Community, local laws 
and polices and were approved by the Ethics Committee 
© 2001 Harcourt Publishers Ltd Neuropeptides (2001) 35(1), 50-57 
54 Klusa et al. 
• sal + sa! 
Bhal + sa 
^ n a l + sal 
• sa l+ r2 -MSH 
0rial+y2-MSH 
@nal+y2-MSH 
-30 min 0 min 30 min 60 min 90 min 120 min 
(Base line) 
60-| B 
' 5 0 
2 40-
| 2 0 
CO 
<-> 10 
I 
M 
Baseline u 
60 min 
[JJ sal+sal 
Bsal+y1-MSH 
0 sal+y2-MSH 
• hal+sal 
Shal+yl-MSH 
ghal+y2-MSH 
120 min 
Fig. 3 A. Effect of haloperidol (hal), naloxone (nal) and y2-MSH on 
tail-flick latencies in BALB/c mice. Haloperidol (1 mg/kg) or naloxone 
(2 mg/kg) were given i.p. at 30 min prior ( - 30 min) to the injection of 
y2-MSH (1 nmol). Sal indicates controls injections with the same 
volume of solvent as used for respective agent. Baseline represents 
tail-flick responses recorded just immediately prior to the -30 min 
time point, n = 8. " indicates P < 0.05 vs saline. + indicates P < 
0.05 vs baseline. B. Assessment of cataleptic effects of haloperidol 
(hal), Yr a n d y2-MSH in BALB/c mice. Haloperidol (0.5 mg/kg) was 
given 30 min prior to the intracisternal injection of 0.3 nmol of 
respective peptide. Sal indicates controls injections with the same 
volume of solvent as used for respective agent. Baseline represents 
the catalepsy recorded just immediately prior to administration of 
haloperidol. n = 10. " indicates P < 0.05 vs saline. 4- indicates 
P < 0.05 vs baseline. # indicates P < 0.05 vs hal 4- sal. 
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Fig. 4 A. Effect of ethanol (EtOH) and MSH-peptides on taii-flick 
latencies in BALB/c mice. Ethanol (4.0 g/kg) was given i.p. 10 min 
prior to intracisternal injections of a-, y, or y2-MSH (1 nmol in 10 u.l) 
The Control represents animals injected i.p. with the same volume 
of saline as used for ethanol. The animals of the plain EtOH 
group were given intracisternal saline (10 ul). n =9-10. * indicates 
P < 0.05 vs saline, o indicates P < 0.05 vs EtOH Ctr l . B. Effect of 
bicucculine (bic) and MSH-peptides on tail-flick latencies in BALB/c 
mice. Bicuculline (0.5g/kg) was given i.p. 5 min prior to intracis-
ternal injections of a-, y,- or y2-MSH (each 1 n m o l ) . Sal indicates 
control injections with the same volume of solvent as used for 
respective agent, n = 8. ' indicates P < 0.05 vs saline, o indicates 
P < 0.05 vs sal + y2-MSH. Baselines represent tail-flick responses 
recorded just immediately prior to the i.p. injections. 
Assessment of cataleptic activities 
Fig. 3B shows the effect of i.p. administration of 0.5 mg/kg 
haloperidol on the cataleptic duration in the mice, as well 
as the influences of 0.3 nmol of, respectively, y r and 
y2-MSH. Haloperidol was administered 30 min prior to 
the intracisternal injection of peptides or saline vehicle 
and the presence of catalepsy was then assessed 30, 60 
and 120 min after the intracisternal injections. As seen 
haloperidol caused a distinct catalepsy throughout the 
experiment, while both y r and y 2-MSH caused weak cata-
leptic activities (Fig. 3B). Interestingly, at the 30-60 min 
both y r and y 2-MSH significandy attenuated the catalepsy 
induced by haloperidol (Fig. 3B). As seen from the Fig. 3B 
this effect was very marked at the 30 min time point, as the 
Yr or 72-MSH peptides attenuated the haloperidol cata-
lepsy down to the same level as that seen when the y r or 
72-MSH were achrtinistered alone. 
Effect of combined treatments of ethanol and MSH-
peptides on tail-flick responses 
Animals were given 4.0 g/kg of ethanol i.p. 10 min prior to 
intracisternal injections of 1 nmol of, respectively, a-, y [ or 
y2-MSH, and the. tail-flick latencies were assessed 
30-120 min following the intracisternal injections. Results 
are shown in Fig. 4A. The ethanol pre-treatment per-se 
caused significant increase in tail-flick latencies during 
the 30-90 min observation periods. a-MSH did not signi-
ficantly alter the ethanol response, while y r M S H signific-
andy attenuated the ethanol response at the 30 -90 min 
periods. By contrast, y 2-MSH significandy potentiated the 
ethanol-induced increase in tail-flick latencies, at the 
30 min time point (Fig. 4A). 
Effect of combined treatments of bicuculline and MSH-
peptides on tail-flick responses 
In the experiment shown in Fig. 4B the effects of the GABA 
receptor blocker bicuculline were assessed. Animals were 
given 0.5 mg/kg of bioiculline Lp., 5 min prior to intracis-
ternal injections of 1 nmol of, respectively, a-, y r or y2-MSH 
and the tail-flick latencies were assessed during a 
30-60 min per iod Bicuculline, per-se, did not induce any 
significant effects on the tail-flick latencies. y 2-MSH alone 
induced a clear and significant increase in the tail-flick 
latencies at both the 30 and 60 min periods, as expected. 
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Fig. 2 Effects of HS014 and combinations of HS014 and yr and y2-MSH peptides on tail-flick latencies in BALB/c mice. A. Effect of HS014 
administered intracisternally at doses of 0.3, 1 and 3 nmol on tail-flick responses for up to 24 h after administration. Saline indicates controls 
injected with the same volume of solvent used for peptides (i.e. 10ul of saline). Baseline represent tail-flick responses recorded 30min prior 
to administration of HS014 or saline, n = 7-9 * indicates P < 0.05 vs saline. B. Effect of pre-treatment with HS014 or y rMSH on the effect of 
y2-MSH on tail-flick latencies. HS014 or y,-MSH were given intracisternally, each at a dose of 1 nmol (in 5 u.l), 30 min prior ( — 30 min) to the 
intracisternal administration of 1 nmol of y2-MSH (in 5|il at 'Omin') and the tail-flick latencies then recorded for up to 120 min following the 
injection of y2-MSH. Sal indicates controls injected with the same volume of solvent used for peptides (saline). Baseline and '0 min' represent 
tail flick responses recorded just immediately prior to the - 3 0 min and zero time points recorded just immediately prior to injection of 
peptides, n = 8. " indicates P < 0.05 vs saline. + indicates P < 0.05 vs baseline. 
with the peak effect being seen at the 60 min and amount-
ing approximate to a doubling over the basal (Fig. 3A). In 
animals pre-treated with i.p. saline, the intracisternal 
injection of y 2-MSH induced the expected increase in 
tail-flick latencies, with the peak effect being reached 
at 30-60 min. In the haloperidol pre-treated animals 
y2-MSH elicited essentially the same increase in tail-flick 
latencies as in the haloperidol controls (i.e. animals given 
i.p. saline). There were no significant differences between 
the haloperidol pre-treated animals, Y2-MSH treated 
animals and the animals receiving combined treatment 
with haloperidol and y2-MSH (Fig. 3A). 
In another series of experiments the animals were 
instead pre-treated with 0.5 mg/kg of i.p haloperidol and 
then injected intracisternally with 0.3 nmol of y2-MSH, 
using a similar protocol as for the tests of the previous 
paragraph. In these tests essentially the same pattern as 
above was seen. Thus, haloperidol, y2-MSH and 
haloperidol -i-Y2-MSH significandy increased the tail-flick 
latencies to the same degree during 30-60 min following 
the intracisternal injections (data not shown). 
Effect of naloxone pre-treatment on the effect of 7-,-MSH 
on tail-flick responses 
Animals were pre-treated by i.p. administration of 2 mg/kg 
of naloxone 30 min prior to the intracisternal administra-
tion of 1 nmol of y 2-MSH, and the effects on tail-flick laten-
cies were assessed (Fig. 3 A). (The naloxone tests were done 
concomitantiy with the tests of haloperidol, allowing these 
two groups to share the same controls). As seen from the 
figure naloxone per-se caused no, or only marginal, effects 
on the tail-flick latencies. Moreover, the naloxone pre-
treatment did not affect the increase in tail-flick latency 
induced by the intracisternal injection of y 2-MSH (Fig. 3A). 
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whereas y 2-MSH induced a distinct analgesic effect, 
7,-MSH was almost devoid of effect. It is well known that 
Yi-MSH show preference for the M C 3 receptor over the 
M C 4 receptor in binding tests. (YI-MSH binds with high 
aifinity to M Q receptors as well). The affinity profile of 
Y2-MSH for MC receptors is quite similar to that of yrMSH, 
although y 2-MSH shows all over about 3-fold lower affin-
ities for MC receptors compared with y r M S H (Wikberg, 
1999). In view of the affinity profiles of y^MSH and 
y2-MSH, the unique ability of y 2-MSH to induce analgesia 
is thus not congruent with the idea that the effect is 
mediated via melanocortic receptors. Moreover, the 
hypothesis that yi-MSH binds to an identical receptor as 
y2-MSH, but is devoid of agonistic effect may be ruled out, 
as we demonstrated in the present study that ypMSH did 
not antagonise the y2-MSH mediated analgesia. (See also 
Oosterom et al., 1998). 
In our earlier study (Klusa et al., 1999) we observed that 
the y 2-MSH induced a cataleptic effect in the rat. It seemed 
essential to elucidate whether or not y-MSH peptides were 
also cataleptic in mice. Thus, in the present study we found 
that both Yr and y2-MSH induced a moderate catalepsy. 
In comparison to the cataleptic activity induced by halo-
peridol these effects of yj- and y 2-MSH appeared weak. 
Moreover, the cataleptic activity induced by ypMSH 
appeared equally strong (or perhaps even more pronoun-
ced) compared to that induced by y 2-MSH. Since y,-MSH 
showed only minor analgesic effects it seems very unlikely 
that the analgesia induced by y 2-MSH is directly due to the 
cataleptogenic effect. It was also an interesting finding that 
Yi - and y 2-MSH were capable of attenuating the catelepsy 
induced by haloperidol. The mechanism underlying these 
effects of y-MSH peptides are presently not well under-
stood. 
However, the data of the present study lend strong sup-
port to the notion that GABAA-receptors are involved in 
the y2-MSH mediated analgesia. Strongest support for this 
idea comes from the observation that the GABAA-receptor 
antagonist bicuculline can completely abolish y2-MSH 
induced analgesia. Moreover, the effect of y2-MSH 
appeared to be additive to the analgesia caused by pre-
treatment of the GABAA-receptor agonist muscimol. 
Moreover the y 2-MSH also appeared additive to the anal-
gesic effect induced by ethanol, the latter which is a known 
potentiator of GABA activation of GABAA-receptors 
Pavies-and Alkana, 1998). However, the analgesic effect 
of y2-MSH appeared not to be additive to that induced by 
diazepam, a ligand capable of binding to the GABAA recep-
tor at a site distinct from that which binds GABA. Another 
interesting observation was that a- and y,-MSH reduced 
the analgesia induced by diazepam. There are some 
reports suggesting interactions between benzodiazepines 
and the a-MSH. Thus, diazepam was reported to signific-
antly decrease a-MSH-induced grooming (Cremer et al., 
1995), while another benzodiazepine, clonazepam, was 
reported to inhibit the release of a-MSH from the neuro-
intermediate lobe in vitro (Tonon et al., 1989). Moreover, 
chlordiazepoxide was reported to inhibit the basal release 
of a-MSH from hypothalamic slices obtained from rats 
(Mableyetal., 1991). 
The finding of the present study that a-MSH injected 
intracisternally induced a short-term hyperalgesia is also 
notable. The mechanism for this action of a-MSH is pres-
ently unknown; perhaps it might be mediated by some of 
the known subtypes of MC receptors. Anyhow, this observ-
ation of the present study is in line with a previous study 
where hyperalgesia was seen after i.c.v. administration of 
a-MSH in rats (Sandman and Kastin, 1981). However, it 
shall'also be noted that some contradiction exist as to the 
effect of a-MSH in rats (Sandman and Kastin, 1981). 
Contradiction also exist as to the effect of a-MSH on pain 
perception, since a-MSH was reported to be analgesic in 
mice, as could be assessed by use of the hot-plate test 
(Ohkubo etal., 1985). 
To summarise, the most pertinent finding of the present 
study is that the y^-MSH induces a central analgesia via a 
mechanism that does appear neither to involve melano-
cortin receptors nor opioid receptors. Instead our data 
indicate that the analgesia is mediated via a mechanism 
involving the stimulation of GABAA receptors. However, 
whether the y 2-MSH effect is mediated directly on GABAA 
receptors or indirectly via stimulation of GABAergic path-
ways remains to be studied. The present study thus re-
inforces the complexity for the pharmacology of 
melanocortic peptides, findings which are in accord with 
our earlier study (Klusa et al., 1999) showing that distinct 
differences exist in the behavioural pharmacology of the 
a-, y r and y 2-MSH peptides. 
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volume of solvent as used for respective agent, n = 7-16. * 
indicates P < 0.05 vs saline. # indicates P < 0.05 vs diaz + sal. 
Baselines represent tail-flick responses recorded just immediately 
prior to the i.p. injections. 
However, in animals pre-treated with bicuculline the 
increase in tail-flick latency induced by y2-MSH was com-
pletely attenuated, at both 30 and 60 min. These effects 
were significant at both the 30 and 60 min time points. By 
contrast, neither a- nor y ,-MSH, gave any significant effects 
on the tail-flick response. Moreover, no effects were seen 
by a- or y,-MSH in animals pre-treated with bicuculline. 
Effect of combined treatments of muscimol and MSH-
peptides on tail-flick responses 
The GABA receptor agonist muscimol was given i.p at a 
dose of 1 mg/kg, 5 min prior to intracisternal injections of 
ot-, y r or y2-MSH (1 nmol each), and the tail-flick latencies 
were assessed during the following 30-60 min period (Fig. 
5A). Muscimol, per-se, induced a significant increase in 
tail-flick latency at 30 min, but not at 60 min. y2-MSH, per-
se, also significandy increased tail-flick latency time at 
both time periods. At 30 min with muscimol the tail-flick 
latency induced by y2-MSH was significant higher than in 
the absence of muscimol. The levels for tail-flick latencies 
seen after a- and y, -MSH were similar as reported for other 
experiments above, a l though at the 30 min time point 
there appeared to b e a minor (probably spurious) increase 
in tail-flick latency induced by bo th a- and y i -MSH. Neither 
a- nor yrMSH gave any significant alterations of the 
response induced by muscimol. 
Effect of combined treatments of diazepam and MSH-
peptides on tail-flick responses 
Diazepam (10 mg/kg) was given i.p., 5 min prior to intracist-
ernal injections of a-, y r or y 2-MSH (1 nmol), and the tail-
flick latencies were assessed during the following 
30-60 min (Fig. 5B). Diazepam, per-se, induced a significant 
increase in tail-flick la tenc iesa tbo th30 and 60 min. y2-MSH, 
per-se, also significandy increased the tail-flick latencies, as 
expected. However, the combined treatment of diazepam 
and y 2-MSH did not alter significantly the tail-flick latencies, 
compared to any of these respective treatments given alone 
(Fig. 5B). Neither a- nor y rMSH w h e n given alone caused 
any significant effects on tail-flick latencies. Interestingly, 
however, bodi the a- and y rMSH treatments significandy 
attenuated the increase in tail-flick latencies caused by dia-
zapam. For a-MSH these effects were significant at bo th the 
30 and 60 min t ime periods, while for y r M S H it was signi-
ficant only at the 30 min time point. 
DISCUSSION 
The present study reinforce the complex and multifaceted 
central nervous system pharmacology of melanocortic 
peptides. Previous studies have indicated that some of 
the central effects induced by MSH peptides, and ana-
logues thereof, are clearly linked with activation of 
melanocortin receptors. These effects include the intense 
grooming activity induced upon icv administration of 
a-MSH, which may be blocked by prior atiministration 
of the MC 4 /MC 3 -blocker HSO 14 (Klusa et al., 1998). 
Another is the inhibition of ingestive behaviour by MSH 
peptides, where a large body of accumulating evidence 
suggest the effect is mediated by activation M C 4 receptors 
located to hypothalamic areas. For example icv administ-
ered a-MSH and p-MSH (but not y ,-MSH) inhibited sponta-
neous food intake in food deprived rats (Kask et al., 2000) 
while HSO 14 increased food intake (Kask et al., 1998). (See 
Wikberg, 1999, for a full discussion on the role of MG, 
receptors for control of feeding behaviour). 
However, the da ta of the present study do not lend 
support to the idea tha t the analgesic effect of y 2-MSH is 
mediated via the activation of melanocortic receptors. One 
reason being that t h e analgesic effect of y 2-MSH was not 
affected by HSO 14. HSO 14 is a blocker of bo th M C 4 and 
MC 3 receptors (albeit with a slight selectivity for the M Q 
receptors [Schioth et al., 1999]). Another reason is that 
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Abstract 
The discoveries of the latest ten years have shed new light in understanding the roles of 
melanocortins and their receptors in brain functions and in the development of different 
pathologies. Since 1992 when genes encoded melanocortin receptor five subtypes were 
identified, cloned and characterized the molecular mechanisms underlying different effects 
such as skin darkening, behaviour, food intake, anti-inflammatory action, analgesia have 
been clarified. The contribution of melanocortins and their receptors in the physiological 
control of organism homeostasis has become as the background for the search of agonists 
and antagonists of separate receptor subtypes, that can be targeted to the melanocortin 
receptors and used as therapeutic drugs for the treatment of psychoneuroendocrine and 
immune system diseases. 
1. WHAT ARE MELANOCORTIN PEPTIDES? 
1.1 BIOSYNTHESIS AND STRUCTURES 
The melanocortins (or melanocyte stimulating hormones, or MSH peptides) are derived 
from the precursor, a 31-36 kDa glycosylated protein called pro-opio-melanocortin or 
POMC (Fig. 1), during its biodegradation or proteolytic processing [1]. The full amino acid 
sequence was discovered only at the end of the 1970 t h by cloning of its cDNA [2]. POMC 
generates a large array of biologically active peptides, including the adrenocorticotropin 
(ACTH), MSH peptides and p-endorphin, p-lipotropin, y-lipoptropin. Proteolytic cleavage 
occurs mostly at sites where two polar amino acids form a peptide bound, e.g., Arg-Arg, 
Lys-Lys, Arg-Lys, Lys-Arg. At present, the following peptides are attributed to the 
melanocortin family: a-MSH, ACTH, p-MSH, yl-MSH, y2-MSH, y3-MSH. These peptides 
differ from each other by their amino acid sequences, however they share a common 
pharmacophore unit (underlined), a tetrapeptide His-Phe-Arg-Trp (Table 1). Interestingly, 
that a-MSH molecule completely coincides with the first 13 amino acid sequence of the 
ACTH, however a-MSH has acetyl group in the N-terminus and amide group in the C-
terminus. 
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TABLE 1. Primary structures of peptides of melanocortin family 
Peptide Amino acid sequences 
ACTH. H2N-SYSMEHFRWGKPVGKKRRPVKVYPNGAEDESAEAFPLEF-OH 
a-MSH: N-Acetyl-SYSMEHFRWGKPV-NH, 
P-MSH: H2N-AEKKLEGPYRMEHFRWGSPPKD-OH 
yl-MSH: H,N-YVMGHFRWDRF-NH7 
Y2-MSH. H2N-YVMGHFRWPRTG-OH 
T3-MSH. H;N-YVMGHFRWDRFGRRNGSSSSGVGGAAO-OH 
The POMC derived peptides have diffuse distribution in the central nervous system, as well 
as in peripheral organs [for review see 3]. a-MSH is mostly synthesized in the intermediate 
lobe, ACTH in the anterior lobe of hypophysis, however POMC is also synthesized and 
processed in other brain areas, especially in the hypothalamus. 
1.2. HISTORY OF THE DISCOVERY OF MELANOCORTINS 
In the beginning of the 20th century, melanocortins were originally recognized at the 
intermediate lobe of hypophysis, and the influence of pituitary extracts on melanocyte 
dispersion in frog skin and, hence its pigmentation (darkening) was observed [4]. 43 years 
later, the a-MSH molecule was identified [5] and it was obtained that this is the right 
peptide which is responsible for frog skin darkening. Only in the 1990 t h a role of a-MSH in 
melanoma formation in human beings was detected [6-8]. Therefore phylogenetically, a-
MSH is an ancient molecule that has remained essentially unchanged during late vertebrate 
evolution, and this molecule is remarkably conserved across different species. In the 1960* 
a lot of studies was devoted to clarification of the functional role a-MSH and ACTH. For 
instance, the scientists' group from the Netherlands, headed by Professor De Wied have 
obtained an influence of ACTH, its fragments and analogues on rodents' behavior [9]. They 
have found that these peptide can induce excessive grooming when administered 
intracerebroventricularly, and may improve short-term memory. One of the most 
remarkable discovery made by E.W.Sutherland (Nobel Prize winner, 1971), was that the 
ACTH-induced steroidogenesis is mediated via intracellular mechanisms that involve 
cAMP, a second messenger molecule formation. However knowledge of melanocortins and 
their functional role has increased tremendously over the last 10 years when five 
melanocortin receptor subtypes were identified, cloned and characterized. 
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2.Melanocortin Receptors (MCRs) 
2.1. RECEPTOR SUBTYPES 
2.1.1. MCIR 
In 1992 the genes encoding G protein coupled MSH receptor, termed M C I R were cloned 
independently by two groups (Prof. Jarl Wikberg, Uppsala University, Sweden, and Prof. 
Rogers Cone, Oregon, USA) [10, l l ] .The localization of this receptor subtype firstly was 
found in melanocytes of the skin and in solid melanoma tumor cells, lately in many other 
cell types including those of different brain areas [12, 13], fibroblasts [14], keratinocytes 
[15], macrophages and monocytes [16, 17], neutrophiles [18], endothelial and glial cells 
[19]. Now the mostly clarified function of M C I R is its binding with a-MSH that leads to 
skin darkening and melanoma tumorogenesis. The new area that is being studied 
intensively over the last 5 years is anti-inflammatory action where probably M C I R and a-
MSH play a crucial role (see below "The Newest Findings..."). 
2.1.2. MC2R 
MC2R which was discovered at the same time as MCIR, is proved to be the ACTH 
receptor of the adrenals, which controls steroidogenesis processes [20]. This receptor 
subtype considerably differs from other melanocortin receptor subtypes, since it binds only 
with ACTH but not with any other melanocortin molecules [21]. Recently, the expression 
of MC2R was identified in the skin [22] that indicates eventual role of MC2R and ACTH in 
the physiology of skin. 
2.1.3. MC3R 
In 1993 the genes encoding MC3R were cloned and their localization was identified in the 
brain, placenta and gut [23]. Lately its expression in the heart was shown [13]. There are 
two very important matters which seems to be put forward in studies of MC3R functional 
role: 1) y-MSH peptides have high affinity to MC3R, particularly y l -MSH shows 40-fold 
selective affinity for rat MC3R vs MC4R [24]; 2) MC3R can be abundantly expressed in 
the brain structures that belong to the mesolimbic system, i.e., the ventral tegmental area 
[25] and the nucleus accumbens [3]. The functional role of MC3R and also of y-
melanocortins is comparatively less studied. However, recent data (see below "The Newest 
Findings...") show a considerable influence of y-melanocortins on the functions mediated 
via the mesolimbic system, particularly those attributed to the psychoactivation states. 
2.1.4. MC4R 
MC4R was found to be expressed in all brain regions of mammals [26]. The high levels of 
MC4R is detected in the nucleus accumbens [26, 27]. Unlike MC3R, MC4R was not 
essentially found in the periphery. However, recent findings showed evidence that MC4R 
may be present in peripheral tissues [28]. The main difference between the MC4R and the 
other receptors is its particularly low affinity for the y-MSH peptides, and slightly higher 
affinity for p-MSH than a-MSH and ACTH [29]. Recently relationship between feeding 
control and MC4R have been studied (see below "The Newest Findings..."). 
258 
2.1.5. MC5R 
The physiological role of MC5R is still obscure. This subtype is widely expressed in many 
peripheral tissues, particularly in the exocrine glands (e.g., adrenal glands, prostate, 
pancreas). There are evidence suggesting that MC5R plays a role in regulation of functions 
of exocrine glands. For instance, MC5R in mice is involved in production of sebum from 
sebaceous glands resulted in water repulsion of their furs and thermoregulation [30]. 
2.2. MCR STRUCTURE AND SIGNAL TRANDUCTION 
The MCRs belong to the class of G protein coupled 7-transmembrane (TM) region or 
heptahelix receptors. All the receptors have several glycosylation sites in their N-terminal 
domain, and conserved cysteins in the C-terrninal part, which may serve as sites for fatty 
acid acylation anchoring the C-terminus to the plasma membrane. Modelling of the peptide-
receptor binding by use of cyclic heptapeptide [Cys 4, Cys'°]a-MSH as a model compound, 
shows that receptor binding site forms a binding pocket by involving most TM domains 
with exception of TM4 and TM5 [31]. Obviously all domains are necessary to arrange 
optimal protein conformation to provide high binding activity. 
A full lengths of the primary structures of MCR family shows that receptor subtypes share 
about 40-60% homology of their sequences (Table 2) [32]. 
TABLE 2. Amino acid identity (in %) between the five cloned human MC receptor subtypes [32] 
MC1R MC2R MC3R MC4R MC5R 
MC1R 100 38 45 47 44 
MC2R 100 42 46 44 
MC3R 100 42 57 
MC4R 100 60 
MC5R 100 
The signal transduction mechanisms provided via MCRs are mostly regarded to stimulatory 
pathways resulting in second messenger cAMP formation [33], however there is some 
evidence indicating the phosphoinositol pathway can also be involved in the signaling of 
the MC3R. 
2.3. BINDING AFFINITIES 
The evaluation of binding affinities (Table 3) showed that ACTH binds only MC2R 
whereas MC3R shows a relative preference for y-MSH peptides. The other receptor 
subtypes bind natural MSH peptides with an order of potency which can be seen in Table 4 
[34,35]. 
TABLE 3. Binding affinities for melanocortins, obtained in MCR transfected COS cells 
[34, 35] 
Ligand MCI MC2 MC4 MC5 
a-MSH 0.12 ±0.023 20.7 ± 3 . 7 641 ± i04 8240 ±1670 
P-MSH 1.17 ±0 .27 13.4 ± 6.4 446 ± 96.5 14400±1670 
Yl-MSH 2 .68±0 .35 7 .06±2 .90 29001 ± 1791 426O0±66O0 
Y2-MSH 11.2 ± 5 . 4 17.7 ± 1 . 9 > 100000 >10O000 
TABLE 4. Comparative pharmacology of melanocortin receptors [34, 35] 
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Receptor 
(MCRs) 
Potency of POMC peptides 
Human MCIR a-MSH>ACTH>£-MSH»y-MSH 
Human MC2R ACTH - . 
Human MC3R y-MSH= a-MSH>ACTH 
Human MC4R a-MSH >ACTH= p-MSH> y-MSH 
Human MC5R a-MSH> |3-MSH»y-MSH 
3. THE NEWEST FINDINGS O F THE FUNCTIONAL ROLES OF MELANOCORTINS A N D THEIR 
RECEPTORS 
Over the recent 5-10 years informations about functional roles of melanocortins and their 
receptors have increased considerably, however the newest findings show complexity of 
melanocortinergic processes and their link to the non-melanocortinergic pathways and 
molecules. 
3.1. MCR1 AND a-MSH 
MCR1 was recently demonstrated to have indirect roles for immune responses. a-MSH 
may exert anti-inflammatory effects by reducing the production o f pro-inflammatory 
cytokines [18], and inflammatory mediator N O in macrophages [15], as well as by 
suppressing of the expression of leukocyte adhesion molecules in vascular epithelium [36], 
That is in good line with previously described findings [37] demonstrated that POMC-
derived peptides may be produced in immunocompetent cells when they receive non-
cognitive (bacterial, viral) stimuli. The peptides then can be released to initiate 
glucocorticoid synthesis along the immuno-adrenal axis, hence induce immunosuppression 
and anti-inflammatory action. Recent data [38] show that not only entire molecule OF a-
MSH but also its shorter fragments (a-MSH 1-10 and a-MSH 11-13) may considerably 
suppress NF-icB production in macrophage cell line expressing MCR1, when they are 
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exposed to inflammatory agents such as LPS and interferon-y. These and other data give 
enough evidence to suggest that MCR1 and a-MSH play a crucial role for providing anti-
inflammatory effects by involving pathways from the activation of receptor, production of 
second messengers to the activation of transcription factors and induction of gene 
expression (Figure 1). 
Figure I. Model for the regulation of a-MSH-induced anti-inflammatory effect. a-MSH binds to MCR and 
possibly activates both signal transduction pathways (via cAMP and IP3 production) resulted in 
inhibition of N F - k B translocation into the nucleus, caused by inflammatory cytokines (LSP+INF-y). 
3.2. MCR4 AND a-MSH 
MC4R is ubiquitously expressed in the brain and for long time it was considered that this 
receptor subtype is essentially absent in periphery. However recently MCR4 is found in 
human adipose tissue, that initiates an interest for the MCR4 as important factor in control 
of body weight [39]. Now there is huge of data demonstrating that MCR4 plays an 
important role in feeding behaviour, and a lot of reviews are devoted to this subject [3, 29, 
30, 32, 40]. So, already in the 1980 t h it was shown that a-MSH and ACTH (1-24) injected 
into the hypothalamus caused a marked inhibition of food intake [41]. In the 1990 t h 
intriguing data were added, for instance that MCR4 knockout mice developed morbid 
obesity [42]. Moreover, several MCR4 mutations in human population were found as 
essentially associated with obesity [40]. A link of melanocortinergic processes with others 
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involved in feeding control was confirmed when it was found that agouti peptide acted as 
MCR4 endogenous antagonist [43]. Afterwards intriguing observations confirmed idea that 
the selective MC4 antagonists induce overeating and severe obesity. In contrast, agonists of 
this receptor subtype exerts anorexive effects. That stimulates intensive drug design to 
obtain selective MCR4 agonists and antagonists. For instance, intracerebroventricular 
administration of novel highly selective MCR4 antagonists HSO 14 and HS024 were found 
to cause 2-4-fold increase in food intake in rats [29, 44]. MC4R is suggested also to be 
involved in opiate addiction [45]. a-MSH interaction with MC4R probably mediates also 
regulation of cardiovascular system [46]. a-MSH probably via MCR4 can stimulate nerve 
regeneration after nerve injury [46,47]. 
3.3. MCR3 AND y-MSHs 
The functional role of both MCR3 and y-MSHs is less studies and less understandable. An 
attention can be paid to structures of y l - and y2-MSH peptides, which show surprising 
homology of their amino acid sequences (see Table 1) with exception of extra C-terminal 
glycine residue in y2- MSH molecule that differs these peptides from each other. Besides, 
y-MSHs have the highest binding activity to MCR3 which is abundantly expressed in the 
dopaminergic mesolimbic system, that in turn belongs to the reward system involved in 
drug dependence and motivational processes, manifestation of schizophrenic 
hyperactivation, and emotions. This system involves two very important brain structures 
playing an essential role in regulation of dopaminergic pathways: they are the ventral 
tegmental area (VTA) and the nucleus accumbens (NACC). The cytoarchitectony of the 
VTA is very complicated, since dopamine DA cells receive a lot of interneurons both the 
inhibitory (e.g.GABAergic) and the excitatory (e.g. glutamatergic) that may modulate 
dopamine (DA) release in the NACC [48]. If DA cells are stimulated the DA release in the 
NACC is increased and that coincides with hyperlocomotion and stereotypical behavioural 
responses (e.g. grooming) in laboratory animals. In schizophrenic patiens or drug addicted 
persons, DA hyperproduction in the VTA may lead to psychoses, paranoidal delutions etc. 
Logically, the questions can be arisen concerning the role of melanocortins in these 
processes: 
1) are there only melanocortinergic mechanisms involved in y-MSH effects? 
2) may dopaminergic and/or other neurotransmitter systems contribute to yMSH action? 
3) what is the neurochemical basis for y-MSHs effects? 
4) what is the endogenous role of these peptides? 
We have tried to find answers to these questions for a period since 1995 in collaboration 
with scientists group headed by Professor Jarl Wikber (Uppsala University) and having 
five-year financial support from the Howard Hughes Medical Institute (USA). What have 
we found? First of all, almost in all experiments we have found different behavioural 
repertoire of both peptides, however their structures are very similar. So, if, yl-MSH 
injected into the VTA induced psychoactivation in rats behaviour (excessive grooming, 
increase in vertical locomotor activity), in contrary, y2-MSH lacked these activities and 
instead it caused a moderate catalepsy. Moreover, y2-MSH completely antagonized the, y l -
MSH-induced behavioural responses (Klusa et al., 1999). These data indicate that yl-MSH 
may act as psychoactivatory peptide probably by stimulating effect on DAergic system, 
whereas y2-MSH acted in opposite manner - as antipsychotic substance. These suggestions 
were confirmed by neurochemical data obtained by peptide administrations into the VTA 
and assessment of DA and its metabolite DOPAC in the NACC [50]: y l -MSH induced a 
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FIGURE 2. Influence of the intra-VTA administered yl-MSH, y2-MSH and y2-MSH+yl-MSH on the dopamine 
(DA) and DOPAC concentrations in the rat nucleus accumbens. Dose of peptides was 3nmol/rat. 
* p<0.05 vs CSF (artificial cerebrospinal fluid), * p<0.05 vs control, i.e. basal values (BI+B2+B3)/3,' 
p<0.05 vsyl -MSH. Injection 1: administration of yl-MSH or -/2-MSH or saline. Injection 2: regards 
only to the combined administration y2-MSH+yl-MSH (arrow at Injection 2 shows administration of 
yl-MSH after pretreatment ofy2-MSH (arrow at Injection 1). 
The same antagonizing phenomenon between both peptides was observed: y2-MSH 
abolished the yl-MSH-induced neurochemical changes in the content of DA and DOPAC 
(Figure 2). These findings allowed us to suggest that the relationships between both y-MSH 
peptides may be considered as functional antagonism (?) based on their opposite influence 
on the mesolimbic dopaminergic system, particulary on their ability to influence DA 
metabolism. 
It is very important that imbalanced DAergic system may lead to the development of 
psychiatric disorders. For instance, schizophrenia can be considered as manifestation of 
hyperactivation of the DAergic system and hypoactivation of the glutamatergic system. 
Modeling of schizophrenic state in laboratory animals (mice) by use of phencyclidine 
(PCP), a drug capable to act as non-competetive antagonist of glutamate NMDA receptors, 
again showed different effects of both y-MSH peptides injected intracisternally (Figure 3): 
yl MSH potentiated the PCP-hyperlocomotion effects, whereas y2-MSH reversed up to the 
control level the locomotor responses increased by PCP [51]. 
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Figure 3. Influence of yl -MSH and -/2-MSH (0.3nmol/mouse, i.e.) on phencyclidine (PCP)-stimulated 
spontaneus locomotor activity in BALB/c mice (n=9). PCP, 5 mg/kg, i.p., 5min prior to yl-MSH or -/2-
MSH injection. Activity counts measured in 30-c30min period after y-MSH peptide administrations 
• P<0.05 vs saline, ** P<0.05-/l-MSH or-/2-MSH vs PCP," P<0.05 -/1-MSH+ PCP or -/2-MSH+PCP 
vs PCP, ° P<0.05 yl-MSH-i- PCP ory2-MSH+ PCP vs yl-MSH or -/2-MSH , resp. 
These data indicate that both y-MSH peptides may also modulate glutamatergic system. 
Moreover, examination of the influence of both peptides on pain perception by use of tail 
flick method in mice has found that y2-MSH (but not yl-MSH) was capable to cause a 
considerable analgesic effect that is mediated via GABAergic mechanisms [52]. y2-MSH-
induced analgesia was not altered by naloxone (opiate receptor antagonist), haloperidol 
(DA receptor antagonist), HS014 (melanocortin receptor antagonist), neither by yl-MSH 
(peptide which antagonized y2-MSH-induced behavioural and neurochemical responses). 
At the same time bicuculline (GABA site antagonist of the GA3A-A receptor) reduced 
completely the y2-MSH-analgesia, and muscimol (GABA site agonist of the GABA-A 
receptor) augmented this effect. y2-MSH-analgesia was not influenced by diazepam 
(benzodiazepine site agonist of the GABA-A receptor), while analgesic effect was 
increased in ethanol-pretreated rats, indicating that ethanol modulatory site of the GABA-A 
receptor may be influenced by y2-MSH. As to yl-MSH (which does not produce analgesic 
effect), it exerted antagonizing effects against analgesia caused by diazepam and ethanol 
[52] Thus these data allow to suggest that y2-MSH influences GABA site of the GABA-A 
receptor, whereas yl-MSH may modulate benzodiazepine site of the GABA-A receptor; 
both y-MSHs in opposite manner may modulate ethanol site of the GABA-A receptor. 
Summarizing the newest data concerning y-MSH peptides one may consider that they may 
be involved in many pleiotropic functions, such as modulation of dopamine-, glutamate-
and GABAergic processes, regulation of pain perception and psychoactivation, and 
probably act as endogenous mutual antagonists (schizophrenic/anti-schizophrenic?). 
Probably these peptides may play a role also in regulation of the mesolimbic reward 
system. 
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4. Drug Design Based On MCR-MSH Binding Data 
Knowledge about the melanocortins and their receptors stimulates to modulate 
melanocortin receptor signaling by a design of new molecules that act as agonists or 
antagonists at the receptor levels. The newest data indicate that new drug design based on 
melanocortin and their receptor subtype binding can open new vistas in understanding of 
both the formation of pathologies where these molecules play an essential role, and the new 
strategies how to treat diseases. The most promising tendencies are given below (Table 5). 
TABLE 5. The new strategies in drug design 
MCR subtype Agon ists/ antagon ists Usefulness in the treatment of 
pathology 
MCR1 
MCR1 
MCR3 
MCR4 
MC5R 
agonists 
antagonists 
agonist s/antagonists 
agonists 
antagonists 
agonist s/antagonists 
anti-inflammatory drugs 
immunoregulators 
melanoma suppressors 
regulation of drug dependence 
psychoregulators (antipsychotic 
drugs?) 
analgesic drugs 
blood pressure regulation (pressor 
activity?) 
anorexive drugs (anti-obesity) 
orexigenic drugs 
blood pressure regulation (depressor 
effect?) 
regulation of excretory gland functions 
The cloning of melanocortin receptors has shed a new light in understanding of the 
functional role of melanocortins and their receptors. That in turn stimulates rationale new 
drug design which can be useful in the treatment in different diseases, particularly those 
attributed to the central nervous system pathologies. This is attractive and rapidly 
developing field with promising opportunities. 
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A b s t r a c t 
By use of the brain microdialysis technique we show that administration of 7 j -melanocyte 
stimulating hormone (7 j -MSH) into the ventral tegmental area of anaesthetized rats causes 
an increase in the release of extracellular dopamine and its metabolite 3,4-
dihydroxyphenylacetic acid in the nucleus accumbens, while 7 2 - M S H causes the opposite 
effect. Moreover, 7 2 - M S H pre-treatment considerably reduced the 7 j -MSH-induced effects. 
Our findings suggest an opposing action of two 7-MSH-activated pathways on the 
mesol imbic dopaminergic system, which could be important in the maintenance of a 
balanced psychoactivation state. 
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Opposite effects of y r and 7 2 - m e i a n o c y t e stimulating hormone on 
regulation of the dopaminergic mesolimbic system in rats1^ 
Baiba Jansone 1 1 , Lena Bergs t rom b , S imons Svirskis 3 , Jonas L i n d b l o m b , 
Vija Klusa a '* , Jarl E.S. W i k b e r g b 
'Department of Pharmacology. Faculty of Medicine. University of Latvia. IA Satiates Street, LV-1001 Riga, Latvia 
hDepartment Pharmaceutical Biosciences. Division of Pharmacology, University of Uppsala, POB 591, S-75I24 Uppsala, Sweden 
Abstract 
By use of the brain microdialysis technique we show that administration of y, -melanocyte stimulating hormone (71 -MSH) into the ventral 
tegmental area of anaesthetized rats causes an increase in the release of extracellular dopamine and its metabolite 3,4-dihydroxyphenylacetic 
acid in the nucleus accumbens, while y2-MSH causes the opposite effect. Moreover, 72-MSH pre-tieatment considerably reduced the y r 
MSH-induced effects. Our findings suggest an opposing action of two y-MSH-activate _ pathways on the mesolimbic dopaminergic system, 
which could be important in the maintenance of a balanced psychoactivation state. 
© 2004 Published by Elsevier Ireland Ltd 
Keywords: Melanocyte stimulating hormone 7,; Melanocyte stimulating hormone y2\ Microdialysis; Ventral tegmental area; Nucleus accumbens; Dopamine; 
3.4-Dihydroxyphenylacetic acid 
Pro-opiomelanocortin (POMC) is a precursor protein which 
is processed into several neuropeptides that include the 
,~~melanocnrtin peptides (a-, 7-melanocyte stimulating 
s,^hormonesjJMSH^ and adrenocorticotropic hormone), as well 
""-as lipotropin and endorphin molecules [21. Since the 
discovery of five subtypes of melanocort in receptor 
( M C R | _ 5 ) [1,3,9,10,16], tremendous progress has been 
made to clarify the endogenous roles of melanocortins and 
their receptors. Among all melanocortins, 7-MSH peptides 
are less studied and their functional roles are least under-
stood. However, some light has been shed by findings that 
demonstrate an abundant expression of M C R 3 and M C R 4 in 
the ventral tegmental area (VTA) and in the nucleus 
accumbens (NACC) [12,14]. Moreover, a high affinity of 
M C R 3 for 7 -MSH peptide binding [8,12] and comparatively 
low affinity of M C R 4 for 7 -MSH peptide binding [8] has 
been demonstrated. Furthermore, y l - M S H shows a 40-fold 
increase in selective affinity for rat MCR : , vs. MCR 4 [8], 
These data suggest the existence of a functional link 
between the melanocortin and dopamine systems since 
these two systems overlap to some extent anatomically: 
firstly, mesolimbic dopamine (DA) neurons of the VTA 
This article is dedicated to Professor Manfred Zimmemiann's 70th 
birthday with best wishes for his continued vitality 
4_ * Corresponding author. Tel.: +371-1-927-6263; fax:-371-2-736-6306 
E-mail address: vijaklus@latnei.lv (V. Klusa). 
project to the NACC and secondly, 7 -MSHs display high 
binding activity for MCR 3 . 
We have found previously [6] that y r and 72-MSH, 
peptides with strikingly similar structures ( 7 I -MSH: H 2 N-
Y V M G H F R W D R F - N H 2 and 72 -MSH: H 2 N-
YVMGHFRWDRFG-OH) induce different, even opposite 
behavioural responses in rats after their intra-VTA adminis-
tration: while 7 , -MSH causes pronounced grooming and 
vertical activity (similarly to a -MSH), while 7 2 - M S H lacked 
these effects; instead it induced moderate catalepsy. More-
over, we showed that 72-MSH acted as antagonist of y r M S H 
[6], These d: . indicated that the mesolimbic DAergic system 
might be involved, at least in part, in the mediation of the 
behavioural effects induced by melanocortic peptides. In 
earlier studies we have shown that the grooming effect caused 
by intracerebroventricular, as well as intra-VTA injections of 
a-MSH, is blocked by an M C R 4 antagonist [5], and that 
injection of a -MSH into the VTA mediates release of DA in 
the ipsilateral NACC [7]. 
The present study was designed to clarify the influence of 
71- and 72-MSHs on the dopaminergic mesolimbic system, 
and to identify the peculiarities of the behavioural repertoire 
induced by these peptides. Therefore, we investigated the 
influence of 71- and 72-MSH administered intra-VTA on the 
release of DA and its metabolite DOPAC in the NACC 
using the microdialysis technique in rats. 
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113 Male Sprague-Dawley rats weighing 270-340 g were melanocarin receptor subtypes 3 and 4 (MCR3 and MCR4) 169 
114 housed with free access to food and water at 21 ± 1 °C. are expressed abundandy (for reviews see [14,15]) and their 170 
115 lights on 07:00-19:00 h. Rats were anaesthetized with affinities for 7-MSH peptides binding have been demon- 171 
116 Inactin (80 mg/kg per rat, intraperitoneally) and placed in a strated. In turn, the dopaminergic mesolimbic system 172 
117 Kopf stereotaxic frame. Stereotaxic surgery was performed belongs to the reward system which is involved in drug 173 
lis according to method described elsewhere [7]. Peptides dependence and motivational processes [13], as well as in 174 
119 (from Sigma) were injected manually into the VTA at the manifestations of schizophrenic hyperactivation and 175 
120 ^ dose of 3 nmol/0.5 ^1 cerebrospinal fluid (CSF) via a guide emotions. This system involves two very important brain 176 
121'' cannula with bregma as reference: B - 5.0 m m , L - 0.9 mm structures playing an essential role in regulation of 177 
122 and V - 7.2 mm [11], by use of a Hamilton Microliter dopaminergic pathways: they are the ventral tegmental 178 
123 syringe. Animals received CSF injections served as a area (VTA) and the nucleus accumbens (NACC). The 179 
124 control group. The microdialysis probe (cut-off 20 kDa PES; cytoarchitectony of the VTA is very complicated, since A10 1 so 
125 AgnTho's AB, Lidingo, Sweden) was placed into the left DA cells receive numerous interneurones, both inhibitory isi 
126 NACC with bregma as reference: B +2.2 m m , L -1 .5 m m (e.g.~ABAergic) and excitatory (e.g. glutamatergic), that 182 
127 and V — 7.1 mm, and perfused with artificial CSF at 2 ui/ may modulate dopamine (DA) release in the NACC [13]. If 183 
128 min. Peptide administration was not started until three DA cells are stimulated, the DA release in the NACC is 184 
129 samples at 20-min intervals showed less than 15% variation increased which coincides with hyperlocomotion and ]85 
130 of the DA and DOPAC content. The total time for collection stereotypical behavioural responses (e.g. grooming) in 186 
131 of samples after the injection o f a peptide was 2 h. DA and laboratory animals. In schizophrenic patients or drug- 187 
132 DOPAC were immediately determined by high-perform- addicted persons, DA overactivity may lead to psychoses, 188 
133- ance liquid chromatography using electrochemical detec- paranoid delusions, etc. In the present study we have 189 
134 don (ReproSil-Pur C18-AQ; ESA Inc. detector; guard cell investigated how the dopaminergic system contributes to 190 
135 electrode voltage+0.4 V; working electrode voltage 4-0.34 the 7-MSH-induced behavioural effects. As was shown 191 
136 • V). The recycled mobile phase used was 2 g/1 o f sodium earlier, intra-VTA administration of 71-MSH induced 192 
137 acetate monohydrate, 38.75 nig 1-octanesulfonic acid, 3.7 marked grooming and rearing activities in the rat, whereas 193 
138 mg EDTA in 900 ml H 2O/100 ml methanol, pH 4, and the 72-MSH lacked these responses and caused a moderate 194 
139 flow rate was 0.6 ml/min. Only animals with a histological catalepsy; it acted also as a 71-MSH antagonist [6]. 195 
140-- verification (correctly implanted probe and cannula) were Although both the 71-and 72-MSH peptides studied herein 196 
141 included. The average of three baseline samples was are agonists on the rat melanocortin MC 3 and M Q receptors 197 
142 considered as control level and was taken to represent a [15], our findings dispute a simple model wherein MC 3 and/ 198 
143 level of 100%. The data were statistically analysed using or MC 4 receptors become activated only by the MSH 199 
144 one-way analysis of variance followed by the Newman- peptides upon their intra-VTA administration. Despite the 200 
145 Keuls Multiple Comparison test and paired r-test. fact that 7,- and 72-MSH structures are almost identical, 201 
146 1 The dose of 3 nmol (in 0.5 (j.l)?for 7-MSH peptides was differing from each other only by an extra C-terminal Gly in 202 
147 selected because of the pronounced behavioural responses the 72-MSH molecule, we have demonstrated a striking 203 
148 we previously observed it to elicit [6]. Baseline dialysate difference in the effects of 71-MSH versus 72-MSH. While 204 
149 contents of DA and DOPAC were 32.3 ± 0.3 fmol and intra-VTA administration of 71-MSH increased the release 205 
150 ^24 .6 ± I nmol, respectively, in 40-u.l samples. Adminis- of DA and DOPAC in the NACC, 72-MSH decreased it. 206 
151 tration of 71-MSH into the VTA resulted in a significant Moreover pre-treatment with 72-MSH considerably 207 
152 increase in the extracellular DA and DOPAC release in the reduced the 71-MSH-induced alterations in DA and 208 
153 NACC, and the influence on DOPAC level was markedly DOPAC concentrations. These opposite effects on meso- 209 
154 higher than that on DA level (Fig. la,b). By contrast, the limbic dopamine transmission correlate well with our 210 
155 intra-VTA injection of 72-MSH caused a pronounced previous observations on the peptide's behaviour. It is 211 
156 decrease in the DA and DOPAC contents in the NACC plausible that the 71-MSH-induced grooming and rearing 212 
157 dialysates, the decrease in the DOPAC levels being more hyper-reactivity can be attributed to a stimulating action on 213 
158 pronounced than the decrease in DA. Intra-VTA pre- the dopaminergic mesolimbic system. The cataleptic state 214 
159 treatment with 72-MSH (72-MSH injected 40 min prior to caused by 72-MSH, on the other hand, may be attributed to 215 
160 71-MSH) significantly attenuated the effect of 7,-MSH on the inhibition of the dopaminergic mesolimbic system. 216 
161 DA and DOPAC (Fig. la,b). Thus, our findings indicate a distinct behavioural and 217 
162 Over the last 5-10 yea's, the functional roles of neurochemical repertoire of both 7-MSH peptides: psy- 218 
163 melanocortins and their receptors has been considerably choactivation of the 71-MSH and in contrast, antipsychotic 219 
164 clarified; however, the newest findings show complexity of action of the 72-MSH. A most intriguing phenomenon 220 
165 melanocortinergic processes on the one hand, and their link obtained in the above studies is an antagonistic relationship 221 
166 to the non-melanocortinergic pathways and molecules on between 71- and 72-MSH peptides. The latter findings 222 
167 the other hand. Particularly, interest has been focused on the allowed us to suggest that the relationships between both 7- 223 
168 dopaminergic mesolimbic system, in whose structure the MSH peptides may be considered, at least in part, as 224 
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Fie. 1. Average levels of extracellular DA (a) and DOPAC (b) in the anaesthetized rats nucleus accumbens measured by microdialysis following intra-VTA 
administration of artificial CSF (control). y,-rvfSH and y 2 - M S H (each peptide 3 nmol). and influei.je of the pre-treatment of - y r M S H (3 nmol) on the effect of 
y i - M S H (3 nmol). Changes are expressed a.s percentages ( ± S.E.M.) from basal levels of DA and DOPAC (calculated as the mean of the three samples before 
the treatment of M S H peptides and amounting to for DA 32.3 ± 0.3 fmol/4f) y.1 and for DOPAC 24.6 ± 1 nmol/40 ul). n = 7. *P < 0.05 vs. CSF. ~P < 70.05 
vs. -y|-MSH (a). *P < 0.05 vs. 7 , - M S H ^b). ~ 
f u n c t i o n a l a n t a g o n i s m b a s e d o n their oppos i te in f luence on 
the m e s o l i m b i c d o p a m i n e r g i c s y s t e m , p a r t i c u l a r l y on their 
a b i l i t y to in f luence D A m e t a b o l i s m in a d is t inct m a n n e r . 
D i f f e r i n g ef fects w e r e f o u n d also in studies o f the capac i ty 
o f 7 , - a n d 7 2 - M S H s to i n d u c e ana lges ia in m i c e [ 4 ] . T h u s , 
in t rac is te rna l i n j e c t i o n o f 7 2 - M S H caused a stable and l o n g -
-ac t ing cen t ra l a n a l g e s i a m e d i a t e d v ia 7 - a m i n o b u t y r i c a c i d ^ 
1 ( G A B A a ) r e c e p t o r , w h e r e a s 7 , - M S H s i n d u c e d o n l y a-
n e g l i g i b l e e f fect . T h e d a t a o f the present a n d our p r e v i o u s 
studies s h o w that b o t h 7 - M S H pept ides m a y be i n v o l v e d in 
such f u n c t i o n s as m o d u l a t i o n o f d o p a m i n e - and G A B A e r g i c 
processes, r e g u l a t i o n o f p a i n p e r c e p t i o n and p s y c h o a c t i v a -
t i o n , p r o b a b l y b y a c t i n g as e n d o g e n o u s antagonists . W e 
suggest an i m p o r t a n t f u n c t i o n a l ro le o f 7 - M S H pept ides in 
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m a i n t a i n i n g a b a l a n c e d p s y c h o a c t i v a t i o n in n o r m a l a n d 
p a t h o l o g i c a l states m e d i a t e d by the i r oppos i te act ions a t 
least at the l e v e l o f the d o p a m i n e r g i c m e s o l i m b i c s y s t e m . 
H o w the i n t e r a c t i o n b e t w e e n m e l a n o c o r t i n e r g i c a n d n o n ^ " ' " ' 
m e l a n o c o r t i n e r g i c systems c a n be realized r e m a i n s to be . , 
e luc idated. - — 
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